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Abstract 
Leishmaniasis is a neglected tropical disease caused by Leishmania parasites 
associated with an important burden worldwide. Visceral leishmaniasis (VL) is the most 
severe form of the disease, and it is fatal if left untreated. Disease control relies mostly on 
chemotherapy, which is frequently associated to safety issues, drug resistance, among 
other disadvantages that hinder disease eradication in endemic areas. Therefore, the 
search for new drugs and novel drug targets becomes imperative.   
In order to identify new potential molecular targets, an in silico comparative genomic 
analysis has been performed. Asparagine synthetase A (AS-A) and ribose-5-phosphate 
isomerase B (RPIB), which lack human homologues, have been selected as promising 
candidates. This thesis presents the first functional characterization of these two proteins in 
Leishmania infantum and Trypanosoma brucei, including both biochemical and genetic 
studies.  
Asparagine synthase (AS) is responsible for the conversion of aspartate into 
asparagine (Asn) in an ATP-dependent manner, using ammonia or glutamine as a nitrogen 
source. There are two structurally distinct AS: the strictly ammonia dependent, type A, and 
the type B, which preferably uses glutamine. Interestingly, we found that AS-A enzymes 
from trypanosomatids can use both ammonia and glutamine as nitrogen donors. Moreover, 
we have successfully generated ASA null mutants by targeted gene replacement in L. 
infantum and these parasites do not exhibit significant growth or infectivity defects. Indeed, 
a severe impairment of in vitro growth was only observed when null mutants were cultured 
in Asn limiting conditions. Our results demonstrate that despite being important upon Asn 
deprivation, LiAS-A is not essential for parasite survival, growth or infectivity in normal in 
vitro and in vivo conditions. The same pattern was observed in the related parasite T.  
brucei, using RNAi studies. Therefore, we exclude AS-A as a suitable drug target against 
trypanosomatids. 
Ribose-5-phosphate isomerase belongs to the non-oxidative branch of the pentose 
phosphate pathway, catalysing the interconversion of D-ribose-5-phosphate (R5P) and D-
ribulose-5-phosphate (Ru5P). Trypanosomatids encode a type B RPI, whereas humans 
have a structurally unrelated type A. RPIB from trypanosomatids preferentially converts 
Ru5P into R5P. We demonstrated that its knockdown in T. brucei dramatically impairs 
parasites infectivity. Moreover, null mutants generation in L. infantum was only possible 
when an episomal copy of RPIB gene was provided, and the latter was preserved both in 
vitro and in vivo, even in the absence of drug pressure for a long period indicating the gene 
is essential for survival. In vitro, sKO promastigotes exhibited no defect in growth, 
metacyclogenesis or macrophages infection, however, an impairment in intracellular 
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amastigotes’ replication was observed. Additionally, mice infected with LisKO mutants 
presented a reduced parasite burden in the liver, rescued by RPIB complementation. To 
gain further insights whether RPIB essentiality is due to its isomerase function, sKO mutants 
were complemented with an episomal copy of RPIB carrying a mutation on Cys69 that 
abrogates isomerase function. In this case, the inability to remove the second allele of RPIB 
gene suggests the essentiality is due to the annotated metabolic function. Moreover, T. 
brucei is reluctant to complete RPIB removal, and mice experienced an extended survival 
upon infection with sKO mutants.   
In summary, our results genetically validate RPIB as a novel drug target candidate 
in trypanosomatids. 
 
Keywords: L. infantum; T. brucei; asparagine synthetase A; ribose-5-phosphate isomerase 
B; genetic validation; biochemical analysis 
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Resumo 
A leishmaniose é uma doença tropical negligenciada causada por parasitas do 
género Leishmania, com grande impacto na saúde pública mundial. A leishmaniose 
visceral é a forma mais severa da doença, sendo fatal caso não seja tratada.  O seu 
controlo singe-se principalmente à quimioterapia, a qual está frequentemente associada a 
toxicidade, resistência, entre outras limitações que comprometem a erradicação da doença 
nos países endémicos. Deste modo, a descoberta de novos fármacos e novos alvos 
terapêutico é uma prioridade.  
Com o objectivo de identificar potenciais alvos moleculares no parasita que não 
apresentam homólogos em humanos foi realizada uma análise genómica comparativa. De 
entre os vários genes candidatos selecionamos a asparagina sintetase A (AS-A) e a ribose-
5-fosfato isomerase B (RPIB) para estudos funcionais. Nesta dissertação encontra-se a 
primeira caracterização bioquímica e genética destas duas proteínas em Leishmania 
infantum e Trypanosoma brucei. 
A AS é responsável pela conversão de aspartato em asparagina (Asn), consumindo 
ATP, e utilizando a amónia ou a glutamina como fonte de azoto. Na natureza, existem dois 
tipos de AS, que são estruturalmente distintos: o tipo A, caracterizado como estritamente 
dependente de amónia, e o tipo B, que utiliza preferencialmente glutamina. Curiosamente, 
as AS-A dos tripanossomatídeos demonstraram ser capazes de utilizar quer amónia, quer 
glutamina como fontes de azoto. Adicionalmente, foram gerados parasitas trangénicos, 
knockout para o gene que codifica a AS-A. Estes parasitas não apresentam qualquer 
defeito no que diz respeito quer ao seu crescimento, quer à sua infectividade. Aliás, apenas 
em condições limitantes de Asn é que o seu crescimento in vitro é substancialmente 
afectado. Apesar de ser importante na ausência de Asn, em condições normais, a AS-A é 
dispensável para a sobrevivência do parasita, para o seu crescimento e infectividade quer 
in vitro, quer in vivo. Um comportamento semelhante foi observado num parasita da mesma 
família, T. brucei, utilizando a tecnologia de RNA de interferência. Como tal, a AS-A não 
parece ser uma alvo terapêutico apropriado em tripanossomatídeos.  
Relativamente à RPIB, esta proteína está envolvida no ramo não-oxidativo da via 
das pentoses fosfato, catalisando a interconversão da D-ribose-5-fosfato (R5P) em D-
ribulose-5-fosfato (Ru5P). Os tripanossomatídeos codificam uma RPI do tipo B, enquanto 
o hospedeiro humano possui uma RPIB estruturalmente distinta e designada como do tipo 
A. A RPIB dos tripanssomatídeos converte preferencialmente a Ru5P em R5P. O 
knockdown da RPIB no T. brucei compromete dramaticamente a sua infectividade. Por sua 
vez, em L. infantum, a obtenção de mutantes knockout para o gene que codifica a RPIB foi 
apenas conseguida na presença de episoma contendo o gene, que foi preservado quer in 
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vitro quer in vivo na ausência de composto de selecção por um longo período de tempo. 
Este cenário indica que o gene é essencial para a sobrevivência do parasita. In vitro, os 
mutantes single knockout (sKO) no estadio promastigota não manifestaram qualquer 
comprometimento no seu crescimento, metaciclogénese, infecção de macrófagos ou 
diferenciação, mas sim na replicação da forma amastigota. É igualmente importante 
salientar que ratinhos infectados com os mutantes sKO apresentaram uma diminuição da 
carga parasitária no fígado, sendo este defeito revertido quando estes parasitas são 
complementados com um episoma contendo o gene que codifica para a RPIB. 
Adicionalmente, para clarificar se a essencialidade da RPIB para o parasita era devida à 
sua função enzimática, os mutantes sKO foram complementados com um episoma 
contendo uma forma mutada do gene que gera uma proteína sem actividade isomerase. 
Neste caso, não foi possível remover o segundo alelo do gene sugerindo que a 
essencialidade é devida à função isomerase. Foi também impossível inactivar o gene em 
T. brucei após várias tentativas, e os mutantes sKO que foram obtidos apresentaram uma 
menor infectividade, prolongando a sobrevivência de ratinhos infectados com estes 
parasitas.  
Em conclusão , os resultados apresentados nesta dissertação validam 
geneticamente a RPIB como um novo candidato a alvo terapêutico em tripanossomatídeos.  
 
Palavras-chave: L. infantum; T. brucei; asparagina sintetase A; ribose-5-fosfato isomerase 
B; validação genética; análise bioquímica 
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Figure 5. Developmental stages of Leishmania parasites. Scheme depicting the main 
structural features and intracellular organelles from Leishmania promastigote (left) and 
amastigote (right) forms. Adapted from Besteiro et al, 2007…………………………………47 
 
Figure 6. L. mexicana promastigotes’ cell division.  A-F correspond to phase-contrast 
image, displayed in order of the cell cycle progress and correspond to a single z-stack. The 
kinetoplast (K) and the nucleus (N) are DAPI stained. At the end of S phase, the new 
flagellum (NF) emerges from the flagellar pocket, and is considerably shorter than the old 
flagellum (OF). K and N enter division on the OF side of the cell (A). During the mitosis, one 
N is repositioned to the NF side of the cell (C). K segregation occurs only after nuclear 
anaphase, eventually, one daughter K is positioned in the NF side of the cell (E). The scale 
bar corresponds to 5 µm. Adapted from Wheeler et al, 2011………………………………..49 
 
Figure 7. L. major and T. brucei genomes comparison: synteny maps.  The 36 different 
colours in the T. brucei (left) panel represent the location of the indicated synteny blocks in 
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the 36 chromosomes of L. major, and the 11 colours in the L. major (right) panel illustrate 
the locations of the indicated synteny blocks in the 11 chromosomes in T. brucei. Adapted 
from El-Sayed et al, 2005………………………………………………………………………..52 
 
Figure 8. Transcription and processing of mRNA in trypanosomatids. On top, there is 
a hypothetical chromosome with three different polycistronic gene clusters (PGC1-3). RNA 
polymerase II mediated transcription begins upstream of the first gene of the PGCs 
(arrows). The G-run is normally present at divergent strand-switch regions (SSR). 
Nucleosomes close to the transcription initiation regions include histone variants H2AZ and 
H2BV. The N-terminal of histone H3 is acetylated at K9/K14 (K9ac) and tri-methylated at 
K4 (K4me). The N-terminal of histone H4 is acetylated at K10 (K10ac) and at 
K5/K8/K12/K16 (not shown in the figure). The bromodomain factor 3 (BDF3) and 
transcription factors TRF4 and SNAP50 also bind at the transcription initiation regions. RNA 
polymerase II mediated transcription of some PGCs stops close to tRNA genes in DNA 
regions that contain nucleosomes with H3V and H4V histone variants. The PGCs primary 
transcripts (shown only for PGC2 in the figure) are processed by trans-splicing and 
polyadenylation to ultimately generate a mature mRNA. By trans-splicing, a capped SL RNA 
(yellow box) is added to the 5’ end of every single mRNA. The cap in the SL RNA is indicated 
by an asterisk at the 5’ end of the RNA. The polycistronic primary transcript contains 
pyrimidine enriched regions (striped box in the intergenic regions) that are necessary for 
both trans-splicing and polyadenylation. The four As at the 3’ end of the mature mRNAs 
depict the polyA tail. Adapted from Martinez‐Calvillo et al, 2010…………………………….54 
 
Figure 9. Schematic representation of the mechanism of RNAi in T. brucei. dsRNA 
endogenously produced or transfected is processed by a RNase III enzymes known as 
Dicer (DCL1 and DCL2)  into small siRNA molecules. These molecules associate with 
AGO1, which corresponds to the catalytic core of RISC, with the siRNA sense strand being 
released and the antisense remain bound to RISC complex, directing it to the target mRNA. 
The latter is cleaved at a single site. Adapted from Teixeira et al, 2012……………………57 
 
Figure 10. Transfection scheme to generate null, conditional null and exclusive 
expressor mutants in T. brucei. Replacement cassettes that contain the selectable 
marker (SM) flanked by the 5’ and 3’ UTRs of the target gene are transfected into T. brucei 
parasites to sequentially knock-out each allele by homologous recombination. This is 
possible for non-essential genes. For essential genes, conditional null mutants are 
generated by transfecting a tet-regulatable allele into an rRNA intergenic region in cells prior 
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to both alleles removal or after the removal of the first allele. In these cells, the alleles 
removal occurs in the presence of tet, as in its absence, there is a repression of the 
transcription of the regulatable allele and whether this is lethal or nor not for the parasites, 
the gene is essential or not, respectively. The transfection of an additional allele into the 
tubulin locus generates exclusive expressor cell lines, which express constitutively the 
allele, even upon tet-removal. Adapted from Merritt & Stuart, 2013…………………………60 
 
Figure 11. Leishmania development in the sand fly vector. The developmental 
sequence of the five major promastigote forms: procyclic, nectomonad, leptomonad, 
haptomonad and metacyclic promastigotes. Adapted from Bates, 2007……………………64 
 
Figure 12. Sagital section of Leishmania infected female sand fly. The upper panel 
depicts the position of the PSG plug within the anterior midgut and foregut. The plug must 
be partially regurgitated (1) before the blood feeding can occur (2), and consequently 
injecting metacyclic promastigotes and the PSG in the skin of the host. The lower panel 
displays at detail of the anterior midgut and the foregut: the PSG plug exerts pressure on 
the stomodeal valve, extending into the pharynx region. Metacyclic promastigotes are 
concentrated in the anterior pole of the plug, but can be found along the foregut in both the 
cibarium and the proboscis. Adapted from Bates, 2007………………………………………64 
 
Figure 13. Leishmania recognition and uptake by host cell receptors. Promastigotes 
are represented in blue, amastigotes in red, MØ in brown and PMN in green.  A) GP63, a 
metalloprotease highly expressed in promastigotes, cleaves C3 opsonins into C3b that 
binds CR1. CR1 and factor I cleave C3b into iC3b that binds CR3. CR3 may directly bind a 
yet unknown antigen present in the promastigote surface. LPG terminal sugars may be 
recognised by MRs, although not formally proven. GP63 also binds fibronectin, which 
bridges the binding to FnRs. B) GP63 is scarcely expressed in amastigotes, but so is LPG, 
allowing GP63 access to C3 and subsequently to CR3. Additionally, antibody and 
fibronectin binding to amastigotes allow their internalization via FcγRs and FnRs, 
respectively. C) At the inoculation site, after the sand fly bite, promastigotes enter 
predominantly in PMNs, like neutrophils, via CR3, and posteriorly enter MØ and DCs. Both 
promastigotes and amastigotes may directly enter DCs via DC-SIGN, through a so far 
unidentified ligand. Adapted from Ueno et al, 2012……………………………………………66 
 
Figure 14. Iron acquisition by Leishmania in macrophages. Iron uptake inside the 
phagolysosome by Leishmania parasites is mediated by a heme transporter (LHR1) and an 
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ion transporter (LIT1) in the heme and ferrous ion form, respectively. Additionally, 
Leishmania ferric reductase, LFR1, converts ferric iron to ferrous iron, and the latter is 
transported by LIT1. Leishmania expresses TXNPx that inhibits the host iron efflux pump 
NRAMP1, expressed in the phagolysosome, increasing iron reserves inside this 
compartment and depleting the cytosolic ones. The depletion of intracellular iron triggers 
the upregulation of TfRs enhancing iron uptake by receptor-mediated endocytosis. 
Leishmania infected macrophages also express higher levels of hepcidin that induces iron 
exporter ferroportin degradation, reinforcing iron retention inside these phagocytes. 
Adapted from Podinovskaia & Descoteaux, 2015……………………………………………..69 
 
Figure 15. Leishmania compromises TLR and cytokine signalling pathways. In the 
picture, GP63 is highlighted. GP-63 cleaves and activates the host protein tyrosine 
phosphatases (PTPs), such as SHP-1, PTP1B and TCPTP. For instance, SHP-1 is involved 
in the downregulation of IRAK-1, MAPK and JAK/STAT signalling pathways and PTP1B 
inactivates JAK2. Arrows indicate activation; red crosses indicate signalling alteration or 
inhibition; abrogated lines indicate downregulation of specific kinases. Adapted from Olivier 
et al, 2012………………………………………………………………………………………….70 
 
Figure 16. Leishmania GP63 mediated impact on host cell signalling and functions. 
GP63 can cleave several important proteins: the myristoylated alanine-rich C kinase 
(MARKs), which is a critical substrate to PKC-dependent signalling; the adaptor molecules 
p130CAS and PEST, involved in the actin cytoskeleton remodelling; mTOR, affecting 
translation initiation and consequently type I IFN production, as well as transcription factors 
such as NF-kB and AP-1. Arrows indicate GP63 targets that are involved in signalling 
pathways; red crosses indicate signalling cascade alteration; abrogates lines indicate 
functional inhibition. Adapted from Olivier et al, 2012…………………………………………72 
 
Figure 17. Leishmania virulence factors. The image depicts GPI-anchored surface 
molecules, such as GP63, LPGs, PPGs and GILPs, which are mainly associated to 
membrane microdomains. Some virulence factors that are not anchored to the membrane 
can be released via exosomes (GP63) or via classical secretion through the flagellar pocket 
(GP63, PPGs, secreted acid phosphatases (SAPs) and cysteine proteases (CPs)). Adapted 
from Olivier et al, 2012……………………………………………………………………………73 
 
Figure 18. Drug discovery approaches: phenotype-based versus target-based. In the 
phenotype-based approach, lead compounds are firstly obtained, followed by target 
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deconvolution, whereas in the target-based approach, firstly the molecular targets are 
validated, and only then screened to identify lead molecules. Adapted from Terstappen et 
al, 2007…………………………………………………………………………………………….85 
 
Figure 19. Three-hybrid systems for target deconvolution. The components are a DNA-
binding domain fused to a ligand binding domain (DHFR), a ligand molecule (MTX) linked 
to the compound of interest and a component that consists of a transcriptional activation 
domain fused to a protein from a cDNA library. The binding of the compound to its target 
protein will allow the three components interaction, enabling the activation of a reporter 
gene expression. DHFR, dihydrofolate reductase; MTX, methotrexate. Adapted from 
Terstappen et al, 2007…………………………………………………………………………...87 
 
Figure 20. Polyamine metabolism in trypanosomatids and mammalian cells. ARG is 
crucial for L-ornithine production, the polyamine precursor, in most cell types but not in T. 
cruzi. A) In human cells, the decarboxylases (ODC and AdoMetDC) have extremely short 
half-lives, whereas the synthases (SpdS and SpmS) are constitutively expressed. SAT and 
PAO enable a back-conversion from spermine to spermidine and finally to putrescine via 
acetylated intermediates (AcSpm and AcSpd). Importantly, polyamine transporters (black 
circles) allow polyamine uptake from extracellular medium, and are crucial for the regulation 
of their intracellular levels. B) In T. brucei, ODC and AdoMetDC have long half-lives, and 
SpmS is absent. Spd and glutathione (GSH) are conjugated by two enzymes (GSS and 
TryS) in order to generate trypanothione, a key molecule for anti-oxidant defence. C) In L. 
donovani, polyamine biosynthesis occurs in a similar fashion to T. brucei, but Leishmania 
has a more efficient polyamine transporter (POT1). D) T. cruzi does not have ODC, but has 
AdoMetDC and two aminopropyltransferases. One may be a SpmS, as these parasites 
have Spm, which can also be conjugated with GSH by TryS. The latter has a wide 
polyamine substrate specificity, generating trypanothione and several analogues. T. cruzi, 
is dependent on putescine uptake from the extracellular medium and has a high-affinity 
transporter for the purpose. AcSpd, acetylated spermidine; AcSpm, acetylated spermine; 
AdoMet, S-adenosylmethionine; AdoMetDC, S-adenosylmethionine decarboxylase; ARG, 
arginase; dcAdoMet, decarboxylated S-adenosylmethionine; GHS, glutathione; GSS, 
glutathionylspermidine synthase; MTA, 50-deoxy-50-methylthioadenosine; ODC, ornithine 
decarboxylase; PAO, polyamine oxidase; Put, putrescine; ROS, reactive oxygen species; 
SAT, spermidine/spermidine N1-acetyltransferase; Spd, spermidine; Spm, spermine; TryR, 
trypanothione reductase; TryS, trypanothione synthetase. Adapted from Heby et al, 
2007………………………………………………………………………………………………..91
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Figure 21. Trypanothione-based thiol metabolism in T. brucei. Trypanothione (T(SH)2) 
is synthesized from GSH and Spd. GSH is produced by GSH1 and GSH2 and formed by 
glutamate, cysteine and glycine. TryS conjugates two molecules of GSH with a single 
molecule of Sp, generating trypanothione. Trypanothione disulfide (TS2) is back to the 
active dithiol upon reduction by TryR in a NADPH dependent manner. Trypanothione can 
be conjugated to metal containing drugs, which can be sequestered inside the cell or 
extruded by a specific transporter.TryR and TryS are not detectable in the mitochondria, it 
remains to be disclosed whether the parasite possesses a redox shuttle mechanism 
between this organelle and the cytosol. Proteins that have been reported as essential or 
dispensable for T. brucei are represented in black or light grey, respectively. 1-C-Grx1, 
monothiol glitaredoxin; C, cytosol; dSAM, decarboxylated S.adenosyl-L-methionine; GSH1, 
γ-glutamylcysteine synthetase 1; GSH2, GSH synthetase 2; ISC, iron sulphur clusters; K, 
kinetoplast; M, mitochondrion; N, nucleus; ODC, ornithine decarboxylase; Prx, 2-cys-
peroxiredoxins; Px, GSH-peroxidase-type enzymes; RR, ribonucleotide reductase; Sp, 
spermidine; SpS, spermidine synthase; Trx, thioredoxin; TryR, trypanothione reductase; 
TryS, trypanothione synthetase; TXN, tryparedoxin; UMSBP, universal minicircle sequence 
binding protein. Adapted from Krauth-Siegel et al, 2008……………………………………..94 
 
Figure 22. Fatty acid synthesis in kinetoplastids. A) T. brucei parasites are depicted 
representing kinetoplastids in general, as most of the studies were undertaken in this 
organism. These parasites replicate extracellularly in the bloodstream of the mammalian 
host, red blood cells are also shown (red). B) Additionally, parasites harbour two distinct 
pathways for fatty acid synthesis that are localized in two different organelles. C) FASII 
pathway localizes to the mitochondrion (light violet), generating lipoic acid and palmitic acid. 
D) Kinetoplastids also harbour an elongase-based pathway that localises to the 
endoplasmic reticulum. Unlike all other organisms, kinetoplastid FAE is used for de novo 
synthesis of fatty acids. In this pathway, butyrate and malonate are used as substrates to 
generate myristate/stearate and adrenate. Major products are highlighted in red. Ac-CoA, 
acetyl-CoA; Ac, acetate; ACP, acyl carrier protein; DEH, acyl-CoA dehydratase; EAR, 
enoyl-ACP reductase; ELO, elongase; ER, endoplasmic reticulum; FASII, fatty acid 
synthesis type II; FAE, fatty acid elongation; HAD, hydroxyacyl-ACP dehydratase; KAR, 
ketoacylACP reductase; KAS, ketoacyl-ACP synthase; KCR, ketoacyl-CoA reductase; Mal, 
malonate; Mal-CoA, malonyl-CoA. Adapted from Ramakrishnana et al, 2013…………….99 
 
Figure 23. Rearrangement of L. mexicana carbon metabolism in different 
developmental stages. The image depicts key pathways of carbon utilization in 
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promastigotes (A) and amastigotes (B). Major carbon sources (blue box) and overflow 
metabolites (open box). Fluxes through dotted pathways are down-regulated relative to the 
other stage. Steps inhibited by NaFAc and MSO are illustrated. aKG, a-ketoglutarate; 
AcCoA, acetyl-CoA; Ala, alanine; Asp, aspartate; Cit, citrate; Fum, fumarate; FA, fatty acids; 
G6P, glucose-6-phosphate; G3P, glyceraldehyde 3-phosphate; Gln, glutamine; Glu, 
glutamate; Mal, malate; OAA, oxaloacetate; OAc, acetate; PEP, phosphoenolpyruvate; 
PPP, pentose phosphate pathway; Pro, proline; Pyr, pyruvate; SCoA, succinyl-CoA; Suc, 
succinate; TCA, tricarboxylic acid cycle. Adapted from Saunders et al, 2014……………105 
 
Figure 24. Pentose phosphate pathway in trypanosomatids.  The green dots represent 
substrates and products that are shared with other pathways. The enzymes of the oxidative 
and non-oxidative branch are depicted in orange and light blue, respectively: G6PDH, 
glucose-6-phosphate dehydrogenase; 6PGL, 6-phosphogluconolactonase; G6PDH, 6-
phosphogluconate dehydrogenase; RPIB, ribose-5-phosphate isomerase B; RPE, ribose-
5-phosphate epimerase; TKT, transketolase; TAL, transaldolase; AL, aldolase. The figure 
also illustrates 1) membrane transporters of R5P and/or nucleotides; 2) the phosphorylation 
of ribose by ribokinase (question mark); 3) the riboneogenesis pathway that accounts on 
aldolase (AL), sedoheptulose biphosphatase (SBP) and tansketolase (TKT). DHAP, 
dihydroxyacetone phosphate. Essential enzymes are marked in yellow, and enzymes 
absent in Leishmania and T. brucei are marked in black and red, respectively. Adapted from 
Comini et al, 2013……………………………………………………………………………….107 
 
Figure 25. Translational control by elF2 kinases in mammalian cells. Mammals that 
possess four elF2 kinases: GCN2, HRI, PKR and PEK/PERK, which are activated under 
different stressful conditions, such as amino acid, glucose or purine deprivation, among 
others. The phosphorylation of elF2 leads to a repression of general protein synthesis, as 
well as an activation of gene-specific translation. In the case of GCN2-mediated elF2 
phosphorylation, upon activation of ATF4, there is an increase in ASB transcription. ATF4, 
activating transcription factor 4; elF2α, eukaryotic initiation factor 2α; GCN2, general control 
nonderepressible kinase 2; HRI, heme regulator elF2α kinase; PERK, protein kinase RNA- 
like endoplasmic reticulum kinase; PKR, protein kinase R. Adapted from Trinh & Klann, 
2013………………………………………………………………………………………………114 
 
Figure 26. The role of asparagine catabolism in M. tuberculosis intracellular survival. 
In macrophages, Asn enters M. tuberculosis phagosome by an unknown mechanism. Asn 
is uptaken by the bacteria through AnsP2 and one or more other transporter yet to be 
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identified. Further, it is hydrolysed by cytosolic AnsA resulting in nitrogen assimilation into 
glutamine and glutamate and release of ammonia. AnsA is also secreted in the phagosome 
and hydrolyses Asn, producing aspartate and ammonia. Aspartate is imported by AnsP1. 
The released ammonia neutralises the protons and allows pH buffering. AnsA, 
asparaginase; AnsP1/AnsP2, amino acid transporters; Asn, asparagine. Adapted from 
Gouzy et al, 2014………………………………………………………………………………..116 
 
Figure 27. Asn homeostasis in L. infantum. The left and right panels represent 
promastigote and amastigote forms, respectively, the latter living inside the phagolysosome 
of MØs. Promastigotes are able to synthesize and uptake Asn in the same extent. AS-B is 
likely not functional in these forms. Intracellular amastigotes uptake Asn from the 
phagolysosome or synthesize it via AS-A. Again, AS-B can also play a role although it is 
unlikely. The host cell, MØs, is also able to uptake Asn and synthesize it via AS-B in this 
case. AAT, amino acid transporter; AS-A, asparagine synthetase A; AS-B, asparagine 
synthetase B. Red question marks indicate whether the transporter or the enzyme have not 
been identified/characterized…………………………………………………………………..237 
 
Figure 28. Nutrient availability within the phagolysosome of MØs. The phagolysosome 
contains several carbon sources, such as amino acids, sugars or lipids that are delivered 
via endocytic, autophagic or endoplasmic reticulum vesicles or lysosomal membrane 
transporters. Arg, arginine; EE, early endosome; Glc, glucose; Glc6P, glucose 6-phosphate; 
GlcA, glucuronic acid; GlcN, glucosamine; His, histidine; Ile, isoleucine; LE, late endosome; 
Leu, leucine; Lys, lysine; Man, mannose; Phe, phenylalanine; Rib, ribose; TAG, 
triacylglycerol; Trp, tryptophan; Tyr, tyrosine; Val, valine; Xyl, xylose. Adapted from 
McConville et al, 2015…………………………………………………………………………..246 
 
Figure 29. RPIB isomerase activity is detrimental for Leishmania parasites. The 
dashed rectangles represent steps that may be critical for the parasites in the absence of 
RPIB. Particularly in amastigotes there is a general decrease in nutrient uptake, thus a lower 
ribose import may render the parasites more dependent on RPIB function for R5P synthesis 
(dashed rectangle and arrows in blue). In Leishmania, the riboneogenesis pathway is 
absent, rendering the parasites more dependent on RPIB (dashed rectangle in purple). The 
accumulation of Ru5P may decrease the activity of the enzymes of the oxidative branch by 
negative feedback, leading to reduced levels of NADPH, ultimately rendering the parasites 
more susceptible to ROS (dashed rectangle and arrows in black). The accumulation of 
Ru5P may also lead to increased levels of X5P, which may block cell proliferation by 
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interfering with MAPK signaling. This has only been described in mammalian cells so far 
(dashed rectangle and arrows in orange). The red squares represent substrates and 
products that are shared with other pathways. The enzymes of the oxidative and non-
oxidative branch are depicted in dark and light green, respectively: G6PDH, glucose-6-
phosphate dehydrogenase; 6PGL, 6-phosphogluconolactonase; G6PDH, 6-
phosphogluconate dehydrogenase; RPIB, ribose-5-phosphate isomerase B; RPE, ribose-
5-phosphate epimerase; TKT, transketolase; TAL; transaldolase. Enzymes from glycolysis 
(AL, aldolase) and riboneogenesis (SBP, sedoheptulose biphosphatase) are represented 
in red and violet, respectively. Glycolysis, oxidative PPP, non-oxidative PPP and 
riboneogenesis metabolic flow are depicted with red, dark green, light green and violet lines. 
6PG, 6-phosphogluconate; 6PGL, 6-phsophogluconalactone; DHAP, dihydroxyacetone 
phosphate; E4P, erythrose-4-phosphate; F6P, fructose-6-phosphate; G3P, glyceraldehyde-
3-phosphate; G6P, glucose-6-phosphate; R5P, ribose-5-phosphate; Ru5P, ribulose-5-
phosphate; S7P, sedoheptulose-7-phosphate; S1,7BP, sdoheptulose-1, 7-biphosphate; 
X5P, xylulose-5-phosphate. Modified from Comini et al, 2013……………………………..248 
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4-PEH 4-Phospho-D-erythronohydroxamic acid 
4E-BP1 Eukaryotic initiation factor 4F binding protein 
6PGDH 6-Phosphogluconate dehydrogenase 
6PGL 6-Phosphogluconolactonase 
AAT Amino acid transporters 
ABC ATP-binding cassette 
ACP Acyl carrier protein 
AdoMet S-adenosylmethionine 
AdoMetDC S-adenosylmethionine decarboxylase 
AdoMetT1 S-adenosylmethionine transporter 
AGO1 Argonaute 
ALD Fructose-1,6-bisphosphate aldolase 
ALX LipoXin A4 receptor 
AmphB Amphotericin B 
AMPK AMP activated protein kinase 
APA 3-Aminooxy-1-aminopropane 
APC Anaphase promoting complex 
AQP Aquaglyceroporin 
ARG Arginase 
AS Asparagine synthetase 
AS-A Asparagine synthetase A 
AS-B Asparagine synthetase B 
Asn Asparagine 
AsnRS Asparaginyl-tRNA synthetase 
ATF4 Activating transcription factor 4 
ATP Adenosine triphosphate 
BMMØ Bone marrow derived macrophages 
BLEO Streptoalloteichus hindustanus bleomycin resistance protein 
BSD Blasticidin S deaminase 
CDK Cyclin dependent kinase 
CL Cutaneous leishmaniasis 
CP Cysteine protease 
CR Complement receptor 
CRIPSR Clustered regularly interspaced palindromic short repeat 
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dAdoMet                      Decarboxylated S-adenosylmethionine 
DC                              Dendritic cell 
DCL1                          Dicer-like enzyme 1 
DCL2                          Dicer-like enzyme 2 
DDL1                          Delta-like ligand 1 for Notch 3 
DDT                            Dichlorodiphenyltrichloroethane 
DHEA                          Dehydroepiandrosterone 
DHFR-TS                    Dihydrofolate reductase - thymidylate synthase 
DNA                            Deoxyribonucleic acid 
DSB                            Double-strand DNA breaks 
dsRNA                       Double strand RNA 
dTMP                          Deoxythymidine-monophosphate 
dUMP                         Deoxyuridine-monophosphate 
E4P                             Erythrose-4-phosphate 
EA                               Epiandrosterone 
elF2α                          Eukaryotic initiation factor 2α 
elF4F                           Eukaryotic initiation factor 4F  
ELISA                          Enzyme-linked immunosorbent assay 
ELO                             Elongase 
ENO                            Enolase 
EPC                            Ethanolamine phosphorylceramide 
F6P                             Fructose-6-phosphate 
FAE                             Fatty acid elongation 
FASII                          Fatty acid synthesis type II 
FBPase                       Fructose-1, 6-biphosphatase 
Fcγ                              Fragment crystallizable 
FKBP FK506 binding protein 
FnRs    Fibronectin receptors 
FT Folate transporter 
G3P Glyceraldehyde-3-phosphate 
G6P Glucose-6-phosphate 
G6PDH     Glucose-6-phosphate dehydrogenase 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GAS   Group A Streptococcus 
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GCN2                          General control nonderepressible kinase 2 
GFP                             Green fluorescent protein 
GILP                            Glycosylinositolphospholipid  
GOI                             Gene of interest 
GP                               Glutathione peroxidase 
GR                               Glutathione reductase 
GSH                             Glutathione 
gRNA                          Guide RNA 
H2F  Dihydrofolate 
H4F Tetrahydrofolate 
HAT  Human African trypanosomiasis 
HCS High content screening 
HDR  Homology-directed repair 
HIV  Human immunodeficiency virus 
HK  Hexokinase 
HRI  Heme regulator elF2α kinase 
HSP  Heat shock protein 
HTS High throughput screening 
HYG  Hygromycin B phosphotransferase 
IFNγ  Interferon gamma 
IL  Interleukine 
IPC  Inositol phosphorylceramide 
IV  Intravenous 
iNOS  Inducible nitric oxide synthetase 
JAK  Janus kinase 
kDNA  Kinetoplast DNA 
KKT Kinetoplastid kinetochore protein 
LAMP1  Lysosome-associated membrane protein 1 
LCF Leishmania chemotactic factor 
LFR Leishmania ferric ion reductase 
LHR1 Leishmania heme receptor 1 
LIT1 Leishmania ferrous iron transporter 1 
LKB1 Liver kinase B1 
LPG Lipophosphoglycan 
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LRO  Lysosome-related organelles 
LRV  Leishmania RNA virus 
MØ  Macrophage 
MAPK  Mitogen-activated protein kinase 
MARK  Myristoylated alanine-rich C kinase 
MDR1 Multi-drug resistance protein 1 
MKP  Mitogen-activated protein kinase phosphatase 
MMEJ  Micro-homology mediated end joining 
ML  Mucocutaneous leishmaniasis  
MR  Manose receptor 
mRNA Messenger RNA 
mTOR Mammalian target of rapamycin 
mTORC1  mTOR complex 1 
NADP+  Nicotinamide adenine dinucleotide phosphate 
NEO  Neomycin phosphotransferase 
NHEJ Non-homologous end joining 
NMR  Nuclear magnetic resonance 
NO Nitric oxide 
NRAMP1  Natural resistance-associated macrophage protein 1  
ODC  Ornithine decarboxylase 
PAC  Puromycin N-acetyl transferase 
PAO  Polyamine oxidase 
PC  Phosphatidylcholine 
PCR  Polymerase chain reaction 
PE Phosphatidylethanolamine 
PERK Protein kinase RNA- like endoplasmic reticulum kinase 
PFK Phosphofrutokinase 
PG Phosphatidylglycerol 
PGAM Phosphoglycerate mutase 
PGC Polycistronic gene cluster 
PI Phosphatidylinositol 
PKC Protein kinase C 
PKDL Post kala-azar dermal leishmaniasis 
PKR Protein kinase R 
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PM  Peritrophic membrane  
PMN Polymorphonuclear cells 
Poly P Polyphosphate 
POT1  Polyamine transporter 1 
PPG  Proteophosphoglycan 
PPi  Pyrophosphate 
PPP Pentose phosphate pathway 
PS  Phosphatidylserine 
PSG  Promastigote secretory gel 
PTP Protein tyrosine phosphatase 
PTR1  Pteridine reductase 1 
PTS  Peroxisomal targeting sequence 
PUFA  Polyunsaturated fatty acids 
PV  Parasitophorous vacuole 
PYK Phosphoglycerate kinase 
QDPR Quinonoid dihydropteridine reductase 
R5P  Ribose-5-phosphate 
RdRp RNA-dependent RNA polymerase 
RFLP Restriction fragment length polymorphism 
rK39 Recombinant K39 
RISC RNAi silencing complex 
RNA Ribonucleic acid 
RNAi RNA interference 
RNase Ribonuclease 
ROS Reactive oxygen species 
RPI Ribose-5-phosphate isomerase 
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1. History, taxonomy and evolution 
In India 1885, Cunningham described the Leishmania parasite for the first time, from 
a sore designated Delhi boil, which at the time was thought to have fungal origin. Thirteen 
years later, Borovsky has reported the agent to be a protozoan and described its 
morphology (Bari, 2006).  
However, William Leishman and Charles Donovan were the first to relate the agent 
to the disease, after independently discovering the parasite in the spleens of patients with 
kala azar, today known as visceral leishmaniasis (VL). In 1904, the agent responsible for 
this infection received the taxonomic designation of Leishmania donovani (Bari, 2006).  
In 1924, it was proposed that the sand fly was the vector of L. donovani by John 
Sinton. This was further supported by others, like Robert Knowles, who provided evidences 
to support that theory. Nevertheless, only in 1931 Short et al. provided the first unequivocal 
experiment showing the transmission of L. donovani by the bite of the sand fly (Sacks & 
Kamhawi, 2001).  
Leishmania parasites belong the subkingdom Protozoa, order Kinetoplastida, family 
Trypanosomatidae, and genus Leishmania (Stevens et al, 2001). In the last quarter of the 
20th century, the evaluation of antigenic features (Anthony et al, 1985; de Ibarra et al, 1982) 
or polymorphism patterns in the kinetoplast DNA (Rodriguez-Gonzalez et al, 2007) allowed 
the identification of a total of 31 Leishmania species, 20 of which thought to be pathogenic 
to humans.  
The modern phylogenetic studies have helped elucidating the taxonomy of the 
Leishmania genus and clearly suggest the existence of two major divergent lineages, 
Euleishmania and Paraleishmania (Cupolillo et al, 2000). The latter includes several 
species that infect sloths or rodents such as porcupines and squirrels, collectively known 
as L. hertigi complex. Additionally, some members of Endotrypanum, a Leishmania close 
related genus, also belong to Paraleishmania lineage (Cupolillo et al, 2000). On the other 
hand, the Euleishmania division comprises all the species that are pathogenic to humans 
and is subdivided into the Viannia and Leishmania subgenera (Cupolillo et al, 2000). The 
latter encompasses three species complexes with a worldwide distribution, L. mexicana, L. 
donovani and L. tropica, which cause cutaneous, visceral and cutaneous leishmaniasis, 
respectively (Pont-Sucre et al, 2013), as illustrated on figure 1. The lizard infecting group, 
designated as Sauroleishmania seems closely related to Leishmania subgenera (Croan et 
al, 1997). The Viannia subgenera, in its turn, includes species of the L. braziliensis complex, 
responsible for cutaneous (CL) and mucocutaneous (ML) leishmaniasis (Stevens et al, 
2001).  
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Figure 1. Phylogenetic tree illustrating the Leishmania/Endotrypanum subtree of the 
Kinetoplastida. An indication of the geographical distribution (OW, Old World; NW, New 
World), common disease pathology (CL, cutaneous; VL, visceral; MC, mucocutaneous) or 
subgenera (Leishmania (L.) or Viannia (V.)) are represented. Adapted from Croan et al, 
1997).  
 
The family Trypanosomatidae also includes the genus Trypanosoma, which 
contains the human parasites Trypanosoma brucei and Trypanosoma cruzi, responsible for 
the sleeping sickness and Chagas disease, respectively. T. brucei, T. cruzi and Leishmania 
spp. have different patterns of evolution and the divergence between the Leishmania and 
Trypanosoma lineages is also ancient (Stevens et al, 2001).  
 
2. Life cycle 
Leishmania is a digenetic protozoan that requires a vertebrate host and an insect 
vector to complete its complex life cycle.  It alternates between two major forms: the 
promastigote form that parasitizes the sand fly vector, and the amastigote form that 
proliferates inside the phagolysosome of the mammalian host macrophages (MØs) (Kaye 
& Scott 2011; Sacks & Noben-Trauth, 2002).  
Leishmania promastigotes, which are motile flagellated forms, colonize the digestive 
tract of Phlebotomus spp. and Lutzomyia spp. female sand flies. Within the vector midgut 
promastigotes undergo several transformations (Kaye & Scott 2011; Sacks & Noben-
Trauth, 2002). Indeed, promastigotes attach to the midgut wall, and while migrating to the 
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anterior part differentiate into non-replicative infectious metacyclic promastigotes (Kaye & 
Scott 2011; Sacks & Noben-Trauth, 2002). The infection of the mammalian host is initiated 
through the bite of the sand fly that inoculates metacyclic promastigotes in the skin, which 
can be directly or indirectly phagocytosed by MØs (Kaye & Scott 2011; Van Zandbergen et 
al, 2004). It is unanimously accepted MØs are the predominantly infected cells by 
Leishmania in the vertebrate host, nonetheless, they are not the first or the only ones to be 
recruited (Kaye & Scott 2011; Van Zandbergen et al, 2004). For instance, neutrophils rapidly 
arrive to the inoculation site, internalize Leishmania promastigotes, and after infection, dying 
neutrophils secrete chemotactic factors for MØs (Van Zandbergen et al, 2004). Both MØs 
and dendritic cells (DCs) are able to remove neutrophil apoptotic bodies containing 
Leishmania promastigotes (Van Zandbergen et al, 2004). The internalized parasites are 
delivered to the phagolysosome, where they eventually differentiate into amastigotes. This 
intracellular form has no external flagellum, is replicative, periodically escape the host cell 
to rapidly reinfect other cells, exploring a mechanism poorly characterized to the date (Kaye 
& Scott 2011). Among the possibly infected cells are phagocytic (MØs and DCs) and non-
phagocytic cells (fibroblasts). Interestingly, the latter have been implicated in the 
establishment of chronic latent infections (Antoine et al, 2004; Bogdan et al, 2000). The 
cycle is completed when the sand fly takes another blood meal, taking free amastigotes or 
infected cells. These infected cells are disrupted in the insect midgut releasing the 
amastigotes, which rapidly transform into replicative non-infectious promastigotes and the 
cycle is then perpetuated (Kaye & Scott 2011; Sacks & Noben-Trauth, 2002). 
A simplified version of Leishmania life cycle is illustrated in figure 2.  
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Figure 2. Leishmania spp. life cycle. Leishmania promastigotes are transmitted to the 
mammalian host through the bite of an infected female sand fly. These forms once 
inoculated in the dermis are phagocytosed by MØs and inside the phagolysosome 
differentiate into replicative amastigotes. Infected MØs are taken by the sand fly vector 
during the blood meal, releasing in the insect midgut amastigotes that rapidly transform into 
replicative non-infectious promastigotes. These latter forms attach to the posterior midgut 
wall, and differentiation into metacyclic promastigotes is accompanied by anterior migration. 
This non-replicative infectious form can be transmitted to the vertebrate host in the following 
blood meal, completing the cycle. Adapted from Sacks & Noben-Trauth, 2002. 
 
3. Leishmaniasis 
3.1. Disease burden and geographic distribution 
Leishmania parasites have successfully evolved to survive and proliferate inside the 
mammalian host, ultimately causing disease. However, only a small fraction of those 
infected by Leishmania parasites will eventually develop the disease (WHO, 2015). 
Leishmaniasis is classically divided in three major medical conditions: cutaneous, 
mucocutaneous and visceral. Usually, a species of Leishmania is implicated in a clinical 
form of the disease, but not necessarily exclusively (Murray et al, 2005). Considering all 
forms of the disease, leishmaniasis is prevalent in 98 countries, distributed in five different 
continents, rendering approximately 350 million of people at risk of contracting the infection 
(WHO, 2015). Only in 33 of these 98 countries reporting is mandatory, thus the real burden 
is probably much higher than the actual estimation of 1.3 millions of new cases per year 
(Alvar et al, 2012; WHO, 2015). Among all infectious diseases, leishmaniasis accounts for 
Chapter I – Leishmania spp. and leishmaniasis 
39 
 
the ninth largest disease burden, and among parasitic infections in particular, the 20,000 to 
30,000 annual deaths are only surpassed by malaria (Alvar et al, 2012; WHO, 2015).  
 
3.2.  Cutaneous leishmaniasis 
CL is the most common form, causing skin lesions on exposed parts of the body, 
mainly ulcers, which can cause serious disability. CL has a worldwide distribution, but most 
cases (~95%) occur in America, the Mediterranean basin, the Middle East and Central Asia 
(Fig. 3). CL is endemic in 70 countries, but strikingly, more than two thirds of CL cases take 
place in 6 countries: Afghanistan, Algeria, Brazil, Colombia, Iran and the Syrian Arab 
Republic. Estimates point to 0.7 to 1.3 million new cases worldwide annually WHO, 2015). 
 
Figure 3. Worldwide distribution of cutaneous leishmaniasis (WHO, 2012).  
 
Several species of Leishmania can be responsible for CL. In the Old World, L. 
tropica, L. major and L. aethiopica are the main causative agents. On the other hand, in the 
New World, CL can result from infection by species of both the Leishmania and Viannia 
subgenera, such as L. amazonensis and L. braziliensis, respectively (Alvar et al, 2012; 
WHO, 2015). Nevertheless, some species usually associated with visceral ailment may also 
cause cutaneous lesions, like L. infantum, which is the most frequent cause of CL in Europe 
(Alvar et al, 2012; WHO, 2015). CL is mainly a zoonotic disease, although humans may 
serve as L. tropica reservoirs.  
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Typically, an erythema appears at the site of the sandfly bite, which further develops 
into a slow growing papule or nodule that normally takes weeks to reach its final size. 
Following, a crust is formed and eventually falls off, exposing the ulcerated lesion. Ulcers 
progressively heal over months or even years, but often leave life-long scars (Alvar et al, 
2012; David & Craft, 2009). The high diversity of CL causative species, as well as the 
variability of the host status underlie the encountered differences in the clinical 
manifestations of the disease, regarding in particular, ulcers formation, inflammation level 
or required time for lesions to self-heal (Alvar et al, 2012; David & Craft, 2009).  
 
3.3. Mucocutaneous leishmaniasis 
ML leads to a partial or total destruction of mucous membranes of the nose, mouth 
and throat and almost 90% of the cases occur in South America, particularly in Bolivia, 
Brazil and Peru (WHO, 2015). It is caused by species of the Viannia subgenera, namely L. 
braziliensis, L. panamensis and L. guyanensis.  
Posteriorly to the resolution of a primary cutaneous lesion, Leishmania species 
responsible for ML are able to metastasize, via blood or lymph, to the mucosal tissues 
surrounding the mouth or the upper respiratory tract (Alvar et al, 2012; David & Craft, 2009). 
The mucocutaneous lesions appear only in 5 to 10% of the patients, with a latency period 
ranging from a few months to many years. Usually in the beginning, the appearance of an 
erythema and ulceration of the nares take place and the appearance of nodules in the nasal 
septum follows. Subsequently, the septum is perforated and eventually collapses, 
broadening the nose. In several patients, pharynx, larynx and trachea can also be affected 
(Alvar et al, 2012; David & Craft, 2009). Importantly, spontaneous healing in ML is very 
seldom, and it is potentially fatal, normally due to opportunistic bacterial infections (David & 
Craft, 2009). Moreover, another preoccupying aspect, not always emphasized, is that the 
ML driven facial disfigurement profoundly burdens the patients as they are likely doomed to 
lifelong social stigma.  
Typically in ML, there is a massive tissue destruction accompanied by immune cell 
infiltration and inflammation, in an uncontrollable fashion, and curiously, few parasites are 
found in the lesions (Ronet et al, 2011). Taken all together, these evidences pointed to a 
major contribution of the host genetic background in the outcome of the disease, and 
inclusively, polymorphisms in genes encoding for mediators of the inflammatory response 
have been implicated (Ronet et al, 2011). Actually, the current view is now that the 
occurrence of ML is determined by the host genetic background, but the severity of the 
pathology may be exacerbated by parasite-driven factors (Hartley et al, 2012). One of these 
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factors is the presence of Leishmania RNA Virus (LRV), a double-stranded RNA virus that 
parasites some Leishmania species (Zangger et al, 2013).  
 
3.4.  Visceral leishmaniasis  
VL, also known as kala-azar, is fatal if left untreated. Inclusively, all the mortality 
associated to leishmaniasis results mainly from visceral disease with 20,000 to 30,000 
annual deaths (WHO, 2015). The asymptomatic period of VL varies from a few weeks to 
one year (or more). The disease usually progresses gradually over several months. The 
main signs and symptoms include irregular rounds of fever, weight loss, augmentation of 
the spleen and liver and anaemia (Alvar et al, 2012).  
As depicted in figure 4, it is particularly endemic in the Indian subcontinent (India, 
Bangladesh, Nepal) and East Africa (Sudan, Ethiopia and Somalia). Annually, estimates 
point to 200,000 to 400,000 new cases of VL worldwide, but mostly (more than 90%) occur 
in Bangladesh, Brazil, Ethiopia, India, South Sudan and Sudan (WHO, 2015). However, the 
degree of under-reporting is much accentuated.  
Figure 4. Worldwide distribution of visceral leishmaniasis (WHO, 2012).  
 
L. donovani is the causative agent of VL in Asia and East Africa, whereas L. infantum 
equally leads to visceral compromise but in the Mediterranean Basin and South America 
(Murray et al, 2005). Differently, while dogs are the most important reservoirs of VL caused 
by L. infantum, in the case of L. donovani, the disease is mostly anthroponotic (Chappuis 
et al, 2007). Another striking difference is that L. donovani is capable of causing disease in 
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people of all ages, although children and young adults are the most affected. In the case of 
L. infantum, small children used to be the main age group, however, as HIV (Human 
Immunodeficiency Virus)/L. infantum co-infections emerged, nowadays adults actually 
represent almost half of VL cases in Europe (Chappuis et al, 2007; WHO, 2015).  
The disease manifestation always include splenomegaly, not always accompanied 
by hepatomegaly. For instance, lymphadenopathy is not as frequent and occurs mainly in 
Sudan (Van Griensven & Diro, 2012). Spleen, liver, bone marrow and lymph nodes’ 
phagocytes are extremely parasitized, albeit lymphocyte infiltration is scarce. In the spleen, 
the disruption of the lymphoid architecture is common and plasma cells are abundant and 
probably related to the polyclonal hypergammaglobulinemia (Van Griensven & Diro, 2012). 
The observed anaemia is likely a result of splenic sequestration and suppression of bone 
marrow function, but additionally, complement activation also seems to make a contribution. 
The first two also lead to thrombocytopenia and neutropenia (Van Griensven & Diro, 2012). 
The latter is probably responsible for an increased susceptibility to secondary infections, 
like tuberculosis or pneumonia, which are frequent causes of death (Van Griensven & Diro, 
2012). The presence of immune complexes can sometimes lead to nephritis, proteinuria 
and hematuria. Liver function may be altered (Chappuis et al, 2007; Murray et al, 2005; Van 
Griensven & Diro, 2012; WHO, 2015). Inclusively, prothrombin depletion can lead to 
mucosal haemorrhage at advanced stages, when jaundice and ascite can also occur.  
Importantly, in L. donovani endemic regions, 10 to 60% of the patients experience 
the so called post kala-azar dermal leishmaniasis (PKDL), which is a skin rash that appears 
within 6 months to one year after VL resolution (Ramesh et al, 2007). Nevertheless, there 
are also cases of PKDL described in patients not previously diagnosed with or treated for 
VL. PKDL typically appears with the formation of erythematous macules and papules, which 
can eventually evolve to nodules. Any part of the body may be affected, but the most 
frequently affected sites are the face, the trunk and the extremities (Ramesh et al, 2007). 
Although the responsible parasite species is the same, comparing PKDL in India or Sudan 
leads to important differences, namely in the percentage of people that experience PKDL 
after treatment for VL, the timeframe between both presentations and the disease 
characteristics (Ramesh et al, 2007).  
The cause, risk factors and pathogenesis of PKDL are largely unknown, although 
several host factors (Ramesh et al, 2007) and the possibility that PKDL is a drug related 
phenomenon (Croft, 2008) have been broadly considered. Traditionally, PKDL has been 
proposed to be a relevant L. donovani reservoir during intra-epidemic periods of VL (Addy 
& Nandy, 1992) Inclusively, research aiming detailed disclosure of the transmissibility of 
different morphologies of PKDL remains a priority (Ramesh et al, 2007; WHO, 2012).  
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3.5.  Visceralization determinants 
Leishmaniasis is associated with a wide spectrum of clinical manifestations, ranging 
from cutaneous to visceral forms of the disease, as described above. Actually, one of the 
oldest and most important questions in Leishmania research is precisely why some species 
are confined to the skin whereas others find their way to the viscera, and therefore which 
are the determinants of the visceralization process. Genetic, immunologic and animal 
models have begun to provide some insights on the process, however, overall it is still 
modestly comprehended (McCall et al, 2013). Generally vector, host and pathogen related 
factors are important mediators. Moreover, the knowledge of this process is deeply 
appealing to understand the disease evolution, as well as the survival mechanisms in the 
targeted organs (McCall et al, 2013).  
Experimental animal models using different infection routes have highlighted 
interesting features. When using a subcutaneous needle infection, L .major not only 
generates skin lesions but also disseminates to the visceral organs in BALB/c mice, 
contrasting with C57BL/6 mice, in which visceralization is not observed (Laskay et al, 1995). 
This per se evidences the importance of the host immune response in the process. Using 
the same injection route, L. donovani for instance causes a minimal swelling at the site of 
the injection but also fails to visceralize (Melby et al, 1998), emphasizing that subcutaneous 
injection does not mimic the observed disease onset in humans. Animal models of VL based 
on intradermal infection have been established in both mice (Ahmed et al, 2003) and 
hamsters (Gomes et al, 2008), displaying parasite clearance in the skin coupled with 
dissemination to internal organs. Although the initial inoculum is much higher than the one 
of the sand fly, they are still the models that more closely mimic the “natural” infection and 
therefore more valuable to gain hints on the cells and pathways involved in the 
visceralization process (McCall et al, 2013).  
Animal models based on intravenous infection in their turn do not mimic at all the 
natural course of the infection, although they are commonly adopted to study VL using 
BALB/c mice (McCall et al, 2013). As the normal requirement for the parasite to migrate 
from the skin to the visceral organs is bypassed, these models ultimately focus on the ability 
of the parasites to survive and proliferate in the organs. However, at least they have led to 
some important conclusions. For instance, intravenous injection of L. major causes a very 
limited parasite burden in the spleen and in the liver, in opposition to L. donovani or L. 
infantum (Zhang & Matlashewski, 2001), suggesting that independently of the mechanisms 
to exit the skin, overall, visceral species are better adapted to survive in the viscera (McCall 
et al, 2013).  
Chapter I – Leishmania spp. and leishmaniasis 
44 
 
Several factors have been reported to play a role in the permissiveness of the host 
to VL. Actually, considering that only a small percentage of the people infected with a 
visceral species of Leishmania develops disease (Badaró et al, 1986), this already points 
to an important contribution of the host genetic and immunological background. Regarding 
the host genetics, several polymorphisms in genes encoding for cytokines and their 
receptors (Bucheton et al, 2007; Frade et al, 2011; Karplus et al, 2002; Mehrotra et al, 2011; 
Mohamed et al, 2003), as well as in natural resistance-associated MØ protein 1 (NRAMP1, 
Bucheton et al, 2003), mannan-binding lectin (Alonso et al, 2007) and the delta-like 1 ligand 
for Notch 3 (DDL1, Mehrotra et al, 2012) have been implicated. Apart from genetic factors, 
some acquired factors can also play an important contribution, such as HIV infection 
(Desjeux & Alvar, 2003), malnutrition (Maciel et al, 2008) or youth (Muller et al, 2008), which 
increase the risk to develop symptomatic VL due to compromised immune responses. 
Inclusively, in HIV co-infected patients, VL can be caused by Leishmania species that 
normally are associated with cutaneous disease (Gramiccia, 2003). These observations 
indicate that an effective Th1 cellular response is indispensable to control the disease, 
although not sufficient per se (McCall et al, 2013).  
Additionally, there are also vector related factors that seem to play a role in 
visceralization. The level of vasodilatation upon the sand fly bite was proposed to be one of 
them, as the higher it was, better access to visceral organs would be provided, and therefore 
vector species might influence the disease progression (McCall et al, 2013). For instance, 
L. chagasi transmitted by Lutzomyia longipalpis sand flies can cause CL or VL in South 
America, and the saliva of flies from cutaneous regions induced lower vasodilatation 
(Warburg et al, 1994). However, this might not be as straight forward as it seems, as 
sequence analysis of the salivary proteins from a Phlebotomus species associated with L. 
infantum-driven cutaneous infections in the Old World demonstrated that those proteins 
were actually more closely related to those of vectors transmitting visceral L. donovani or 
L. infantum than the ones transmitting cutaneous L. major and L. tropica (Rohousova et al, 
2012). Another vector related factor that seems to be important is the number of the 
inoculated parasites, as a higher dose may elicit a more intense local immune response 
that can restrain the parasite dissemination to the visceral organs (Maia et al, 2011). 
Moreover, protection against VL has been achieved using sand fly salivary proteins in 
hamsters (Gomes et al, 2008), in a nonhuman primate model (Oliveira et al, 2015) and the 
same may also apply to humans (Vinhas et al, 2007; Aquino et al, 2010). Consequently, 
the role of the sand fly in pathology experiences a growing interest.  
Notwithstanding, although vector and host factors influence the appearance of 
symptomatic VL, parasite-driven factors seem to be the most important visceralization 
Chapter I – Leishmania spp. and leishmaniasis 
45 
 
determinants. A very indicative observation is that intravenous infection of inbred mice with 
L. infantum strains recovered from patients with CL were unable to establish VL in 
opposition to strains recovered from patients with the visceral form (Sulahian et al, 1997). 
Overall, differences in species or even subspecies-specific genes, genetic polymorphisms, 
pseudogenes and expression of virulence and stress response genes can be crucial for the 
pathology (McCall et al, 2013). 
In this context, it is imperative to mention the A2 gene family, as it represents a gene 
family that is clearly required for visceralization. It is expressed in visceral species such as 
L. donovani and L. infantum, while it corresponds to pseudogenes in cutaneous species 
such as L. major and L. tropica (Charest & Matlashewski, 1994; Ghedin et al, 1997). A2 
genes are arranged in tandem on chromosome 22 and are made almost entirely of 40 to 90 
copies of the same repetitive ten amino acid sequence (Zhang et al, 1996). Their expression 
is triggered by promastigote differentiation into amastigotes (Charest & Matlashewski, 
1994), as well as stressful conditions such as heat shock (McCall & Matlashewski, 2010), 
unfolded protein stress (UPS, Gosline et al, 2011) and misfolded protein stress (Barak et 
al, 2005). Partial knockout of these genes led to a decrease in the parasite burden in the 
liver of BALB/c mice (Zhang & Matlashewski, 2001), and in opposition, their insertion in L. 
major led to an increase in parasite survival in the viscera (Zhang et al, 2003). Another 
evidence of the key role of A2 genes for parasite survival in visceral organs is that their 
expression is downregulated in PKDL (Sharma et al, 2010). Visceral Leishmania species 
are more resistant to higher temperatures than cutaneous species, and the promastigotes 
of the latter are also more susceptible to heat shock (Callahan et al, 1996; McCall & 
Matlashewski, 2010). Additionally, the fever found in VL increases oxidants production by 
phagocytic cells (Beachy & Repasky, 2011), but visceral Leishmania species are also more 
resistant to these reactive species (Sarkar et al, 2012). A2 may be an important player in 
these characteristics of viscerotropic species as it does protect against heat shock (McCall 
& Matlashewski, 2010) and oxidative stress (McCall & Matlashewski, 2012). Actually, A2 is 
a candidate for a VL vaccine in dogs, and potentially in humans (Fernandes et al, 2012). 
Out of over 8,000 genes, only 19 turned to be L. donovani specific, being absent or 
pseudogenes in cutaneous species (Peacock et al, 2007). Some of these genes were 
investigated and ectopically expressed in L. major to see whether it would induce 
visceralization (Zhang & Matlashewski, 2010). Apart from A2 family genes, a cytosolic 
protein of unknown function, a nucleotide sugar transporter localized in the Golgi and a 
cytosolic glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which is a key glycolytic 
enzyme (Zhang & Matlashewski, 2010) were identified as potential visceralization factors. 
With the exception of the first protein, the last two are also present in L. mexicana and 
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besides promoting visceralization when ectopically expressed in L. major, they also 
increase the skin lesions, suggesting they are virulence, rather than visceralization 
determinant factors (Zhang & Matlashewski, 2010). Ectopic expression in L. major did 
increase the survival rate in visceral organs, but never in an extent comparable to L. 
donovani (Zhang & Matlashewski, 2010). These results also suggest that L. donovani gene 
specific combinations, along with gene amplifications, polymorphisms and post-
transcriptional regulation may play an important role in the whole process (Zhang & 
Matlashewski, 2010).  
Moreover, it is important to highlight the MØ population targeted by Leishmania 
differs, as cutaneous species infect monocyte-derived MØ (De Trez et al, 2009), whereas 
visceral species infect Kupffer cells, spleen MØ and bone marrow derived MØ (BMMØ) 
(McCall et al, 2013). These MØ populations differ at several levels, namely in the expression 
of surface markers and cytokine production (Taylor et al, 2005). Cutaneous and visceral 
species have adapted to these different cellular environments, although the susceptibility 
and microbicidal potential of these different MØ populations in the context of Leishmania 
infection have not been specifically addressed (McCall et al, 2013).  
Overall, there are still many questions in the visceralization process, regarding the 
mechanism (free parasites or infected cells; via blood or lymph; same mechanism or not for 
the different organs; chronology; etc) and the identification of novel visceralization factors 
(for instance, factors that allow L. donovani to switch from visceral (VL) to cutaneous 
(PKDL)). Additionally, in an evolutionary perspective, was visceralization a newly acquired 
characteristic? What is the importance of the reservoir?   
 
4. Leishmania Cell biology  
Trypanosomatids (among which, Leishmania spp, Trypanosomes) are kinetoplastids, 
corresponding to a large group of flagellated parasitic protozoans that have several singular 
and remarkable features. Apart from the impact of some of them on public health, they 
represent a fascinating model to study several cellular functions and mechanisms. These 
parasites are equipped with several specific and unique cellular organelles. One of the most 
notable is the kinetoplast, which corresponds to a special part of their single mitochondrion 
containing a complex DNA structure. Another striking characteristic is the presence of 
glycosomes, peroxisome-related microbodies that contain most of the glycolytic pathway, 
among others. Moreover, the genomic organization and plasticity, trans-splicing, RNA 
editing mechanisms and eukaryotic polycistronic transcription of protein-coding genes 
never cease to impress. 
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4.1. Specific cellular organelles  
Two distinctive characteristics of trypanosomatids are the presence of a flagella (Fig. 
5) and a flagellar pocket (Fig. 5), which corresponds to an invagination of the plasma 
membrane (Landfear & Ignatushchenko, 2001). Actually, the membrane of these organisms 
has been divided in three morphologically different domains: the pellicular plasma 
membrane, the flagellar pocket, and the flagellar membrane (Balber, 1990). Although they 
are physically contiguous and part of the plasma membrane, they have unique protein 
compositions and specialized functions (Landfear & Ignatushchenko, 2001). The pellicular 
plasma membrane involves the cell body and is attached to a dense and stable 
arrangement of microtubules. It contains many classical nutrient transporters, it confers cell 
body shape , and in some cases, it can be heavily coated with proteins or glycolipids 
(Landfear & Ignatushchenko, 2001), which can for instance play a role in immune evasion, 
as the variant surface glycoproteins (VSGs) in T. brucei (Van der Ploeg, 1990) or 
lipophosphoglycan (LPG) in Leishmania spp (Turco & Descoteaux, 1992).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Developmental stages of Leishmania parasites. Scheme depicting the main 
structural features and intracellular organelles from Leishmania promastigote (left) and 
amastigote (right) forms. Adapted from Besteiro et al, 2007.  
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The flagellar pocket, particularly, is responsible for larger nutrients uptake by 
receptor-mediated endocytosis, integration of proteins in the cell surface and protein 
secretion (Field & Carrington, 2009; Landfear & Ignatushchenko, 2001).  
The flagellum is a classical motility organelle but can be involved in additional 
biological activities, such as parasite attachment to the insect host epithelium (da Cunha e 
Silva et al, 1989). In the particular case of Leishmania promastigotes’ flagellum, its axoneme 
is organized in a canonical fashion, displaying a “9+2” microtubule arrangement (da Cunha 
e Silva et al., 1989; Landfear & Ignatushchenko, 2001). On the other hand, amastigotes are 
often and inaccurately described as “aflagellated”, as they do present a short flagellum, 
which is likely to be important for sensorial purposes (Gluenz et al, 2010). The central pair 
of microtubules is absent in these forms, but is occupied by one or more of the peripheral 
pairs, which is considered a 9v (variable) arrangement (Gluenz et al, 2010).  
Other of their most remarkable possessions is the kinetoplast (Fig. 5), unique to the 
single mitochondrion of parasites belonging to Kinetoplastida order. It is noteworthy the 
kinetoplast not only possesses an incredibly complex and singular network structure but 
also hosts a novel RNA editing mechanism (Lukes et al, 2002).  
The glycocomes are another singular organelle of these parasites once more 
emphasizing their uniqueness. Glycosomes (Fig. 5) are specialized peroxisomes that 
harbour most part of the glycolysis, the pentose phosphate pathway (PPP), β-oxidation of 
fatty acids, gluconeogenesis, purine salvage and biosynthesis of pyrimidines, ether lipids 
and squalenes (Parsons et al, 2001; Szoor et al, 2014). The compartmentalization of these 
metabolic pathways is thought to prevent accumulation of toxic intermediates as well as to 
facilitate a rapid response to environmental stimuli (Besteiro et al, 2007; Kaye & Scott, 
2011). The glycosome number as well as the qualitative and quantitative enzymatic content 
differs among trypanosomatids, in a species and life cycle stage dependent manner 
(Parsons et al, 2001; Szoor et al, 2014).  
Moreover, trypanosomatids also possess acidocalcisomes (Fig. 5), which are acidic 
organelles whose function might be related to cations and phosphorus storage, calcium 
homeostasis, pH maintenance and osmoregulation, among others (Docampo et al, 1995; 
Moreno & Docampo, 2009). Their membranes present a great number of pumps (Ca2+-
ATPase, V-H+-ATPase, H+-PPase), exchangers (Na+/H+, Ca2+/H+) and channels 
(aquaporins). Great amounts of phosphorus can be found in their matrix, present as 
pyrophosphate (PPi) and polyphosphate (poly P), complexed with calcium and other 
cations, as well as enzymes involved in their metabolism (Moreno & Docampo, 2009). 
Acidocalcisomes resemble lysosome-related organelles (LRO) from mammalian cells in 
many aspects. Moreover, in some microorganisms like Toxoplasma gondii and T. cruzi, 
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they also interact with other organelles, namely vacuoles, which reinforces their association 
with the endosomal/lysosomal pathway (Moreno & Docampo, 2009).  
 
4.2.  Cell division 
Studies on L. mexicana have revealed that cell division in Leishmania is generically 
similar to other trypanosomatids. However, if the regulation of some cellular processes is 
common, others may be specifically adapted to the biology of each species (Wheeler et al, 
2011). L. mexicana exponentially growing promastigotes progress through the cell cycle in 
an asynchronous manner. Impressively, these promastigotes display several different 
morphologies that reflect different stages of a single proliferative cycle (Wheeler et al, 2011). 
Typically, trypanosomatids possess one nucleus (N), one kinetoplast (K) and one flagellum 
(F), and each replicates once during a cell cycle. In Leishmania, the flagellum growth 
initiates first, followed by mitosis, and only after the onset of nuclear anaphase, kinetoplast 
division takes place (Fig. 6). The following morphologies are then subsequently present 
1K1N1F, 1K1N2F, 1K2N2F, 2K2N2F and 2x (1K1N1F). Interestingly, these events are 
concentrated in the remaining 20% of the cell cycle (Wheeler et al, 2011).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. L. mexicana promastigotes’ cell division.  A-F correspond to phase-contrast 
image, displayed in order of the cell cycle progress and correspond to a single z-stack. The 
kinetoplast (K) and the nucleus (N) are DAPI stained. At the end of S phase, the new 
flagellum (NF) emerges from the flagellar pocket, and is considerably shorter than the old 
flagellum (OF). K and N enter division on the OF side of the cell (A). During the mitosis, one 
N is repositioned to the NF side of the cell (C). K segregation occurs only after nuclear 
Chapter I – Leishmania spp. and leishmaniasis 
50 
 
anaphase, eventually, one daughter K is positioned in the NF side of the cell (E). The scale 
bar corresponds to 5 µm. Adapted from Wheeler et al, 2011.  
 
L. mexicana nuclear and kinetoplast S phase are synchronous and correspond to 
40% of the overall cycle. Its nuclear S phase is rather long when comparing to 
trypanosomes (Elias et al, 2007; Woodward & Gull, 1990), and it does not correlate to the 
genome size. This can instead reflect differences in chromosome number, genome 
architecture or in DNA replication machinery processing (Wheeler et al, 2011). The 
kinetoplast S phase is more similar to other trypanosomatids, though. However, unlike T. 
brucei (Woodward et al., 1990), Leishmania undergoes mitosis before kinetoplast 
segregation is complete (Wheeler et al, 2011). 
In both Leishmania and T. brucei basal body duplication pattern is similar and the 
changes in the cell shape during cytokinesis seem symmetrical, contrasting with mitosis 
and kinetoplast division, which are asymmetrical (Fig. 6). This suggests that the regulation 
of these events in the two organisms may rely on common mechanisms (Wheeler et al, 
2011). On the other hand, concerning the flagellum growth regulation, Leishmania sharply 
contrasts with T. brucei, suggesting that different regulatory mechanisms may be involved 
(Wheeler et al, 2011).  
The Leishmania flagellum starts growing in G1, remains constant during S phase, 
and the new flagellum eventually emerges from the flagellar pocket at the end of S phase 
(Wheeler et al, 2011). At division, in contrast to T. brucei (Farr & Gull, 2009), the two 
daughter cells have flagella of unequal length (the new flagellum is usually considerably 
shorter). One of the most notorious aspects in Leishmania is that flagellum length 
apparently keeps growing over several consecutive cycles (Wheeler et al, 2011).  
Curiously, during L. mexicana cell division, abscission may not occur after 
cytokinesis, generating doublets, meaning two cells connected by a cytoplasmatic bridge in 
their posterior ends, which correspond to 10% of the total population (Wheeler et al, 2011). 
Doublets go through the cell cycle normally and in a synchronous manner. The in vivo 
relevance of these forms is debatable as they may actually be an in vitro culture artefact or 
alternatively, in the sand fly gut, they may be advantageous to the daughter cell, facilitating 
its attachment to the epithelium (Wheeler et al, 2011).  
Another important question is the fact these parasites have different life cycle 
stages, and these differentiation events may involve a specialized division in which one of 
the daughter cells has a modified morphology and/or biochemistry (Wheeler et al, 2011). 
Recently, an asymmetric cell division was characterized in T. cruzi, showing how it discards 
the flagellum during the remodelling of the trypomastigote form into oval amastigotes that 
possess no external flagellum (Kurup & Tarleton, 2014).  
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Concerning the cell division machinery, kinetoplastids display an amazing feature 
that even challenges the long lasting issue of the eukaryotic tree of life root position 
(Akiyoshi & Gull, 2014). They do possess the CDK/cyclin system, aurora B, anaphase 
promoting complex (APC) and proteasomes, suggesting that the basic cell cycle machinery 
is conserved (Akiyoshi & Gull, 2013). However, in comparison to all the remaining 
sequenced eukaryotes, they lack any conventional kinetochore protein homologue. This 
challenged the assumption of kinetochore universality and recently, 19 novel kinetochore 
proteins (KKT1-19) were identified in T. brucei, the majority of them appear conserved 
among kinetoplastids (Akiyoshi & Gull, 2014). Furthermore, these parasites build these 
protein macrocomplexes that orient chromosome segregation, using a different set of 
proteins, which display a variety of features not found in conventional kinetochores 
(Akiyoshi & Gull, 2014).  
 
4.3.  Genome organization and gene expression  
One of the biggest revolutions in the field was the genome sequencing of several 
Leishmania spp. The availability of the nuclear genome provided new insights on parasite 
evolution, immune evasion strategies and many unusual aspects of the biology of these 
eukaryotes. In 2005, the first Leishmania genome became available, the genome of L. major 
(Ivens et al, 2005). In 2007, the genomes of L. infantum and L. braziliensis were also 
sequenced, and ever since, others have progressively followed (Peacock et al, 2007; 
Raymond et al, 2011; Rogers et al, 2011).  
The comparison of the genome of different Leishmania spp., associated with distinct 
disease presentations, showed that among the 8300 predicted genes, surprisingly only 78 
were actually species specific. This was also extremely important to screen for potential 
parasite related visceralization determinants (Peacock et al, 2007). Interestingly, even L. 
tarentolae, which is not a human pathogen, presents 90% conservation, and only lacks 250 
genes in comparison to the core of Leishmania spp. genome (Raymond et al, 2011). 
Additionally, when comparing both gene content and genomic architecture with T. brucei 
(Fig. 7) and T. cruzi, a core of approximately 6200 genes is conserved in large syntenic 
polycistronic gene clusters (El-Sayed et al, 2005). This impressive conservation once more 
reinforces that a massively diverse genetic background does not underlie the distinct life 
cycles and disease outcomes in trypanosomatids.  
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Figure 7. L. major and T. brucei genomes comparison: synteny maps.  The 36 different 
colours in the T. brucei (left) panel represent the location of the indicated synteny blocks in 
the 36 chromosomes of L. major, and the 11 colours in the L. major (right) panel illustrate 
the locations of the indicated synteny blocks in the 11 chromosomes in T. brucei. Adapted 
from El-Sayed et al, 2005.  
 
Kinetoplastids possess, like all other eukaryotes, two genomes: nuclear and 
mitochondrial (kinetoplast). The nuclear genome is around 34 Mb, with inter-species 
variations, and each chromosome has between 0.3 and 2.8 Mb (Bastien et al, 1992; 
Wincker et al, 1996). The karyotype is variable in number, as Old World and New World 
species present 36 and 34 or 35 chromosomes, respectively (Wincker et al, 1996; Britto et 
al, 1998).  
Leishmania nuclear genome is renowned for the extensive plasticity (Bastien et al, 
1992), which ultimately may allow a rapid and appropriate adaptation to environmental 
changes, but often drives genetic manipulation quite challenging. As the core genome of 
Leishmania is relatively conserved, this plasticity may have a significant contribution to 
virulence or drug resistance differences, observed in different clinical isolates (Sterkers et 
al, 2011; Ubeda et al, 2008). From high spontaneous chromosomal polymorphisms 
(Sterkers et al, 2011) to spontaneous or stress-driven genetic amplification (Grondin et al, 
1996; Olmo et al, 1995; Navarro et al, 1994; Segovia, 1994; Ubeda et al, 2008; Ubeda et 
al, 2014), several mechanisms have been described.  
A few years ago, the possibility of genetic exchange between parasites was a 
controversial subject, as it was generally accepted that Leishmania multiplies by binary 
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fission (Banuls et al, 2007). However, there were several independent reports of 
interspecies hybrids (Chargui et al, 2009; Odiwuor et al, 2011; Ravel et al, 2006) over time. 
In 2009, a study clearly demonstrated the formation of hybrids in the sand fly (Akopyants et 
al, 2009), using L. major, and later in 2011, using L. donovani (Sadlova et al, 2011). 
Recently, a cross-species genetic exchange between cutaneous and visceral strains in the 
vector was reported (Romano et al, 2014), as well as the rate of sexual and asexual 
reproduction in vector-isolated parasites (Rogers et al, 2014).  
As for the mitochondrial genome, the kinetoplast DNA (kDNA) corresponds to a 
huge network of thousands of catenated circular DNAs, being the most structurally complex 
known mitochondrial DNA structure. It is formed by maxicircles (20 to 40 kb) and minicircles 
(0.5 to 10 kb), present in a few dozen identical copies per network or thousands of copies 
per network similar in size but heterogeneous in sequence, respectively (Estévez & 
Simpson, 1999; Gott & Emeson, 2000; Lukes et al, 2002). Maxicircles encode for classical 
mitochondrial gene products, as rRNA or subunits of the respiratory chain, but impressively, 
some of the protein-coding genes are encrypted. The transcripts of these encrypted genes 
must undergo post-translational modifications, through a novel RNA editing mechanism that 
comprises deletion and insertion of uridine residues in specific sites of the transcripts, to 
ultimately generate a functional mRNA (Estévez & Simpson, 1999; Gott & Emeson, 2000; 
Lukes et al, 2002). This editing process requires guide RNAs (gRNA), which are mainly 
encoded by minicircles, and only a few of them by maxicircles. Actually, the only known 
function of the minicircles DNA is encoding and providing enough gRNAs for the RNA 
editing process (Estévez & Simpson, 1999; Gott & Emeson, 2000; Lukes et al, 2002).  
Apart from the above described genomic plasticity and RNA editing mechanism, the 
transcription initiation in Leishmania, as well as in all kinetoplastids, remarkably differs from 
the remaining eukaryotes. One of the most notorious differences concerning gene 
expression is the almost complete absence of RNA polymerase II promoters (Alsford et al, 
2012; Clayton, 2002; Requena, 2011). It is generally accepted that in these organisms, RNA 
polymerase II mediated transcription is initiated upstream of most 5’ genes of each cluster, 
generating polycistronic transcripts, which will be then processed by trans-splicing at the 5’ 
end (Martinez-Calvillo et al, 2003), as depicted on figure 8. Trans-splicing replaces the 
capping system, found in the majority of eukaryotes, and basically requires a common 39 
nucleotide methylated mini-exon sequence or spliced leader (SL), which is trans-spliced 
upstream the start codon of the mRNA (Sturm et al, 1999; Clayton, 2002). The SL gene in 
Leishmania is present in a 150 copies tandem array that corresponds to 0.1% of the parasite 
genome (Lamontagne & Papadopoulou, 1999). In striking contrast to the majority of protein 
encoding genes in trypanosomatids, the SL gene has an identifiable promoter with a short 
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consensus initiator element (Luo et al, 1999) and it is transcribed by RNA polymerase II 
(Gilinger & Bellofatto, 2001).  
 
Figure 8. Transcription and processing of mRNA in trypanosomatids. On top, there is 
a hypothetical chromosome with three different polycistronic gene clusters (PGC1-3). RNA 
polymerase II mediated transcription begins upstream of the first gene of the PGCs 
(arrows). The G-run is normally present at divergent strand-switch regions (SSR). 
Nucleosomes close to the transcription initiation regions include histone variants H2AZ and 
H2BV. The N-terminal of histone H3 is acetylated at K9/K14 (K9ac) and tri-methylated at 
K4 (K4me). The N-terminal of histone H4 is acetylated at K10 (K10ac) and at 
K5/K8/K12/K16 (not shown in the figure). The bromodomain factor 3 (BDF3) and 
transcription factors TRF4 and SNAP50 also bind at the transcription initiation regions. RNA 
polymerase II mediated transcription of some PGCs stops close to tRNA genes in DNA 
regions that contain nucleosomes with H3V and H4V histone variants. The PGCs primary 
transcripts (shown only for PGC2 in the figure) are processed by trans-splicing and 
polyadenylation to ultimately generate a mature mRNA. By trans-splicing, a capped SL RNA 
(yellow box) is added to the 5’ end of every single mRNA. The cap in the SL RNA is indicated 
by an asterisk at the 5’ end of the RNA. The polycistronic primary transcript contains 
pyrimidine enriched regions (striped box in the intergenic regions) that are necessary for 
both trans-splicing and polyadenylation. The four As at the 3’ end of the mature mRNAs 
depict the polyA tail. Adapted from Martinez‐Calvillo et al, 2010.  
 
Due to this near absence of RNA polymerase II promoters, there is a great loss in 
terms of transcriptional regulation of gene expression in these parasites. Instead, it seems 
they have adopted and explored post-transcriptional mechanisms (Alsford et al, 2012; 
Clayton, 2002; Requena, 2011). Leishmania ability to post-transcriptionally regulate gene 
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expression can rely on modulation of both mRNA stability (Brittingham et al, 2001; Muller 
et al, 2010a; Muller et al, 2010b) and protein translation rate (Boucher et al, 2002; Zeiner et 
al, 2003).  
The combination of genomic and proteomic approaches demonstrated that an 
almost constitutive expression of Leishmania genome occurs in both promastigotes and 
amastigotes (Leifso et al, 2007; McNicoll et al, 2006), with few examples of stage specific 
proteins, like amastin family, specifically expressed in amastigotes (Moore et al, 1996; 
Nourbakhsh et al, 1996; Souza et al, 1992; Wu et al, 2000). However, quantitative 
proteomics has revealed a great variability in protein expression levels in both stages 
(Leifso et al, 2007; McNicoll et al, 2006; Rosenzweig et al, 2008), which shows how efficient 
these post-transcriptional mechanisms are.  
 
4.3.1. Genetic manipulation of trypanosomatids 
Up until the 1990s, studying gene specific functions within trypanosomatids was 
much harder. With the advents of complete genomes sequencing and DNA transfection 
systems, gene knockout and overexpression became possible, leading to significant 
advances in the study of the biology and pathology of these parasites (Clayton, 2002).  
Transient or stable transfection of DNA can be achieved. The transcription of the 
latter is driven by endogenous RNA polymerases, whenever is integrated in a chromosome 
or, in the case of Leishmania for instance, by “trapping” on circular episomes (Beverley, 
2003). There are several positive and negative selectable markers available. Regarding the 
positive selection, some of the most common used markers are HYG (hygromycin B 
phosphotransferase), PAC (puromycin N-acetyl-transferase), BLEO (Streptoalloteichus 
hindustanus bleomycin resistance protein), BSD (blasticidin S deaminase) or NEO 
(neomycin phosphotranferase). As for the negative selection, the most used are TK 
(thymidine kinase) or CDA (cytidine deaminase) (Beverley, 2003).  
Successful integration of protein tags, for protein localization studies for instance, or 
integration of reporter genes like green fluorescent protein (GFP) or luciferase, for in vitro 
drug screening assays or in vivo imaging among other applications, have been extensively 
explored over the years (Clayton, 2002; Beverley, 2003).  
Concerning the study of gene function, different techniques can be used, which 
induce either gain or loss of function.  
To abolish gene function, some of the most common available approaches include 
gene knockdown and gene knockout. The first is broadly used in T. brucei, after the 
discovery of a functional RNAi pathway (Djikeng et al, 2001; Durand-Dubief & Bastin, 2003; 
Ngô et al, 1998; Patrick et al, 2009; Shi et al, 2004; Shi et al, 2006). In metazoans, RNAi 
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plays a role in mRNA levels and translation regulation, DNA arrangements, genome 
surveillance, anti-viral response, among others. The phylogenetic distribution of key 
required genes, encoding for proteins like Dicer or Argonaute, suggests that this pathway 
has been present in the common eukaryotic ancestor (Lye et al, 2010). However, in 
eukaryotic microorganisms, the scenario is complex, as some retained active RNAi 
pathways, whereas others did not (Kolev et al, 2011; Lye et al, 2010). RNAi deficiency in 
eukaryotes has arisen independently a number of times through the eukaryotic lineage, in 
trypanosomatids in particular, it happened twice, first with T. cruzi, and a second time after 
the divergence of the Viannia subgenus from other Leishmania species. T. cruzi and all 
Leishmania species, with exception of Viannia subgenus, do not present a functional RNAi 
pathway (Kolev et al, 2011; Lye et al, 2010).  
In T. brucei (Fig. 9), the type III RNase known as Dicer-like enzymes, DLC1 and 
DLC2, process long dsRNA molecules that derive from sense and antisense transcripts 
from retroposons and repeats into small interference RNAs (siRNAs) in the cytoplasm and 
the nucleus, respectively (Kang & Hong, 2008; Kolev et al, 2011; Owino et al, 2008). During 
RNAi silencing complex (RISC) assembly, Argonaute (AGO1) directly binds the siRNAs 
cleaving them into sense and antisense oligonucleotides. The latter remain associated to 
RISC. After RISC assembly, the antisense strand directs this complex to the target mRNA, 
which is cleaved in a single site in the centre of the double strand region between the guide 
siRNA and the mRNA (Kang & Hong, 2008; Kolev et al, 2011; Owino et al, 2008).  
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Figure 9. Schematic representation of the mechanism of RNAi in T. brucei. dsRNA 
endogenously produced or transfected is processed by a RNase III enzymes known as 
Dicer (DCL1 and DCL2)  into small siRNA molecules. These molecules associate with 
AGO1, which corresponds to the catalytic core of RISC, with the siRNA sense strand being 
released and the antisense remain bound to RISC complex, directing it to the target mRNA. 
The latter is cleaved at a single site. Adapted from Teixeira et al, 2012.  
 
Although deletion of RNAi genes in T. brucei causes a transient chromosome miss-
segregation and defective mitosis, accompanied by an increase in retroposon transcripts, 
parasites lacking the RNAi are capable of completing a life cycle, therefore the biological 
role of this pathway is not clear (Janzen et al, 2006).  
The first study in T. brucei demonstrated that a dsRNA transfection elicited a 
significant downregulation of the target mRNA, however, the effect was transient and lasted 
about one cell cycle (Ngô et al, 1998). This indicated there was no amplification of the 
response to dsRNA, which in other organisms is linked to the activity of RNA-dependent 
RNA polymerase (RdRp). Proficient trypanosomatids do not seem to harbour a potential 
gene encoding this enzyme (Kolev et al, 2011). In order to overcome this transient effect 
and develop a methodology that would enable functional studies upon gene 
downregulation, a tetracycline (tet)-regulated expression of dsRNA was engineered (Kolev 
et al, 2011).  
The RNAi tool rapidly became the method of choice to downregulate genes in T. 
brucei, The further emergency of the RNAi based genome wide screens was a break 
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through, providing numerous “hits” that can be then individually studied and validated, 
allowing a massive contribution in the dissection of several aspects of the parasite biology, 
drug target validation and drug resistance mechanisms (Alsford et al, 2011; Alsford et al, 
2012; Erben et al, 2014; Glover et al, 2015; Mony et al, 2014; Preubert et al, 2014). 
Disappointingly, due to the number of missing elements of the RNAi pathway in T. cruzi and 
most of Leishmania species (Kolev et al, 2011), engineer it in these organisms would not 
be feasible. 
RNAi studies have some disadvantages, including the possibility of off target effects, 
and even though, few complementation studies can be found in the literature (Loureiro et 
al, 2015; Sienkiewicz et al, 2010). Another is the fact that the knockdown can be more or 
less efficient, and sometimes, even low protein levels may suffice to ensure normal cellular 
function (Kang & Hong, 2008; Kolev et al, 2011; Owino et al, 2008). Knockdown can also 
be performed at the protein level, like the HaloTag based system (Neklesa et al, 2011). In 
Apicomplexa parasites for instance, several systems in which the knockdown is achieved 
by the induction of protein degradation have been successfully used, as the auxin-based 
(Philip & Water, 2015) or the FK506 binding protein (FKBP) based (Zhang et al, 2014c) 
systems, among others. For trypanosomatids, none has been successfully engineered so 
far.  
Another common strategy to abrogate gene function is gene knockout. If the gene 
is not essential, it can be removed by homologous recombination, using untranslated 
regions (UTR), upstream and downstream the gene of interest (GOI), 5’ and 3’ UTR, 
respectively, on either side of a selectable marker (Clayton, 2002). Because 
trypanosomatids are diploid, a complete knockout requires two rounds of transfection, using 
two different selectable markers (Clayton, 2002). It is also possible to achieve gene ablation 
by deleting just part of the coding region, designated gene disruption (Dumas et al, 1997; 
Mottram et al, 1996). This can lead to deceptive results if the parasite is still able to express 
fragments of the protein (Clayton, 2002) that can be toxic or simply preserve the activity of 
the full length protein. The phenotypes observed for mutant parasites must be interpreted 
carefully as prolonged in vitro culture or cloning can lead to modifications in biological 
properties per se. For this reason, it is imperative to re-transfect null mutants with the gene 
that has been deleted in order to evaluate whether the phenotype can be rescued (Clayton, 
2002). 
In the case of an essential gene, usually the first allelic copy is successfully removed, 
but not the second, leading to a lethal phenotype with no transfectants survival in T. brucei 
or double resistant mutants in Leishmania that still possess a copy of the GOI, though. 
Along with chromosome aneuploidy, DNA amplification by gene rearrangement, which is a 
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highly dynamic and stochastic process, is one of the strategies Leishmania successfully 
explores in order to respond to environmental changes, such as drug pressure (Genest et 
al, 2005; Ouellette et al, 1991; Papadopoulou et al, 1994; Ubeda et al, 2014). Several 
mechanisms to defend essential genes have been reported over the years in Leishmania, 
such as whole genome amplification (Cruz et al, 1993), single chromosome amplification 
(Cruz et al, 1993) or intrachromosomal tandem duplication (Mukherjee et al, 2011).  
Consecutive inability to generate viable transfectants and aneuploidy generation in 
T. brucei and Leishmania, respectively, are then suggestive of gene essentiality. In 
Leishmania, the classical strategy to approach this, broadly used for drug target validation 
for instance, consists in providing an ectopic copy of the gene (episomal or integrated), and 
under such circumstances the second allele removal must be successful, ultimately 
generating the so-called facilitated null mutants (Mukherjee et al, 2009; Wang et al, 2005; 
Wiese, 1998). However, whether this approach is the ultimate proof of essentiality is quite 
debatable, as a transgene expression may simply facilitate parasite survival during genetic 
manipulation and selection (Dacher et al, 2014). As Leishmania tends to lose episomal 
vectors in the absence of drug pressure, their preservation in such conditions has been 
used as an additional readout of essentiality (Mukherjee et al, 2009), but again, this can 
merely mean that the transgene provides an advantage for in vitro or in vivo growth (Dacher 
et al, 2014). This classical approach does not allow to decipher the biological implications 
of the gene loss and limits structure/function analysis based on mutagenesis or genetic 
complementation, for instance (Dacher et al, 2014). An elegant manner in attempt to 
overcome some of these issues is to use an episomal vector, like pXNG, containing TK 
marker that allows for negative selection by bioactivating ganciclovir, which then becomes 
toxic (Dacher et al, 2014; Murta et al, 2009). The vector carries a GOI copy, and in case of 
gene essentiality, Leishmania should preserve the vector even when exposed to the 
selection drug. Moreover, this type of vector also allows plasmid shuffle studies, as the 
original plasmid can be switched for others carrying mutated or truncated versions of the 
GOI, which ultimately provide structural/biological insights on the protein (Dacher et al, 
2014).  
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In the case of T. brucei, a conditional system is available to study essential genes 
(Fig. 10). Basically, a tet-regulatable copy of the GOI is inserted in an rDNA intergenic locus 
prior to the removal of the two allelic copies of the gene or after the removal of the first one 
by homologous recombination. Upon tet removal, which represses transcription of the 
regulatable allele in null mutants, if the parasites die, the gene is proved essential (Merritt 
& Stuart, 2013; Wyllie et al, 2009). Another elegant addition to this scheme is the generation 
of an exclusive expressor cell line, which constitutively expresses a WT or mutated allele, 
through its insertion in the β-tubulin locus of a conditional null mutant (Fig. 10). Upon tet 
withdrawal, this allele will be expressed and can be used for functional complementation 
purposes (Merritt & Stuart, 2013). One of the applications is to test the rescue from loss of 
gene function upon tet removal in conditional null mutants.  
 
Figure 10. Transfection scheme to generate null, conditional null and exclusive 
expressor mutants in T. brucei. Replacement cassettes that contain the selectable 
marker (SM) flanked by the 5’ and 3’ UTRs of the target gene are transfected into T. brucei 
parasites to sequentially knock-out each allele by homologous recombination. This is 
possible for non-essential genes. For essential genes, conditional null mutants are 
generated by transfecting a tet-regulatable allele into an rRNA intergenic region in cells prior 
to both alleles removal or after the removal of the first allele. In these cells, the alleles 
removal occurs in the presence of tet, as in its absence, there is a repression of the 
transcription of the regulatable allele and whether this is lethal or nor not for the parasites, 
the gene is essential or not, respectively. The transfection of an additional allele into the 
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tubulin locus generates exclusive expressor cell lines, which express constitutively the 
allele, even upon tet-removal. Adapted from Merritt & Stuart, 2013. 
 
The generation of this type of conditional mutants in Leishmania has been hindered 
by the absence of inducible expression systems (Dacher et al, 2014), as only recently, one 
has been described in L. mexicana (Kraeva et al, 2014).  
In T. brucei, there is an additional knock-out strategy available using Cre 
recombinase and loxP sites, allowing both null and conditional null mutants generation 
(Scahill et al, 2008; Kim et al, 2013). This approach is especially advantageous when 
multiple simultaneous gene knock-outs are intended, as once using the conventional 
techniques, not only there is a limited number of selection markers available, as it would 
definitely be more laborious and time-consuming (Scahill et al, 2008; Kim et al, 2013). Cre 
recombinase removes the GOI in a complete and instantaneous fashion, upon recognition 
of loxP sequences in the orientation that permits gene deletion over inversion or 
translocation (Scahill et al, 2008; Kim et al, 2013). A constitutive expression of the 
recombinase can induce genotoxicity, therefore it can be either stably incorporated into an 
rDNA spacer with tet-inducible expression or transiently transfected (Scahill et al, 2008). 
The latter relies on the short term incorporation of episomal vectors in T. brucei. In 
Leishmania, the only option would be inducible expression, which then again has only 
recently been described. The null or conditional null mutants are at last obtained by negative 
selection, using the previously referred TK marker (Scahill et al, 2008; Kim et al, 2013). 
In the recent years, the discovery of CRIPSR (clustered regularly interspaced short 
palindromic repeat)/Cas9 gene editing has emerged as a promising break-through for gene 
therapy, but also, it has been brought to the spotlight as a valuable tool for genetic 
manipulation in basic research (Dow et al, 2015; Hsu et al, 2014; O’Connell et al, 2014; 
Shalem et al, 2014; Wang et al, 2014). These days, there is a boom of CRISPR/Cas9 
technology everywhere, and fortunately, molecular parasitology is taking the first steps 
exploring its potential (Lander et al, 2015; Peng et al, 2014; Sidik et al, 2014; Sollelis et al, 
2015; Zhang et al, 2014a; Zhang et al, 2015). For people working in T. brucei it may not be 
as exciting due to the diverse and valuable tools already available, but for Leishmania and 
T. cruzi genetic manipulation, this can be definitely revolutionary. Actually, despite generally 
T. cruzi is more difficult to manipulate than Leishmania, it seems in the case of 
CRISPR/Cas9 technology, the efficiency is superior in the first (Zhang et al, 2015).  
The CRISPR/Cas9 is a prokaryotic immune system, consisting of an RNA-guided 
endonuclease that facilitates site-specific DNA cleavage in a wide range of microorganisms. 
The gRNA directs the Cas9 to its target DNA, and this nuclease induces double-strand DNA 
breaks (DSBs). Those can be repaired by homologous recombination or non-homologous 
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end joining (NHEJ) pathway in mammalian cells, but in L. donovani, the repair relies on 
homology-directed repair (HDR) and micro-homology mediated end joining (MMEJ) (Zhang 
et al, 2015). This is in agreement with previous in silico studies, which suggested NHEJ was 
absent in trypanosomatids. So far in Leishmania, the introduction of mutations, antibiotic 
selection markers, protein tags (like GFP) and gene deletion have been achieved using 
CRISPR/Cas9-mediated gene editing (Sollelis et al, 2015; Zhang et al, 2015). For gene 
deletion in particular, previously characterized non-essential genes were knockedout as 
proof of concept, and off target effects discarded by whole genome sequencing (Sollelis et 
al, 2015). The development of an inducible version would be great for essential genes 
studies. Moreover, the improvement of the system efficiency would be also important in 
order to enable a future genome-scale knockout screening in Leishmania (Zhang et al, 
2015). Such screenings have already been carried out in human cells, for instance (Shalem 
et al, 2014; Wang et al, 2014).  
As for the gain of function studies, overexpression has been extensively used and 
depending on the available tools for each organism, episomes or integrated cassettes can 
be used, with constitutive or inducible expression (Clayton, 2002).  
In summary, forward genetics has been challenged by diploidy and the lack or 
difficulty of sexual crossing, but several methods, as genetic rescue, transposon tagging or 
RNAi-based mutant screens, among other, have been developed, complementing the ability 
to perform reverse genetic manipulations (Beverley, 2003; Damasceno et al, 2015). 
Currently, several novel molecular genetic tools are now allowing a rapid progress in the 
field. 
 
5. Host-parasite interaction 
5.1.  Interaction with the vector 
Sand flies (order Diptera, family Psychodidae, subfamily Phlebotominae) are the 
natural vectors of Leishmania spp. However on rare occasions, the vector requirement can 
be bypassed, such as in transplacental transmission, laboratory accidents or needle sharing 
(Murray, 2005). About 70 species have been proved to be Leishmania vectors, belonging 
to Lutzomyia or Phlebotomus genus in the New or Old World, respectively (Bates, 2008). 
Only female sand flies can transmit the parasite as they need periodic blood meals in order 
to get the required nutrients for egg development. They can be permissive or specific 
vectors, whether they allow the development of one or several Leishmania species, 
respectively (Bates, 2008; Volf & Myskova, 2007).  
The development of the parasites in the vector midgut is initiated when the sand fly 
takes a blood meal, taking free amastigotes or infected cells. Both blood components and 
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parasites become involved by a type I peritrophic membrane (PM), which is secreted by the 
epithelial cells and composed by an arrangement of proteins and glycoproteins held 
together by chitinous microfibrils (Secundino et al, 2005). PM is semipermeable enabling 
the diffusion of digestive enzymes that will catabolize the ingested contents (Secundino et 
al, 2005). Amastigotes differentiation into procyclic promastigotes is triggered by the 
temperature decrease and pH increase when compared to the mammalian host, occurring 
within 6 to 12 hours post feeding (Dostalova & Volf, 2012).  
Procyclic promastigotes are small, ovoid, with a short flagellum, highly replicative 
and have great amounts of proteophosphoglycan (PPG) at their surface membrane. This 
glycoconjugate functions as a shield against proteolytic damage by digestive enzymes 
(Secundino et al, 2010). Procyclic forms undergo several developmental stages in the 
vector (Sacks & Noben-Trauth, 2002; Kaye & Scott, 2011). Two days after the blood meal, 
they differentiate into nectomonad forms that correspond to longer and highly motile 
parasites, which eventually escape the PM, as it starts to dismember, in order to avoid 
excretion. Parasites migrate anteriorly, oriented by chemotactic gradients of molecules like 
sugars, and insert their flagella in the thoracic gut epithelia to effectively avoid defecation 
(Bates, 2007; Bates, 2008). This attachment is mediated by promastigotes’ LPG and lectins 
expressed by epithelial cells (Sacks et al, 1995). LPG is extremely polymorphic and is one 
of the most determinant factors for species-specific vectors (Bates, 2007; Bates, 2008). As 
soon as the midgut empties, nectomonads differentiate into shorter and replicative 
leptomonads that synthesize a secretory form of the PPG, one of the major components of 
the promastigote secretory gel (PSG). Interestingly, the continuous production of PSG leads 
to the generation of a PSG plug that occupies the thoracic midgut in a great extent (Bates, 
2007). Some leptomonads differentiate into leaf-shaped haptomonads that attach to the 
stomodeal valve and corrupt its structure and function through the secretion of a chitinase, 
which is important for both vector colonization and transmission (Rogers et al, 2008).  
Around day 5, the midgut has already emptied all the reminiscences from the blood 
meal and the PSG occupies a considerable area of the anterior part of the midgut. During 
the production of the PSG, many leptomonads undergo metacyclogenesis, a process that 
leads to the differentiation into metacyclic promastigotes, the final stage of the parasite in 
the sand fly. Metacyclics are smaller than nectomonads, displaying a flagellum that is longer 
than the cell body (Bates, 2007). An active autophagic pathway is critical for 
metacyclogenesis, mostly to enable parasite survival under starvation, considering nutrients 
are probably limited at this point (Besteiro et al, 2006, Bates, 2008). Figure 11 illustrates 
Leishmania development in the sand fly vector from procyclic promastigote to metacyclic 
promastigote forms.  
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Figure 11. Leishmania development in the sand fly vector. The developmental 
sequence of the five major promastigote forms: procyclic, nectomonad, leptomonad, 
haptomonad and metacyclic promastigotes. Adapted from Bates, 2007. 
 
Sand flies feed on the emerging blood from wounded superficial vessels and keep 
it fluid by continuously secreting saliva (Bates, 2007, Bates, 2008). They ingest the blood 
through the proboscis and the most accepted hypothesis is that the parasites transmitted 
to the mammalian host are regurgitated (Fig. 12). When an infected fly tries to feed, the 
presence of the PSG plug blocks the blood entrance in the midgut, therefore, the fly must 
first regurgitate part of that plug to allow the blood flow passage (Rogers et al, 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Sagital section of Leishmania infected female sand fly. The upper panel 
depicts the position of the PSG plug within the anterior midgut and foregut. The plug must 
be partially regurgitated (1) before the blood feeding can occur (2), and consequently 
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injecting metacyclic promastigotes and the PSG in the skin of the host. The lower panel 
displays at detail of the anterior midgut and the foregut: the PSG plug exerts pressure on 
the stomodeal valve, extending into the pharynx region. Metacyclic promastigotes are 
concentrated in the anterior pole of the plug, but can be found along the foregut in both the 
cibarium and the proboscis. Adapted from Bates, 2007. 
 
The damage to the stomodeal valve induced by the parasite secreted chitinase also 
plays a contribution, as this valve remains open, promoting the reflux of the parasites from 
the midgut to the mouth (Rogers et al, 2008). The formation of the PSG plug and the 
regurgitation look like an efficient mechanism the parasite has evolved in order to condition 
the fly and facilitate transmission. 
 
5.2. Interaction with the mammalian host 
Leishmania parasites have evolved different strategies in order to manipulate and 
subvert the cellular machinery. From the silent entry in the host cells to the interference with 
signalling pathways that trigger the immune response or from hijacking the host cell 
metabolism to the manipulation of apoptotic and autophagic pathways, are among the arms 
of this successful parasite.  
 
5.2.1. Host cell invasion and the establishment of infection  
During Leishmania transmission, apart from virulent metacyclic promastigotes, dead 
parasites and PPGs are also inoculated in the skin of the mammalian host during the blood 
meal (Van Zandbergen et al, 2006).  Neutrophils and MØs are rapidly recruited to the site 
of the sand fly bite (Kaye & Scott, 2011; Peters et al, 2008; Van Zandbergen et al, 2004), 
inclusively, the inoculated PPGs are strong stimulators of MØ recruitment (Rogers et al, 
2009; Rogers et al, 2010). On the other hand, dead parasites seem to be required for an 
efficient infection, as they expose phosphatidylserine (PS) in the outer leaflet of the plasma 
membrane, allowing a silent entry in neutrophils (Peters et al, 2008; Van Zandbergen et al, 
2006). This silent invasion triggers the production of anti-inflammatory cytokines like TGF-
β (Fadok et al, 1998). Leishmania parasites release Leishmania chemotactic factor (LCF) 
that attracts neutrophils and interacts with lipoxin A4 receptors (ALX), deactivating their 
oxidative burst (Van Zandbergen et al, 2002; Wenzel & Van Zandbergen, 2009). 
Leishmania also produces an inhibitor of the neutral elastase, one of the most important 
proteases involved in the neutrophils’ microbicidal response (Faria et al, 2011). However, 
promastigotes do not differentiate into amastigotes inside these phagocytes. Therefore, 
neutrophil infection is transient and following apoptosis, both MØs and DCs remove their 
apoptotic bodies, which contain Leishmania parasites (Peters et al, 2008; Van Zandbergen 
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et al, 2004). Overall, MØs are indeed the most important cells regarding infection 
establishment and persistence (Kaye & Scott, 2011; Van Zandbergen et al, 2004), and this 
way parasites manage to reach their primary host cell in disguise, using the so-called 
“Trojan Horse” strategy (Afonso et al, 2008). 
The very first interaction of the promastigotes with the MØ is flagellum-mediated, as 
this may induce the release of survival factors by the parasite in order to modulate the 
phagocytic process (Forestier et al, 2011; Rotureau et al, 2009). As depicted in figure 13, 
there are several MØ receptors involved in Leishmania recognition and uptake, including 
complement (CRs), mannose (MRs), fibronectin (FnRs) and Fcγ receptors (FcγRs) 
(Podinovskaia & Descoteaux, 2015; Ueno & Wilson, 2012; Walker et al, 2014). It is 
noteworthy that different receptors may be involved in promastigotes or amastigotes 
recognition and uptake.  
 
Figure 13. Leishmania recognition and uptake by host cell receptors. Promastigotes 
are represented in blue, amastigotes in red, MØ in brown and PMN in green.  A) GP63, a 
metalloprotease highly expressed in promastigotes, cleaves C3 opsonins into C3b that 
binds CR1. CR1 and factor I cleave C3b into iC3b that binds CR3. CR3 may directly bind a 
yet unknown antigen present in the promastigote surface. LPG terminal sugars may be 
recognised by MRs, although not formally proven. GP63 also binds fibronectin, which 
bridges the binding to FnRs. B) GP63 is scarcely expressed in amastigotes, but so is LPG, 
allowing GP63 access to C3 and subsequently to CR3. Additionally, antibody and 
fibronectin binding to amastigotes allow their internalization via FcγRs and FnRs, 
respectively. C) At the inoculation site, after the sand fly bite, promastigotes enter 
predominantly in PMNs, like neutrophils, via CR3, and posteriorly enter MØ and DCs. Both 
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promastigotes and amastigotes may directly enter DCs via DC-SIGN, through a so far 
unidentified ligand. Adapted from Ueno & Wilson, 2012.  
 
Interestingly, different receptors may have a different impact on the infection course. 
For instance, CR-mediated uptake, via CR3 or CR1, inhibits inflammation, superoxide burst 
and lysosome markers accumulation, like cathepsin D or lysosome-associated membrane 
protein 1 (LAMP1), creating more favourable conditions for the parasite establishment 
(Ueno & Wilson, 2012). In contrast, Leishmania uptake mediated by any of the other three 
receptors can trigger more inflammatory conditions, which can result in parasite clearance 
(Ueno & Wilson, 2012). Leishmania attachment to the MØs is rather fast (10-20 minutes) 
(Forestier et al, 2011), however, the downstream events regarding the phagolysosome 
assembly depend on the host receptors involved in parasite recognition and uptake. If the 
phagolysosome biogenesis as well as parasite survival/clearance seem to be affected by 
receptor choice, parasite uptake does not (Podinovskaia & Descoteaux, 2015; Polando et 
al, 2013).  
Upon recognition at the host cell surface, promastigotes are internalized via 
calveolae composed of cholesterol-rich membrane lipid microdomains, contrasting with 
amastigotes in which phagocytosis seems to occur independently of such domains 
(Chattopadhyay & Jafurulla, 2012; Rodriguez et al, 2011; Roy et al, 2014). Interestingly, the 
disruption of lipid microdomains, through cholesterol depletion, compromises Leishmania 
promastigotes uptake via nonopsonic pathways, however, opsonized parasites are 
internalized normally (Chattopadhyay & Jafurulla, 2012). Actually, Leishmania 
promastigotes promote lipid microdomain formation, by activating the host acid 
sphingomyelinase that produces ceramide, an important component (Majumder et al, 
2012). Leishmania also depends on actin-mediated uptake, thus the integrity of the host 
actin cytoskeleton is necessary (Roy et al, 2014).  
Several human pathogens infect, survive and proliferate inside MØs, however, the 
great majority of them subverts or escapes the phagocytic pathway (McConville et al, 2007). 
But not Leishmania. Interestingly, Leishmania parasites manage to counteract the hostile 
environment of the phagolysosome, successfully surviving and proliferating in this 
compartment (McConville et al, 2007).  
Leishmania LPG is inserted into the above described cholesterol-rich lipid 
microdomains of the phagosome, excluding the exocytosis regulator synaptogamin V and 
subsequently preventing the incorporation of cathepsin D and H+-ATPases (Vinet et al, 
2009). These Leishmania-containing vacuoles poorly interact with endosomes and 
lysosomes, and the recruitment of late endosomal/lysosomal proteins such as LAMP1 and 
Rab7 occurs with a delayed kinetics (Scianimanico et al, 1999). Moreover, LPG scavenges 
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reactive oxygen species (ROS) and prevents their generation by inhibiting NADPH-
dependent oxidases (NOX) recruitment to the phagosome membrane (Lodge et al, 2006; 
Spaeth et al, 2003). These mechanisms temporarily preclude acidification as well as 
activation of the microbicidal machinery, providing sufficient time for promastigotes to 
differentiate into amastigotes (Vinet et al, 2009; Walker et al, 2014). Eventually, some 
lysosomes may fuse with the parasitophorous vacuole (PV) leading to a pH decrease, which 
is accompanied by LAMP1, Rab7 and lysosomal hydrolases acquisition (Antoine et al, 
1998; Forestier et al, 2011).  
Promastigotes differentiation into amastigotes is thought to be mainly triggered by 
the increase in the temperature and the decrease in pH, and it has been suggested the first 
prevails over acidification (Alcolea et al, 2010).  
 
5.2.2. Playing with the host metabolism and signalling cascades: the path 
to intracellular survival and immune evasion 
Once Leishmania parasites reach their definitive host cell, MØs, they apply great 
efforts in order to protect their niche, and one of them is to increase the life span of the host 
cell through apoptosis inhibition. This buys promastigotes time to differentiate into 
amastigotes that are then fully adapted to the life in the phagolysosome (Cecílio et al, 2014; 
Moore & Matlashewski, 1994). However, it is important to mention parasites can delay MØs 
death but cannot avoid it. Some studies also point to Leishmania-mediated induction of host 
cell autophagy, which has been suggested to have an impact on the outcome of the infection 
(Cyrino et al, 2012; Pinheiro et al., 2009).  
Amastigotes survive and multiply in the phagolysosome using a wide range of 
strategies. To begin with, Leishmania parasites are well equipped with a vast antioxidant 
machinery, from which trypanothione synthetase (TryS) and trypanothione reductase 
(TryR) must be highlighted (Tovar et al, 1998). Apart from that, they also manage to 
deactivate ROS generation machinery (Lodge & Descoteaux, 2006), as well as nitric oxide 
(NO) production, in the case of the latter, the expression of the inducible nitric oxide 
synthetase (iNOS) can be suppressed by glycosylinositolphospholipid (GILP), a component 
of the amastigotes’ glycocalyx (Proudfoot et al, 1996). Additionally, these parasites 
profoundly rely on heat shock proteins (HSPs) as they alleviate thermal, acidic and oxidative 
stress (Bifeld & Clos, 2015; Hübel et al, 1995).   
Leishmania amastigotes seem to have more complex nutritional requirements than 
those of the majority of prokaryotes and fungal pathogens. However, the phagolysosome 
must somehow be a permissive niche (McConville et al, 2007).  
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Iron acquisition is a classic example of how Leishmania is able to subvert the host 
cell metabolism in its favor, in a fashion we can designate as metabolic virulence (Fig. 14). 
Iron uptake in Leishmania is mediated by three major proteins: ferric iron reductase (LFR), 
ferrous iron transporter (LIT1) and heme transporter (LHR1). The host is able to reduce iron 
availability in the phagolysosome by expressing NRAMP1, and in response, Leishmania 
produces tryparedoxin peroxidase (TXNPx) that inhibits this iron efflux pump, and also 
upregulates LIT1 (Arango-Duque & Descoteaux, 2015; Podinovskaia & Descoteaux, 2015). 
The inhibition of NRAMP1-mediated iron efflux leads to intracellular iron depletion that 
triggers an upregulation of transferrin receptors (TfRs), and therefore iron uptake through 
the endocytic network. By an unknown mechanism, Leishmania infected cells also express 
higher levels of hepcidin, which leads to the degradation of the iron exporter ferroportin 
(Arango-Duque & Descoteaux, 2015; Podinovskaia & Descoteaux, 2015), contributing to 
iron retention inside MØs.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Iron acquisition by Leishmania in macrophages. Iron uptake inside the 
phagolysosome by Leishmania parasites is mediated by a heme transporter (LHR1) and an 
ion transporter (LIT1) in the heme and ferrous ion form, respectively. Additionally, 
Leishmania ferric reductase, LFR1, converts ferric iron to ferrous iron, and the latter is 
transported by LIT1. Leishmania expresses TXNPx that inhibits the host iron efflux pump 
NRAMP1, expressed in the phagolysosome, increasing iron reserves inside this 
compartment and depleting the cytosolic ones. The depletion of intracellular iron triggers 
the upregulation of TfRs enhancing iron uptake by receptor-mediated endocytosis. 
Leishmania infected macrophages also express higher levels of hepcidin that induces iron 
exporter ferroportin degradation, reinforcing iron retention inside these phagocytes. 
Adapted from Podinovskaia & Descoteaux, 2015.  
 
It has also been reported that L. infantum is able to subvert MØ metabolism by 
modulating important energetic sensors, such as the SIRT1-LKB1-AMPK axis, ultimately 
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triggering the switch from an early aerobic glycolysis to a later mitochondrial metabolism in 
the host, which has a crucial impact on parasite survival (Moreira et al, 2015). It has also 
been shown that GP63 released by L. donovani in the liver cleaves Dicer preventing mir-
122 maturation, which is involved in lipid metabolism, leading to a decrease in cholesterol 
levels in the serum, ultimately promoting parasite growth (Descoteaux et al, 2013).  
Moreover, this successful parasite also employs numerous strategies to efficiently 
evade the immune system. The Th1/Th2 paradigm is the hallmark of the immune response 
to Leishmania parasites. The production of IL-12 by MØs and DCs induces naïve CD4+ T 
cells towards an IFN-γ producing Th1 phenotype, which leads to MØ M1 activation and 
parasite clearance (Diaz-Gandarilla et al, 2013). Th2 cytokines, such as IL-4 or IL-10 and 
TGF-β in the case of CL or VL, respectively, induce an M2 MØ phenotype, related with 
disease susceptibility and progression (Gautam et al, 2011). Therefore, Leishmania 
parasites appear to modulate the immune response towards a Th2 phenotype, although 
this strict polarization seems confined to murine models, as in humans this is not completely 
applicable (McMahon-Pratt & Alexander, 2004; Nylen & Gautam, 2010). Leishmania is able 
to interfere with normal cytokine production, modulate toll-like receptor (TLR) signalling (Fig. 
15) or impair the cellular function, by compromising antigen presentation or inducing cellular 
anergy or exhaustion (Cecílio et al, 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Leishmania compromises TLR and cytokine signalling pathways. In the 
picture, GP63 is highlighted. GP-63 cleaves and activates the host protein tyrosine 
phosphatases (PTPs), such as SHP-1, PTP1B and TCPTP. For instance, SHP-1 is involved 
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in the downregulation of IRAK-1, MAPK and JAK/STAT signalling pathways and PTP1B 
inactivates JAK2. Arrows indicate activation; red crosses indicate signalling alteration or 
inhibition; abrogated lines indicate downregulation of specific kinases. Adapted from Olivier 
et al, 2012. 
 
Regarding the interference with cytokine production, Leishmania can modulate 
several cellular signalling pathways (Figs. 15 and 16). For instance, it can attenuate protein 
kinase C (PKC) activity (Bhattacharyya et al, 2001; Olivier et al, 1992; Fig. 16) or activate 
mitogen-activated protein kinase (MAPK) phosphatases (MKPs), MKP-1 and MKP-3, 
interfering with extracellular signal-regulated kinases (ERK), ERK1 and ERK2, and p38 
MAPK signalling, which regulate IL-10 and IL-12 production by infected MØs (Mathur et al, 
2004). As for the impairment on antigen presentation, one of the mechanisms Leishmania 
employs for the purpose is the induction of ceramide de novo synthesis, which in abundance 
eventually displaces cholesterol, disrupting the membrane lipid microdomains’ architecture 
(Majumder et al, 2012). Leishmania can also drive cells unresponsive to molecules such as 
interferon-γ (IFNγ), for instance by dysregulating Janus kinase (JAK)/signal transducer and 
activator of transcription 1 (STAT1) pathway, through membrane cholesterol depletion (Sen 
et al, 2011; Fig. 15). Moreover, the metalloprotease GP63 may cleave the mammalian 
target of rapamycin (mTOR), inhibiting mTOR complex 1 (mTORC1) formation. 
Consequently, the translational repressor 4E-BP1 will not be inactivated by mTORC1-
mediated phosphorylation, and will inhibit the eukaryotic initiation factor 4F (elF4F), leading 
to an overall translation repression, including interferon response-related proteins (Jaramillo 
et al, 2011; Fig. 16).  
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Figure 16. Leishmania GP63 mediated impact on host cell signalling and functions. 
GP63 can cleave several important proteins: the myristoylated alanine-rich C kinase 
(MARKs), which is a critical substrate to PKC-dependent signalling; the adaptor molecules 
p130CAS and PEST, involved in the actin cytoskeleton remodelling; mTOR, affecting 
translation initiation and consequently type I IFN production, as well as transcription factors 
such as NF-kB and AP-1. Arrows indicate GP63 targets that are involved in signalling 
pathways; red crosses indicate signalling cascade alteration; abrogates lines indicate 
functional inhibition. Adapted from Olivier et al, 2012. 
 
Recently, a study even described parasite-driven changes in the MØ methylome. 
Infection with L. donovani modifies the host DNA methylation status, shutting down genes 
that play an important role on antimicrobial responses, thus facilitating parasite survival and 
persistence (Marr et al, 2014). One of the hypothesis is that parasites export DNA 
methyltransferases or methylation inhibitors, potentially via exosomes (Marr et al, 2014). 
Figure 17 illustrates some of the most important Leishmania virulence factors. 
 
 
 
 
 
 
 
 
Chapter I – Leishmania spp. and leishmaniasis 
73 
 
 
Figure 17. Leishmania virulence factors. The image depicts GPI-anchored surface 
molecules, such as GP63, LPGs, PPGs and GILPs, which are mainly associated to 
membrane microdomains. Some virulence factors that are not anchored to the membrane 
can be released via exosomes (GP63) or via classical secretion through the flagellar pocket 
(GP63, PPGs, secreted acid phosphatases (SAPs) and cysteine proteases (CPs)). Adapted 
from Olivier et al, 2012. 
 
In summary, Leishmania is a well-adapted and successful parasite that has evolved 
many clever and elegant mechanisms to enter, survive and proliferate inside the host cells. 
These parasites are masters of disguise, experts in deceiving the host immune system and 
exploiting the cellular machinery and resources to their best benefit.  
 
6. Leishmaniasis diagnosis  
As previously described, leishmaniasis can lead to a broad spectrum of clinical 
manifestations, however, most of the symptoms associated with the disease are not 
specific. Actually, it can mimic other pathologies, rendering the clinical diagnosis harder. In 
order to achieve a differential diagnosis, which is critical to confirm a clinical suspicion, 
different methods can be employed (Herwaldt, 1999). Those include direct parasite 
observation in infected tissues, immunological detection of Leishmania antigens or anti-
Leishmania antibodies and parasite DNA or RNA detection in tissues samples.  
The direct observation of amastigotes in clinical samples is the gold standard for 
leishmaniasis diagnostic, and naturally, the sensitivity will depend on the parasite number 
and their dispersion in the sample (Herwaldt, 1999; Murray et al, 2005). The biological 
specimens that are more commonly analysed are skin biopsies, in the case of CL and ML, 
or spleen, bone marrow and lymph nodes aspirates, in the case of VL. Some of the major 
disadvantages of this method are the frequent requirement of invasive procedures for 
sample recovery as well as the impossibility of implementation outside a hospital/laboratory 
(Murray et al, 2005).  
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Classic serological diagnosis of leishmaniasis relies mostly on enzyme-linked 
immunosorbent assay (ELISA) based techniques. Due to their high sensitivity and 
specificity, as well as requirement for low technological expertise (eg. 
immunochromatography-based tests), some of these methods have become reference 
(Chappuis et al, 2006). In particular, when the purpose is the detection of anti-Leishmania 
antibodies, two important considerations must be made. Firstly, in some cases, Leishmania-
specific antibodies may persist after cure, therefore these methods do not allow the 
distinction between resolved and active infections, leading to false positive results 
(Santarém et al, 2005). On the other hand, in immunocompromised patients, false negative 
results may arise merely due to immunosuppression. Obviously, the sensitivity and 
specificity of these methods deeply depend on the antigen used. The recombinant K39 
(rK39) protein is the one of the most important antigens used for VL and PKDL diagnosis, 
inclusively an rK39-based dipstick test is commercially available (Sundar et al, 2002). Of 
course, serological methods are indirect approaches that can raise problems in endemic 
areas where the presence of antibodies or parasite material may simply indicate contact 
with the parasite and not necessarily disease (Santarém et al, 2005).   
Another direct method is based on the use of molecular biology techniques, by 
detecting Leishmania unique DNA or RNA sequences (eg. mitochondrial minicircles, rRNA 
genes), which confers a high sensitivity and specificity (Reithinger & Dujardin, 2007). 
Assays based on polymerase chain reaction (PCR) are the major molecular diagnostic 
approach in developed countries and are able to detect Leishmania nucleic acids only a few 
weeks after the symptoms appearance, especially appropriate for samples with low parasite 
loads (eg. blood), displaying high specificity (~100%) and high predictive power (Reithinger 
& Dujardin, 2007). Inclusively, a positive PCR is usually required for the differential 
diagnosis that precedes therapy initiation (Reithinger & Dujardin, 2007), and later to confirm 
a successful treatment in the case of VL (Maurya et al, 2005). PCR-based diagnosis is also 
particularly important in the case of Leishmania/HIV co-infected patients (De Doncker et al, 
2005). The combination of PCR with restriction fragment length polymorphism (RFLP) 
sequencing further allows Leishmania spp. identification. Of course, one of the biggest 
disadvantages is that PCR-based techniques are restricted to laboratory use. 
Overall, in non-endemic countries, molecular approaches prevail over microscopic 
analysis, contrasting with the endemic regions, where the opposite is observed (Reithinger 
& Dujardin, 2007).  
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7. Leishmaniasis control 
In order to accomplish a direct control of the disease, WHO prioritizes the use of 
efficient diagnosis tools, appropriate therapeutical options and compulsory report of all 
cases of leishmaniasis. Due to the absence of human vaccines, leishmaniasis control relies 
mainly on chemotherapy and vector/reservoir control (Kedzierski, 2010).  
 
7.1.  Control of vectors and reservoirs 
There are different indirect strategies to control disease transmission, through the 
control of the vector and the reservoirs, or the adoption of personal protection measures.  
Sand flies rest in dark moist places, typically only a few hundred meters apart from 
their breeding site. Following urbanization in the periphery of cities, sometimes there is an 
invasion of the vector breeding grounds, leading to an increase in the disease incidence. 
Feasible measures to control the sand fly vector include deforestation near urbanized 
grounds as well as the use of insecticides. Focusing on the latter, the use of 
dichlorodiphenyltrichloroethane (DDT) had a massive impact on the vector control in 
endemic areas, with a particular highlight to India, where a dramatic reduction in the number 
of VL cases was observed in some regions (Vanlerberghe et al, 2007). DDT has nefarious 
effects on the environment and human health and has been extensively replaced by 
synthetic pyrethroids (eg. Deltamethrin or cyhalotrin), which have been proven equally 
effective (Davies et al, 2000).  
The control of the reservoirs is also extremely important for both CL and VL. In the 
case of zoonotic VL, we must highlight the importance of the canine reservoir, in which 
measures must be taken in order to both protect the dogs and restrict the availability of 
parasite reservoir. For this purpose, several measures can be adopted such as euthanasia 
of infected dogs, which showed a limited impact, use of insecticide-based devices, like 
deltamethrin-impregnated collars (Gramiccia & Gradoni, 2005) and dog vaccination 
(Gradoni, 2015). Currently, only two vaccines that consist of parasite purified fractions with 
saponin derivatives as adjuvants conferred a significant protection, and have been 
registered as canine vaccines: FML-QuilA (Leishmune®) in Brazil, and LiESP/QA-21 
(CaniLeish®) in Europe (Gradoni, 2015). Of course, these measures will have a reduced 
impact if they are not adopted for the whole canine population and/or if there is still an 
unknown sylvatic reservoir that maintains a sufficient number of infected animals to 
perpetuate the infectious cycle (Gramiccia & Gradoni, 2005).  
Finally, WHO also advises the adoption of personal preventive measures such as 
the use of mechanical barriers, like insecticide-impregnated bednets, avoidance of outdoor 
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activities during the periods when sand flies are more active (twilight to morning fall), 
wearing protective clothing or use of insect repellents (Gramiccia & Gradoni, 2005).  
 
7.2.  Chemotherapy: the search for new drugs urges 
In the last seven decades, the chemotherapy against this disease has relied mostly 
on pentavalent antimonium-based (SbV) drugs, and the commercially available 
formulations include stibogluconate (Pentostam®) and meglumine antimoniate 
(Glucantime®) (Croft & Olliaro, 2011). It is generally accepted that SbV is a prodrug, 
bioactivated through reduction to SbIII. This bioactivation can occur inside the 
phagolysosome or inside the parasite (Frezard et al, 2009). Glutathione (GSH), present 
mainly in the MØs cytosol, and cysteine or cysteinylglycine thiols, found mostly inside the 
lysosomes, can actively reduce SbV (Ferreira Cdos et al, 2003). The entry of SbIII in the 
parasite is mediated by aquaglyceroporin AQP1 (Gourbal et al, 2004). Inside Leishmania 
parasites, the most abundant thiol is trypanothione, a glutathionespermidine conjugate, 
which is able to reduce SbV as well (Ferreira Cdos et al, 2003). Additionally, Leishmania 
enzymes such as thiol dependent reductase 1 (TDR1) and antimoniate reductase have also 
been implicated in SbV bioactivation (Denton et al, 2004). The mechanism of action of these 
drugs is not fully disclosed, but it is known that SbIII is the active species that ultimately 
leads to parasite death, and DNA fragmentation suggests a role for apoptosis (Sudhandiran 
& Shaha, 2003). There are some evidences supporting trypanothione reductase or 
zincfinger proteins as possible molecular targets (Cunningham & Fairlamb, 1995; Demicheli 
et al, 2008). Some studies also suggest antimonials compromise vital metabolic processes 
like fatty acid oxidation or glycolysis (Chakravarty & Sundar, 2010). Moreover, SbV is 
capable of forming complexes with ribonucleosides, which can inhibit purine transporters or 
directly interfere with purine salvage pathway in Leishmania (dos Santos Ferreira et al, 
2006).  
These drugs require repeated parenteral administration during long periods of time, 
unleash several adverse effects (including cardiotoxicity and pancreatitis) and have been 
stroked by the emergence of resistances over usage (Ashutosh et al, 2007; Croft & Olliaro, 
2011). Actually, antimonial resistance is a severe issue in endemic areas, and several 
resistance mechanisms have been described over the years, including loss of AQP1 activity 
(Gourbal et al, 2004), extrusion of trypanothione/SbIII complexes by ATP-binding cassette 
(ABC) transporters, sequestration of SbIII in vacuoles (Legare et al, 2001) or 
downregulation of MAPK1 that is a negative regulator of P-glycoprotein type efflux pumps 
(Garg & Goyal, 2015). These drugs are still highly effective in areas where resistance has 
not emerged yet (Vanlerberghe et al, 2007). Moreover, the combination of antimonial drugs 
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with allopurinol, a xanthine oxidase (XO) inhibitor, and the antibiotic paromomycin have 
much improved the curative efficiency (Gutiérrez et al, 2015).  
Pentamidine, an aromatic diamine, is commonly used as second line drug against 
leishmaniasis and is also used in the treatment of sleeping sickness (first stage). It has been 
suggested it enters Leishmania promastigotes via arginine and polyamine transporters 
(Kandpal & Tekwani, 1997). In the case of T. brucei, this task is on P2 adenosine transporter 
charge, although at least other two transporters can uptake the drug, as AQP2 (Baker et al, 
2012; De Koning, 2001). Although its mechanism of action remains unclear, some 
evidences support the inhibition of polyamine biosynthesis, DNA minor groove binding and 
effect on mitochondrial inner membrane potential (Bray et al, 2003; Croft et al, 2006). 
Resistance to pentamidine has been described for trypanosomes and several Leishmania 
species. In the case of Leishmania, ABC transporters have been implicated in the 
resistance (Coelho et al, 2007). In T. brucei, the resistance mechanisms have been more 
broadly dissected, in particular, AQP2 has been extensively studied (Alsford et al, 2012; 
Baker et al, 2015; Graf et al, 2015; Munday et al, 2014). The latter is a determinant of 
melarsoprol-pentamidine cross-resistance in lab strains and recently the chimerization at 
the AQP2-AQP3 tandem locus was found responsible for this cross-resistance in clinical 
isolates (Graf et al, 2015). The use of pentamidine in the treatment of VL is hindered by the 
higher toxicity it inflicts in the patients when compared to antimonials (Jha, 1983). However, 
it is still a good alternative for CL, as it provides high cure rates with short periods of 
treatment an even performs better than antimonials for some CL species (Berman, 1997).  
Amphotericin B (amphB), a macrolide antifugal, which can be formulated as a 
deoxycholate salt or even better, delivered by liposomes (AmBisome), is extremely efficient 
against VL and a very attractive alternative in areas of antimonial resistance (Thakur et al, 
1993). It was developed as a systemic antifugal drug that targets ergosterol-like sterols, and 
ergosterol happens to be the more abundant sterol in Leishmania membranes (Berman et 
al, 1986; Bern et al, 2006). Besides amphB direct effect on the parasites through formation 
of aqueous pores in the plasma membrane, AmBisome seems to interact with the 
membrane sterols of MØs, preventing Leishmania entry as well (Paila et al, 2010; Ramos 
et al, 1996). In spite of its high efficacy, amphB has severe adverse effects, including a 
pronounced nephrotoxicity. The use of the liposomal formulations has helped reducing the 
toxicity and extend the plasma half-life of this compound, however, it is not an affordable 
alternative in developing endemic countries and therefore not a first line therapy on those 
(Bern et al, 2006). In the treatment of VL caused by L. infantum in Southern Europe, 
AmBisome is the first line treatment (Vanlerberghe et al, 2007). Few cases of resistance 
have been reported and the underlying mechanisms are poorly understood (Brotherton et 
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al, 2014). Laboratory acquired resistance has been associated to ergosterol deficiency in 
the parasite membrane or the enzyme S-adenosyl methionine transferase, which is involved 
in the ergosterol synthesis (Mbongo et al, 1998; Pourshafie et al, 2004). Recently a large 
scale proteomic study identified several proteins that were differentially expressed in amphB 
resistant parasites, among them enzymes involved in metabolic pathways (glycolysis, TCA), 
in transcription and translation, in ROS scavenging and also HSPs (Brotherton et al, 2014).  
Paromomycin, an aminoglycoside antibiotic, has a similar efficacy to amphB, with 
less side effects, a shorter treatment and has been approved for the treatment of VL in India 
(Gutiérrez et al, 2015; Musa et al, 2010). It also requires parenteral administration. It has 
also shown some interesting results for CL treatment (Ben Salah et al, 2009). The 
mechanism of action is not completely clear, but it seems to interfere with mitochondrial 
function and protein translation, in the case of the latter through direct interference with the 
ribosomes (Jhingran et al, 2009). Aminoglycosides have strong potential for the 
development of resistances: a decrease in the uptake, coupled with drug efflux have been 
implicated in laboratory-induced resistance (Bhandari et al, 2014; Jhingran et al, 2009). 
Moreover, the combination of antimonial drugs with paromomycin results in a highly 
efficacious regimen accompanied by a reduction of the side effects of both drugs (Berman, 
1997).  
One of the great efforts in drug discovery against leishmaniasis was to find an 
efficacious oral drug. The first oral compound used against leishmaniasis was 
ketoconazole, an imidazole derivative that inhibit ergosterol biosynthesis. This compound, 
as well as itraconazole and fluconazole, which are also imidazole derivatives, present 
variable success rates against different causative species of CL and in general not very 
promising in monotherapy against VL (Navin et al, 1992; Rashid et al, 1994). They may 
have some interest in the context of a combination therapy against VL (Shakya et al, 2011). 
Allopurinol, a hypoxanthine analogue and xanthine oxidase (XO) inhibitor, inhibits purine 
anabolism in Leishmania (LaFon et al, 1985). Similarly to the imidazole derivatives, it is not 
valuable in monotherapy, in combination it displays some success in CL but not as 
promising in VL (Momeni et al, 2002; Ramesh et al, 2010).  
Miltefosine is the only oral drug prescribed against VL, and it was a major 
accomplishment in the field. It was originally developed as an anti-cancer drug and it has 
been proven highly efficacious for the treatment of CL, ML and VL (Bhattacharya et al, 2007; 
Tappe et al, 2010). It can be safely used in children and treats patients who were refractory 
to antimonials (Berman, 2008). Nevertheless, miltefosine displays an adverse effect that 
constitutes a great limitation to its use in women of reproductive age – its teratogenicity 
(Berman, 2008). Its mechanism of action remains unknown but it seems one of the 
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requirements is the intracellular accumulation of the drug, which is mediated by two 
transporters, ultimately leading to the development of an apoptosis-like death (Paris et al, 
2004). Moreover, some studies indicate it may be related to a disturbance in phospholipids 
synthesis (Rakotomanga et al, 2007; Zufferey & Mamoun, 2012). Additionally, regarding 
two particular characteristics of miltefosine, it is indeed much prone for resistance 
emergence. One is that as an oral drug, the treatment may often be unsupervised and non-
compliance of the treatment can lead to subtherapeutical doses in the patients. The second 
concerns the long half-life of this drug, as it can still be detected in the blood 5 months after 
the treatment (Berman, 2008). 
Laboratory-induced resistant strains unravelled some of the potential resistance 
mechanisms, namely mutations in miltefosine transporters and drug efflux (eg 
overexpression of glycoprotein MDR1) (Perez‐Victoria et al, 2003). In a recent study, a 
transcriptomic analysis of resistant versus susceptible strains to miltefosine revealed 
differential expression of genes related to DNA repair/replication machinery, protein 
translation and folding, lipid metabolism, antioxidant defense and transporters activity 
(Kulshrestha et al, 2014). Miltefosine is certainly the most cost-effective option to treat 
leishmaniasis in the areas of antimonial resistance, however, its use as first line therapy is 
inevitably limited by its teratogenicity and high potential for resistance development 
(Vanlerberghe et al, 2007).  
Sitamaquine (8-aminoquinoline) was specifically developed for VL treatment, 
actually in CL the results were disappointing. In high concentrations it affects parasite 
motility, morphology and growth, however, its mechanism of action is not clear. It seems to 
be inserted in biological membranes through electrostatic interactions and accumulates in 
acidocalcisomes (Lopez‐Martin et al, 2008). More studies are still required to further 
disclose its mode of action, adverse effects, resistance-associated mechanisms in order to 
become or not a reasonable alternative to the already established VL treatments (Loiseau 
et al, 2011).  
Tables 1 and 2 summarize the treatment details and complications and the 
advantages /disadvantages, respectively, for the most commonly used drugs against 
leishmaniasis.  
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Table 1. Summary of the most important drugs used in the treatment of leishmaniasis. 
Modified from De Menezes et al, 2015 
 
 
 
 
Table 2. Advantages and disadvantages of the most important drugs used in the treatment 
of leishmaniasis. Modified from De Menezes et al, 2015 
 
 
It is also important to highlight the particular case of Leishmania/HIV co-infection. A 
successful therapy counts on a competent immune system, thus for instance in the case of 
this co-infection much will depend on the immune status of the patient. Actually, these 
patients tend to have lower cure rates, higher toxicity/fatality rates and predisposal for 
relapses with complicated parasitological contours (Alvar et al, 2008). The latter makes 
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secondary prophylaxis a reasonable measure (Lopez‐Velez et al, 2004). The lack of uniform 
clinical data hinders the establishment of optimal treatment regimes (Alvar et al, 2008).  
As final remark on this subject, leishmaniasis is certainly one of the most neglected 
infectious diseases when it comes to drug development (Modabber et al, 2007). Although 
there are many treatment options available, they present several preoccupying limitations 
concerning toxicity, cost, administration route and importantly, resistance emergence, 
rendering the search for new drugs and novel targets a priority (Guerra et al, 2011).  
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The general metabolism is relatively conserved in eukaryotic cells, however, 
trypanosomatids display distinctive features concerning particular enzymes and pathways, 
compartments as well as sensing and regulatory mechanisms. This uniqueness can be 
explored in order to dissect novel and specific molecular targets, ultimately allowing rational 
design of anti-parasitic drugs.  
 
1. Searching for new drugs and novel drug targets 
In the beginning of the nineteenth century, drug discovery field was revolutionized 
as it became possible to isolate the active molecules responsible for the observed 
pharmacological effects (Terstappen et al, 2007). In the 1990s, following the advances in 
molecular biology and biochemistry, testing molecules in complex systems was abandoned, 
in favour of a target based approach (Fig. 18). This approach, more rational and efficient in 
theory, was further supported by the rise of a post-genomic era, with the sequencing of the 
human and several pathogens genomes (Terstappen et al, 2007). However, currently this 
target based strategy, not as successful as initially expected, has been progressively 
replaced by a phenotypic-based strategy (Fig. 18).  
 
 
Figure 18. Drug discovery approaches: phenotype based versus target based. In the 
phenotype based approach, lead compounds are firstly obtained, followed by target 
deconvolution, whereas in the target based approach, firstly the molecular targets are 
validated, and only then screened to identify lead molecules. Adapted from Terstappen et 
al, 2007.  
 
Therefore, there is a renaissance of a more holistic approach, in which compounds 
are tested in living cells or model organisms, such as nematodes or zebrafish. The most 
common is the use of cells in culture that are more compatible with high throughput 
screening (HTS) with a phenotypic readout. Moreover, cell lines can be genetically 
engineered to mimic aspects of the disease biology or to monitor the activation/inhibition of 
pathways that may be relevant for the process (Terstappen et al, 2007). HTS campaigns 
may comprise viability assays, making use of commercial reagents or reporter genes, such 
as fluorescent proteins or luciferase. Reporter genes can also be used to measure the 
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activation/inhibition of a certain pathway, for instance. In addition, phenotypic alterations 
like morphological changes can be measured using image based high content screening 
(HCS) systems, which use sophisticated algorithms for automated image acquisition and 
analysis (Terstappen et al, 2007).  
Focusing on neglected tropical diseases drug discovery, in the target based 
approach, screenings are designed in order to inhibit proteins that are essential for parasite 
survival and/or infectivity and absent or sufficiently different from the host at a structural 
level (Reguera et al, 2014). Over the years, many efforts have been made to identify 
essential genes in trypanosomatids, and the availability of genomic data on these parasites 
has been crucial for this purpose. Further, in silico HTS virtual screenings and docking 
procedures using 3D X-ray structured atomic coordinates or homology models enable 
structure-based design of new anti-parasitic drugs (Reguera et al, 2014).  
Nevertheless, target-based approach also has its drawbacks. For instance, in the 
case of Leishmania, a desired drug must be able to pass across several membranes and 
remain stable at acidic pH, considering amastigotes dwell in the phagolysosome. Moreover, 
the desired drug must not be metabolized to inactive molecules by host or parasite 
enzymes. It has also been observed that many compounds designed against specific 
targets often display a low selectivity (Reguera et al, 2014).  
Consequently, nowadays phenotype-based strategies comprising HTS of 
compound libraries using whole cell assays is a well-established approach for early drug 
discovery programs in neglected diseases (Faria et al, 2015c). This type of assay normally 
results in a simple readout, precluding the need for a validated target, which can be difficult 
to achieve. In contrast to a biochemical target based assay, the active compounds are 
discovered under physiologically relevant conditions (Faria et al, 2015c). Additionally, whole 
cell based assays have been quite successful in resulting in approved drugs for infectious 
diseases in general (Keller et al, 2011; Pink et al, 2005). 
In the case of trypanosomatids, several HTS assays have been developed (Faria et 
al, 2015c; Mackey et al, 2006; Moon et al, 2014; Siqueira-Neto et al, 2012; Sykes & Avery, 
2009a; Sykes & Avery, 2009b). For intracellular parasites, at least in the clinical relevant 
form, such as Leishmania or T. cruzi, these assays tend to be HCS based, and host cell 
and parasite segmentation may be achieved only by performing nucleic acid staining (Moon 
et al, 2014; Siqueira-Neto et al, 2012) or using transgenic parasites expressing reporter 
genes (Aulner et al, 2013; Sadeghi et al, 2015). In the case of extracellular parasites, as T. 
brucei, viability assays can be used, based on resazurin (Sykes & Avery, 2009b), sybr green 
(Faria et al, 2015c) or ATP levels measurement (Sykes & Avery, 2009a) assays.  
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Many different molecular or biochemical technologies may be used afterwards to 
identify the molecular targets of a compound. Importantly, there is a common aspect to all 
of them: at one stage the affinity between the compound and its putative target is exploited 
(Terstappen et al, 2007). Among the available technologies are affinity chromatography 
based methods, yeast and mammalian three-hybrid systems (Fig. 19), phage or RNA 
display-based methods or protein microarrays (Terstappen et al, 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Three hybrid systems for target deconvolution. The components are a 
DNAbinding domain fused to a ligand binding domain (DHFR), a ligand molecule (MTX) 
linked to the compound of interest and a component that consists of a transcriptional 
activation domain fused to a protein from a cDNA library. The binding of the compound to 
its target protein will allow the three components interaction, enabling the activation of a 
reporter gene expression. DHFR, dihydrofolate reductase; MTX, methotrexate. Adapted 
from Terstappen et al, 2007.  
 
The lead compounds, generated by either target or phenotype based approaches, 
must be tested in in vivo models of the diseases as part of their preclinical development. In 
neglected tropical diseases, the adoption of in vivo real time imaging systems, in which 
fluorescent or bioluminescent parasites are used is a great step forward (Calvo-Álvarez et 
al, 2015; Lewis et al, 2015; McLatchie et al, 2013; Mehta et al, 2008; Millington et al, 2010; 
Pulido et al, 2012). These techniques allow the reduction of the number of animals per 
experiment, as well as the collection of a lot of qualitative and quantitative information 
concerning the infection (Reguera et al, 2014). Not only can the parasite burden be 
extrapolated but also its distribution in the body, for instance in internal organs. In the 
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particular case of visceral models, bioluminescence performs better than fluorescence due 
to the poor penetration of the excitation light and tissue autofluorescence. However, in the 
case of CL and ML models, fluorescence would be more appropriate as it would not require 
the injection of a light-emitting substrate (Reguera et al, 2014). A good alternative is the use 
of infrared fluorescent proteins as the emission/excitation wavelengths penetrate well the 
tissues, minimizing the absorbance by haemoglobin, water, lipids as well as the light 
scattering (Calvo-Álvarez et al, 2015). 
In summary, public and private initiatives are supporting the drug discovery process 
in neglected tropical diseases. The primary goal is to find molecules with high selectivity 
indexes in the first drug-screening phase, which also present good results in a preclinical 
model of the disease. Often promising hit compounds selected in target-based screenings 
ultimately fail due to poor permeability, enzymatic inactivation, among others. More recently, 
target free HTS has emerged as the most promising strategy, however, for this purpose it 
is imperative to find a unanimous screening model. Such a model must comprise the 
interaction of the parasite forms with the definitive host cells, and ideally resemble the 
pathophysiological environment of infected spleens and lymph nodes, combined with 
cutting edge bioimaging devices. This could become a promising ex vivo system to screen 
small molecules against Leishmania. 
 
1.1.  Target validation 
As previously stated, on target based approaches for drug discovery in neglected 
tropical diseases, molecular targets correspond to proteins that are essential for parasite 
survival and/or infectivity and absent or sufficiently different from the host (Reguera et al, 
2014). The availability of genomic data on trypanosomatids has been indispensable for this 
process and several tools have allowed the genetic validation of several drug targets. In the 
case of T. brucei, with the advents of RNAi mediated protein knockdown, much more studies 
concerning target validation can be found in the literature. In most of species of Leishmania, 
the inability to perform RNAi mediated knockdown renders gene knockout the only option. 
Genetic manipulation of trypanosomatids has been extensively addressed on chapter I 
(4.3.1).   
Over the years, many efforts have been made to identify essential genes in 
trypanosomatids. Inclusively, the Special Programme for Research and Training in Tropical 
Diseases (TDR) database, hosted by WHO, is a deposit of potential drug targets obtained 
from biochemical, genetic and pharmacological data of several pathogens (Reguera et al, 
2014). Several enzymes have been validated in Leishmania, such as TryR, a crucial 
component of the anti-oxidant machinery of these parasites (Eberle et al, 2011); 
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dihydrofolate reductase, involved in the purine biosynthesis; cysteine protease B, a 
virulence factor secreted by the amastigotes into the phagolysosome (Caffrey et al, 2011); 
DNA topoisomerases, involved in DNA replication, transcription and recombination, and 
drastically different from the ones in the host (Prada et al, 2013); as well as several kinases 
(Palmeri et al, 2011). In the case of T. brucei, many different pathways have been explored 
such as polyamine biosynthesis, energy, purine, pyrimidine, pteridine or lipid metabolism, 
cell cycle kinases, phosphodiesterases, among others (extensively reviewed by Jacobs et 
al, 2011). 
The validation of a drug target further leads to the need of setting up enzymatic 
assays that allow the screening of inhibitory molecules. For this purpose, the expression 
and purification of a considerable amount of recombinant proteins in native form are 
required. Escherichia coli is the most widely used organism to produce recombinant 
proteins (Khow & Suntrarachun, 2012). Recombinant proteins are coupled with fusion tags, 
which are crucial for protein purification, often by affinity chromatography in a first step 
(Arnau et al, 2006). Affinity tags correspond to exogenous residues that tightly bind a 
chemical ligand or an antibody, enabling a high degree of purification of the target protein 
(Arnau et al, 2006). When the protein cannot be expressed in native conditions, denaturing 
purification has to be used, further limiting activity assays.  
After setting up an in vitro enzymatic assay for the molecular target, kinetic studies 
can be undertaken (Sidoli et al, 2006), in order to determine the catalytic constants 
conveyed by Michaelis-Menten (Km, vmax, kcat) (Cleland, 1967). Inclusively, the kinetic 
parameters determination in the presence or absence of several concentrations of an 
inhibitory molecule disclose whether there is competitive, non competitive or uncompetitive 
like inhibition (Robertson, 2005). In the context of enzymatic inhibition, the determination of 
the inhibition constant (Ki) and the compound concentration that leads to a 50% drop on the 
enzymatic activity (IC50) are also crucial (Robertson, 2005).  
Following the in vitro inhibitory activity, the compounds must be tested in whole cell 
assays to confirm its anti-parasitic activity, and further in mammalian cells to evaluate their 
selectivity. In order to improve potency and selectivity, it is important to understand how and 
where the compound binds its molecular target, allowing structure based lead optimization. 
Currently, there are several methods available to identify the inhibitor binding site: X-ray 
crystallography (Hassell et al, 2007), nuclear magnetic resonance (NMR) spectroscopy 
(Pellecchia et al., 2008), computational docking (Mobley & Dill, 2009) and photo crosslinking 
(Robinette et al, 2006). Frequently, site directed mutagenesis is used to validate the referred 
methods (Claustre et al, 2002).  
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2. Metabolic pathways with distinct features 
In order to identify novel drug targets, great efforts have been made to explore the 
particularities of trypanosomatids metabolism when compared to the host. The following 
sections address some of the most explored metabolic pathways in these parasites.  
 
2.1.  Polyamines 
Polyamines, simple aliphatic compounds found in all tissues and microorganisms, 
play detrimental roles on cell proliferation and differentiation, as well as protein, nucleic 
acids and trypanothione synthesis, being the latter crucial for anti-oxidant defences in these 
parasites (Colotti & Ilari, 2011). L-ornithine is the polyamine precursor, obtained from L-
arginine by arginase (ARG). Following, ornithine decarboxylase (ODC) catalyses the first 
and rate limiting step of polyamine biosynthesis, by converting L-ornithine into putrescine 
(Colotti & Ilari, 2011; Heby et al, 2007). Putrescine is further used as a substrate for the 
constitutive spermidine synthase (SpdS) that adds the aminopropyl group provided by the 
decarboxylated S-adenosylmethionine (dAdoMet), the latter resulting from S-
adenosylmethionine decarboxylase (AdoMetDC) activity. Ultimately, spermine synthase 
(SpmS) performs a similar reaction on spermidine (Spd), generating spermine (Spm), by 
adding another aminopropyl group (Fig. 20) (Colotti & Ilari, 2011; Heby et al, 2007). 
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Figure 20. Polyamine metabolism in trypanosomatids and mammalian cells. ARG is 
crucial for L-ornithine production, the polyamine precursor, in most cell types but not in T. 
cruzi. A) In human cells, the decarboxylases (ODC and AdoMetDC) have extremely short 
half lives, whereas the synthases (SpdS and SpmS) are constitutively expressed. SAT and 
PAO enable a back conversion from spermine to spermidine and finally to putrescine via 
acetylated intermediates (AcSpm and AcSpd). Importantly, polyamine transporters (black 
circles) allow polyamine uptake from extracellular medium, and are crucial for the regulation 
of their intracellular levels. B) In T. brucei, ODC and AdoMetDC have long half lives, and 
SpmS is absent. Spd and glutathione (GSH) are conjugated by two enzymes (GSS and 
TryS) in order to generate trypanothione, a key molecule for anti-oxidant defence. C) In L. 
donovani, polyamine biosynthesis occurs in a similar fashion to T. brucei, but Leishmania 
has a more efficient polyamine transporter (POT1). D) T. cruzi does not have ODC, but has 
AdoMetDC and two aminopropyltransferases. One may be a SpmS, as these parasites 
have Spm, which can also be conjugated with GSH by TryS. The latter has a wide 
polyamine substrate specificity, generating trypanothione and several analogues. T. cruzi, 
is dependent on putescine uptake from the extracellular medium and has a high-affinity 
transporter for the purpose. AcSpd, acetylated spermidine; AcSpm, acetylated spermine; 
AdoMet, S-adenosylmethionine; AdoMetDC, S-adenosylmethionine decarboxylase; ARG, 
arginase; dcAdoMet, decarboxylated S-adenosylmethionine; GHS, glutathione; GSS, 
glutathionylspermidine synthase; MTA, 50-deoxy-50-methylthioadenosine; ODC, ornithine 
decarboxylase; PAO, polyamine oxidase; Put, putrescine; ROS, reactive oxygen species; 
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SAT, spermidine/spermidine N1-acetyltransferase; Spd, spermidine; Spm, spermine; TryR, 
trypanothione reductase; TryS, trypanothione synthetase. Adapted from Heby et al, 2007.  
 
Interestingly, polyamine metabolism in trypanosomatids has some distinct features 
when compared to mammals. Firstly, in human cells, ODC and AdoMetDC, both 
decarboxylases, are extensively regulated and present short half lives, whereas SpdS and 
SpmS are constitutively expressed. ODC and AdoMetDC in T. brucei and Leishmania have 
a considerably higher half-life (Heby et al, 2007). Secondly, human cells have two enzymes 
that catalyse back-conversion from spermine to spermidine to putrescine via acetylated 
intermediates, namely spermidine/spermidine N1-acetyltransferase (SAT) polyamine 
oxidase (PAO), which are absent in trypanosomatids (Heby et al, 2007). Thirdly, human 
cells have the ability to uptake polyamines via specific high affinity transporters, allowing a 
regulation of the intracellular levels of these molecules. T. brucei exhibits negligible uptake 
capacity, but on the contrary, Leishmania has a more efficient high affinity polyamine 
transporter (POT1) for both putrescine and spermidine (Fig. 20C). T. cruzi, for instance, 
lacks ARG and ODC, deeply relying on extracellular putrescine uptake, which inclusively is 
10-50 fold higher than in L. mexicana, in epimastigotes (Carrillo et al, 2006; González et al, 
1992; Hasne & Ullman, 2005). Finally, the most important thiol in human cells is GSH, 
whereas in trypanosomatids is trypanothione. The latter is synthesized by TryS, which has 
a wide polyamine substrate specificity, generating not only trypanothione, but also several 
trypanothione analogues (Colotti & Ilari, 2011; Heby et al, 2007). For instance, besides 
spermidine, T. cruzi also has spermine, which can also be conjugated with GSH by TryS. 
Thus, T. cruzi, in opposition to Leishmania and T. brucei, also has an additional 
aminopropyltransferase, namely SpmS, which produces the so called spermine (Fig. 20) 
(Heby et al., 2007; Colotti et al., 2011).  
L-arginine is an essential amino acid for Leishmania growth, only semi-essential to 
mammalian cells. L. donovani can transport this amino acid via LdAAP3 transporter, which 
localises to the surface membrane and has a high affinity for L-arginine, in opposition to the 
human transporter that equally binds L-lysine and L-ornithine. L. donovani may have the 
ability to sense L-arginine cellular concentration and adjust LdAAP3 expression and activity 
in accordance (Darlyuk et al, 2009).  
Contrarily to human cells, L. mexicana promastigotes express a single ARG, which 
catalyses a detrimental function for the parasite, namely the production of L-ornithine, the 
precursor of polyamines. ARG null mutants become auxotrophic for L-ornithine or 
polyamines (Roberts et al, 2004).  
In their turn, ODC null mutants could not grow in polyamine deficient medium, which 
was overcome by adding putrescine and spermidine, but not spermine. This has also shown 
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that L. donovani lacks polyamine back conversion that is present in human cells (Fig. 20A) 
(Jiang et al, 1999). In T. brucei, ODC knockout cell lines also require exogenous putrescine 
for proliferation, and when those were injected in mice, the parasites were unable to multiply 
and were quickly cleared from the bloodstream (Li et al, 1998). Actually, ODC is currently a 
drug target against human African trypanosomiasis (HAT), and it is irreversibly inhibited by 
eflornithine, a reference drug for the neurological stage of T. b. gambiense infection (Poulin 
et al, 1992). This drug is ineffective against American trypanosomes as those lack its 
molecular target, and rely instead on putrescine uptake, as referred above (Heby et al, 
2007). In T. brucei, this drug is quite successful for several reasons: 1) the parasite ODC is 
stable and has a lower turnover in comparison to the human one; 2) the negligible ability of 
the parasite to uptake polyamines from extracellular environment; 3) the depletion of 
spermidine compromises trypanothione synthesis; 4) the absence of putrescine and 
spermidine leads to a general decrease in macromolecules synthesis, such as VSG; 5) the 
depletion of putrescine leads to an accumulation of AdoMet and dAdoMet, which ultimately 
lead to aberrant methylation in the parasite; 6) the depletion of polyamines leads to parasite 
differentiation into non replicative forms (stumpy forms), which present a lower life span 
(Heby et al, 2007). In the case of Leishmania, 3-aminooxy-1-aminopropane (APA), an ODC 
inhibitor, with potent anti-parasitic activity in both promastigote and amastigote forms of L. 
donovani (Singh et al, 2007) may not be a suitable drug, especially in India, where 
resistance to pentavalent antimonials is a major problem. This relates to the fact that several 
clinical isolates displaying antimonial resistance overexpressed ODC (Singh et al, 2007).  
Recently, a high affinity AdoMet transporter (AdoMetT1) has been identified in L. 
major (Dridi et al, 2010). In the case of L. donovani AdoMetDC and SpdS, null mutants to 
these genes cannot grow unless upon spermidine supplementation, but not putrescine 
(Roberts et al, 2002). The stability of L. donovani AdoMetDC contrasting with the fast 
turnover in human cells suggests that irreversible inhibition of this enzyme may have a 
leishmanicidal effect. MDL 73811 (aka AbeAdo) is a specific irreversible inhibitor of 
AdoMetDC, and a structural analogue of dAdoMet (Roberts et al, 2007), and CGP 40215A 
is a competitive inhibitor of AdoMetDC, with a strong leishmanicidal activity (Mukhopadhyay 
et al, 1996). However, in the case of SpdS, it is equally stable in the parasites and the host 
cells, therefore, inhibitors would likely interfere with both, unless structural differences are 
explored in order to design selective molecules (Roberts et al, 2001). In T. brucei 
bloodstream forms, RNAi mediated knockdown of these two enzymes has led to decreased 
levels of spermidine and parasite death or growth arrest in the first and the second, 
respectively (Willert & Phillips, 2008; Xiao et al, 2009). Actually, AdoMetDC inhibitors have 
shown to display a potent trypanocidal activity (Bacchi et al, 1996).  
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The above described results show that polyamine metabolism is extremely attractive 
in a drug discovery regard. Structural differences between the parasites’ enzymes and their 
human equivalents may be explored for selective inhibitors design, precluding adverse 
effects on the mammalian hosts (Colotti & Ilari, 2011; Heby et al, 2007). 
 
2.2.  Thiols 
Mammals make use of GSH reductase (GR)/GSH peroxidase (GP) system in order 
to regulate the intracellular levels of thiols and ultimately redox metabolism. 
Trypanosomatids lack genes encoding GR, selenocysteine-containing GSH peroxidases, 
thioredoxin reductase (TrxR) and catalase (Berriman et al, 2005; Colotti & Ilari, 2011; El‐
Sayed et al, 2005; Ivens et al, 2005). Instead, their redox metabolism is based on 
trypanothione (T(SH)2), a low molecular weight dithiol, maintained in its reduced form by 
TryR (Fig. 21).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Trypanothione-based thiol metabolism in T. brucei. Trypanothione (T(SH)2) 
is synthesized from GSH and Spd. GSH is produced by GSH1 and GSH2 and formed by 
glutamate, cysteine and glycine. TryS conjugates two molecules of GSH with a single 
molecule of Sp, generating trypanothione. Trypanothione disulfide (TS2) is back to the 
active dithiol upon reduction by TryR in a NADPH dependent manner. Trypanothione can 
be conjugated to metal containing drugs, which can be sequestered inside the cell or 
extruded by a specific transporter. TryR and TryS are not detectable in the mitochondria, it 
remains to be disclosed whether the parasite possesses a redox shuttle mechanism 
between this organelle and the cytosol. Proteins that have been reported as essential or 
dispensable for T. brucei are represented in black or light grey, respectively. 1-C-Grx1, 
monothiol glitaredoxin; C, cytosol; dSAM, decarboxylated S.adenosyl-L-methionine; GSH1, 
γ-glutamylcysteine synthetase 1; GSH2, GSH synthetase 2; ISC, iron sulphur clusters; K, 
kinetoplast; M, mitochondrion; N, nucleus; ODC, ornithine decarboxylase; Prx, 2-cys-
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peroxiredoxins; Px, GSH-peroxidase-type enzymes; RR, ribonucleotide reductase; Sp, 
spermidine; SpS, spermidine synthase; Trx, thioredoxin; TryR, trypanothione reductase; 
TryS, trypanothione synthetase; TXN, tryparedoxin; UMSBP, universal minicircle sequence 
binding protein. Adapted from Krauth-Siegel & Comini, 2008. 
 
In trypanosomatids, TryS is bifunctional, catalysing the synthesis and hydrolysis of 
GSH-Spd adduct – T(SH)2 (Fig. 21). This enzyme displays two catalytic domains, the N-
terminal corresponds to a papain-like cysteine protease domain, and the C-terminal 
corresponds to an ATP dependent synthetase domain (Fyfe et al, 2008). In the C-terminal, 
two molecules of GSH are conjugated with a single molecule of Spd, via 
glutathionylspermidine intermediate, with two molecules of ATP spent. The N-terminal 
domain is able to hydrolyse the just referred reactional intermediate (Fyfe et al, 2008). TryS 
is important in T. brucei, as corroborated by RNAi mediated knockdown and further by gene 
knockout. RNAi experiments demonstrated a loss of proliferation and viability, associated 
with increased susceptibility to oxidative stress (Comini et al, 2004; Wyllie et al, 2009). This 
enzyme has additionally been chemically validated using inhibitors obtained from a HTS 
campaign (Torrie et al, 2009). TryS is unlikely to raise resistance issues because 
trypanosomatids only have a single copy of the gene and there is no bypass mechanism, 
and it is equally unlikely to raise safety issues as there is no human homologue (Colotti & 
Ilari, 2011). In L. infantum, genetic and chemical analyses have demonstrated that TryS, 
but not glutathionylspermidine synthetase, is essential for the parasite survival (Sousa et al, 
2014).  
As previously stated, trypanothione is reduced by TryR, which is a FAD-dependent 
NADPH oxidoreductase (Fig. 21). L. infantum and T. cruzi TryR have been crystallized 
(Baiocco et al, 2009; Colotti & Ilari, 2011). This protein occurs as a dimer and each monomer 
has three different domains, a FAD binding domain, a NADPH binding domain and an 
interface domain (Baiocco et al, 2009). It is essential for L. donovani survival, validating it 
as promising drug target. On the other hand, in the case of T. brucei, conditional gene 
knockout demonstrated that parasites survive up to 90% reduction of TryR activity, 
suggesting that low levels of this enzyme suffice the cellular needs. However, TryR depleted 
parasites display reduced infectivity in mice (Krieger et al, 2000; Tovar et al, 1998).  
Moreover, TryR inhibitors were identified and did not affect the closest mammalian 
homologue, GR (Spinks et al, 2009). Nonetheless, in vivo efficacy in a T. brucei infection 
model was quite disappointing, as redox metabolism was not affected at all, unless TryR 
was titrated down to less than 5% of normal (Krieger et al, 2000). Recent efforts focus on 
the generation of TryR irreversible inhibitors, as competitive ones fail to provide the 
sustained inhibition that is required (Flohe, 2012). It is also noteworthy that TryR inhibition 
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has been widely used in the treatment of the late stage T. b. rhodesiense infection, through 
the use of melarsoprol (Fairlamb et al, 1989). Equally remarkable is the fact that antimonials, 
one of the main drugs used to treat leishmaniasis, interfere with trypanothione metabolism, 
actually, they bind and inhibit TryR (Cunningham & Fairlamb, 1995).  
In summary, the lack of a functional redundancy between the parasite thiol system 
and the mammalian, along with the sensitivity of these parasites to oxidative stress, renders 
the enzymatic components of this metabolism promising drug target candidates (Colotti & 
Ilari, 2011).  
 
2.3.  Energy metabolism 
Trypanosomatids have unique organelles in order to respond to their specific 
lifestyle needs. Among those are glycosomes, peroxisome related organelles which 
comprise enzymes of important metabolic pathways such as glycolysis, PPP, β-oxidation, 
gluconeogenesis, purine salvage and biosynthesis of pyrimidines, ether lipids and 
squalenes (Michels et al, 2006). This compartmentalisation of metabolic pathways can 
prevent the accumulation of toxic intermediates (Haanstra et al, 2008) or enable a fast 
metabolic adaptation to environmental changes (Michels et al, 2006).  
Briefly, most organisms have operational negative feedback mechanisms on 
glycolysis in order to prevent the autocatalytic pathway from losing control (eg. inhibition of 
hexokinase (HK) by glucose-6-phosphate (Newsholme et al, 1967) or phosphofrutokinase 
(PFK) by phosphoenolpyruvate (Blangy et al, 1968)). However, trypanosomatids lack this 
sort of regulation, therefore, in T. brucei it has inclusively been demonstrated that without 
this confinement, ATP produced in later glycolytic steps would be accessible in the first 
reactions. This would cause a turbo explosion within the pathway, and the accumulation of 
toxic intermediates would ultimately lead to death (Haanstra et al, 2008). 
The glycosome number (average: 10-100 glycosomes per cell) as well as the 
qualitative and quantitative enzymatic content differ among trypanosomatids, reflecting the 
metabolic adaptions of the different parasite species and life cycle stages to the 
environment (Parsons et al, 2001; Szoor et al, 2014). Regarding number for instance, T. 
brucei bloodstream forms have around 65 glycosomes with an average diameter of 0.27 
µm, and Leishmania promastigotes only around 50, followed by amastigotes with 5-10 times 
less glycosomes (Szoor et al, 2014). Due to their uniqueness, these organelles provide 
potential drug targets at several levels: 1) in the enzymes they contain; 2) in the metabolic 
communication between their matrix and the cytosol via transporters and channels; 3) their 
biogenesis and degradation (Cull et al, 2015; Gualdrón-López et al, 2013; Michels et al, 
2006).  
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Focusing on metabolic pathways and particularly on hexose metabolism, substantial 
differences can be encountered when comparing Leishmania and T. brucei, or even the 
different developmental stages of each one of these parasites. Leishmania promastigotes 
preferentially catabolise sugars via glycolysis, whose first seven enzymes localise to the 
glycosomes (Opperdoes & Coombs, 2007). Inclusively, in replicative promastigotes a high 
glucose uptake and glycolytic flux can be observed. The ATP and NAD that are consumed 
in the early glycolytic steps are at least partially regenerated by fermentation of 
phosphoenolpyruvate to succinate. Following, glycolysis and succinate fermentation end 
products can be further catabolised in a canonical tricarboxylic acid (TCA) cycle (Saunders 
et al, 2011). A noteworthy feature of promastigote metabolism is the apparent lack of 
feedback regulation of glycolytic fluxes, and subsequently, glucose uptake usually exceeds 
mitochondrial capacity to oxidise glucose, which leads to the secretion of partially 
catabolised metabolites, such as succinate, acetate or alanine (Saunders et al, 2010). 
Interestingly, amastigotes enter a glucose sparing program, characterized by a reduction in 
glucose consumption and a negligible secretion of metabolic end products (Saunders et al, 
2014). This growth limiting state, which will be further discussed in this dissertation, has 
been proposed to facilitate amastigote survival in the nutrient limited environment of the 
phagolysosome (Saunders et al, 2014). For instance in the case of T. brucei bloodstream 
forms, glycolysis of host glucose provides the sole source of carbon for ATP production 
(Michels et al, 2006), in contrast to procyclic forms, which contain an extended glycolytic 
pathway catalysing the aerobic fermentation of glucose to succinate (Coustou et al, 2003). 
In bloodstream forms, the exclusive dependency on glycolysis-mediated ATP production, 
due to an insufficient mitochondrial function, coupled with the structural differences found 
between their glycolytic enzymes and the human counterparts, point these enzymes as 
interesting drug target candidates (Coley et al, 2011).  
Indeed in T. brucei, the genetic validation of glycolytic enzymes as drug targets has 
been obtained by RNAi-mediated knockdown and conditional knockout experiments. The 
glycosomal enzymes include HK (Albert et al, 2005), PFK (Albert et al, 2005), fructose-1,6-
bisphosphate aldolase (ALD) (Caceres et al, 2010), triosephosphate isomerase (TPI) 
(Helfert et al., 2001) and GAPDH (Caceres et al, 2010), while the cytosolic enzymes include  
phosphoglycerate mutase (PGAM), enolase (ENO) and phosphoglycerate kinase (PYK) 
(Albert et al, 2005). Some of them have also been chemically validated, namely HK1 
(Sharlow et al, 2010), PFK (Brimacombe et al, 2014), ALD (Azema et al, 2006), GAPDH 
(Aronov et al, 1999), PYK (Drew et al, 2003) and ENO (de A S Navarro et al, 2007). In 
Leishmania, HK is the only glycolytic enzyme that has been formally validated, as well as a 
gluconeogenic enzyme, fructose-1, 6-biphosphatase (FBPase) (Gualdrón-López et al, 
Chapter II – Exploring Leishmania metabolic pathways 
98 
 
2013). In the case of the latter, L. major null mutants cannot replicate inside the 
phagolysosome as amastigotes and fail to generate normal lesions (Naderer et al, 2006). 
Moreover, a plasma membrane glucose transporter has been chemically validated 
as a drug target in T. brucei (Bakker et al, 1999), and in Leishmania, a hexose transporter 
null mutant cannot survive as amastigote in MØ (Rodríguez-Contreras & Landfear, 2006).  
Apart from sugar metabolism, enzymes involved in other glycosomal pathways have 
been validated as drug targets in Leishmania and/or T. brucei, namely in sterol synthesis, 
purine salvage and sugar nucleotide pathways, as well as PPP (Gualdrón-López et al, 
2013). The latter will be extensively characterized later in this chapter.  
 
2.4.  Lipids 
Lipid metabolism has a major importance for pathogens. Lipids serve as cellular 
building blocks, signalling molecules, energy reserves, post-translational modifiers, and 
virulence factors. Therefore, parasites must rely on a complex system of uptake and 
synthesis mechanisms to satisfy their demands (Ramakrishnana et al, 2013). The energy 
amount that is required for fatty acid synthesis is much higher than the one implicated in 
uptake, thus the latter is likely preferred over fatty acid synthesis pathway. However, when 
the host fatty acid supply is not sufficient, parasites must rely on intracellular synthesis (Lee 
et al, 2006). 
Trypanosomatids encode for enzymes of two distinct pathways to synthesize fatty 
acids, a fatty acid synthesis type II (FASII) pathway and a fatty acid elongation (FAE) 
pathway (Ramakrishnana et al, 2013) (Fig. 22). Both have been characterized in T. brucei 
using genetic and biochemical approaches. The relevance of the FASII pathway in other 
kinetoplastids has not been addressed yet. In T. cruzi and L. major, these parasites encode 
for homologues of the enzymes involved in these pathways, suggesting that their fatty acid 
metabolism may be similar to that of T. brucei (Ramakrishnana et al, 2013). Inclusively, it 
has been demonstrated that expression of L. major dehydratase and ketoacyl reductase 
rescues the respiration defect of yeast mutants for the corresponding enzymes (Pillai et al, 
2003). Moreover, in silico studies indicate the presence of additional FASII components in 
both L. major and T. cruzi, and all candidates are predicted to localize to the mitochondria, 
as they present an N-terminal signal peptide for this compartment (Ramakrishnana et al, 
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2013). Taken all together, these data suggest that the FASII pathway is likely conserved 
among trypanosomatids. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Fatty acid synthesis in kinetoplastids. A) T. brucei parasites are depicted 
representing kinetoplastids in general, as most of the studies were undertaken in this 
organism. These parasites replicate extracellularly in the bloodstream of the mammalian 
host, red blood cells are also shown (red). B) Additionally, parasites harbour two distinct 
pathways for fatty acid synthesis that are localized in two different organelles. C) FASII 
pathway localizes to the mitochondrion (light violet), generating lipoic acid and palmitic acid. 
D) Kinetoplastids also harbour an elongase-based pathway that localises to the 
endoplasmic reticulum. Unlike all other organisms, kinetoplastid FAE is used for de novo 
synthesis of fatty acids. In this pathway, butyrate and malonate are used as substrates to 
generate myristate/stearate and adrenate. Major products are highlighted in red. Ac-CoA, 
acetyl-CoA; Ac, acetate; ACP, acyl carrier protein; DEH, acyl-CoA dehydratase; EAR, 
enoyl-ACP reductase; ELO, elongase; ER, endoplasmic reticulum; FASII, fatty acid 
synthesis type II; FAE, fatty acid elongation; HAD, hydroxyacyl-ACP dehydratase; KAR, 
ketoacylACP reductase; KAS, ketoacyl-ACP synthase; KCR, ketoacyl-CoA reductase; Mal, 
malonate; Mal-CoA, malonyl-CoA. Adapted from Ramakrishnana et al, 2013. 
 
The FASII pathway in trypanosomatids (Fig.22) is overall similar to the FASII 
pathway from other organisms. An acyl carrier protein (ACP) holds the growing acyl chain 
while the chain is modified by a synthase, dehydratase and two reductases (Ramakrishnana 
et al, 2013). The major difference for instance between apicomplexan and kinetoplastid 
parasites is that FASII pathway localises to the apicoplast or the mitochondrion, respectively 
(Stephens et al, 2007). 
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The TbFASII pathway has palmitate as its final product and displays only a moderate 
activity, overall contributing only about 10% of total parasite fatty acid synthesis (Stephens 
et al, 2007). Therefore, an alternative pathway, FAE pathway that localises to the 
endoplasmic reticulum, serves as the major pathway for fatty acid synthesis in these 
parasites (Lee et al, 2006). The ablation of FASII pathway in T. brucei blocks lipoic acid 
production, pointing that the second and probably more important role of this pathway is 
being the major source of octanoic acid for lipoic acid synthesis (Stephens et al, 2007; Fig. 
22). Thiolactomycin, which is thought to be a more specific FAS II inhibitor, and several 
derivatives were found to inhibit growth of T. cruzi, T. brucei, and L. donovani (Jones et al, 
2004; Jones et al, 2005).  
On the other hand, as mentioned above, trypanosomatids rely mostly on FAE 
pathway for fatty acids de novo synthesis. This pathway localises to the endoplasmic 
reticulum membrane and includes several elongases, dehydratases and reductases (Fig. 
22). The best-characterized components are the four elongase enzymes of T. brucei (ELO1-
4), whose functions are remarkably different from other eukaryotes (Lee et al., 2006). In the 
TbFAE pathway, ELO1-3 act on saturated fatty acids, whereas ELO4 is specific for 
polyunsaturated fatty acids (PUFAs). TbELO1 starts the chain elongation using butyryl-CoA 
to generate decanoyl-CoA, which is further extended by TbELO2 to myristoyl-CoA (Lee et 
al, 2006). Until the discovery and characterization of FAE pathway, and due to the low 
abundance of myristic acid in the serum of the mammalian host, it was quite intriguing how 
the parasites would satisfy their great need for this fatty acid. T. brucei GPI anchors are 
composed exclusively of myristic acid, which is unique, requiring a complex fatty acid 
remodelling process to ensure this exclusivity (Ferguson & Cross, 1984; Masterson et al, 
1990). Inclusively, T. brucei bloodstream forms are heavily coated by VSG, anchored to the 
membrane by GPI structures, in order to evade the immune system through antigenic 
variation (Ferguson et al, 1988; Van der Ploeg, 1990). For instance, those were the first 
fully characterized GPI structures in eukaryotes (Ferguson et al, 1988). Interestingly and 
unexpectedly, T. brucei bloodstream forms lacking FAE pathway did not display any growth 
or infectivity defect (Lee et al, 2006). However, in contrast, FAE appears to be essential for 
growth in procyclic forms. Overall, FAE pathway impact on parasite survival may depend 
on both the life cycle stage and the availability of fatty acids in the host environment 
(Ramakrishnana et al, 2013). Importantly, N-myristoyltransferase, the enzyme responsible 
for the attachment of myristate to the GPI anchor, showed to be essential for parasite 
viability based on RNAi-mediated knockdown (Price et al, 2003). Several inhibitors of this 
enzyme have been obtained by rational drug design displaying anti-parasitic activity 
(Frearson et al, 2010; Sheng et al, 2009).  
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Additionally, FAE pathway components have also been detected in T. cruzi and L. 
major, but while T. brucei encodes four elongase genes, T. cruzi seems to contain five and 
L. major fourteen. None of these candidate enzymes have been experimentally studied 
(Ramakrishnana et al, 2013). L. major and T. cruzi present GPI anchors composed of longer 
fatty acids (Ferguson, 1997), and this is probably the reason for the presence of additional 
elongases. Leishmania anchors several virulence factors to the membrane via GPI, namely 
GP63, LPG, PPG or GILP (Olivier et al, 2012), whose role has been explored in the first 
chapter of this dissertation. LPG is composed of very long (24 and 26 carbon) alkyl chains, 
probably derived from very long fatty acids (Ferguson, 1997). 
Concerning phospholipids, T. brucei has a glycerophospholipid composition similar 
to other eukaryotic cells, with phosphatidylcholine (PC) and phosphatidylethanolamine (PE) 
representing the most abundant, followed by phosphatidylinositol (PI), PS, cardiolipin and 
phosphatidylglycerol (PG) (Ramakrishnana et al, 2013). Similarly, in Leishmania, PC is the 
most abundant glycerophospholipid, followed by PE and PI, but for instance cardiolipin and 
PG are present in trace amounts (Wassef et al, 1985; Zheng et al, 2010).  
PI can be used to generate different phosphorylated forms of this phospholipid, 
several of them are important signalling molecules in eukaryotes (Michell, 2008). Besides, 
PI also represents the precursor for GPI anchors (Wichroski & Ward, 2003). Several 
enzymes involved in PI and GPI synthesis were already validated as targets in T. brucei 
(Martin & Smith, 2006; Smith et al, 2001). T. cruzi and Leishmania present orthologue genes 
for myo-inositol–3-phosphate synthase and PI synthase, suggesting that de novo synthesis 
of myo-inositol occurs in all kinetoplastids. Moreover, myo-inositol uptake has been reported 
in several Leishmania species, in which orthologues of the T. brucei myoinositol transporter 
have been found (Drew et al, 1995; Gonzalez-Salgado et al, 2012).  
Still on glycerophospholipid metabolism, for instance miltefosine, the only oral drug 
available to treat leishmaniasis, may interfere with phospholipid biosynthesis. Among the 
possible modes of action are the inhibition of PE N-methyltransferase and CDP-
phosphocholine cytidylyltransferase (Rakotomanga et al, 2007) as well as inhibition of 
extracellular choline uptake (Zufferey & Mamoun, 2002), resulting in changes in parasite 
PC and PE contents. 
As for the sphingophospholipid classes, sphingomyelin (SM), inositol 
phosphorylceramide (IPC) and ethanolamine phosphorylceramide (EPC) constitute 10–
15% of total lipid phosphorus in T. brucei (Sutterwala et al, 2008). The enzymes involved in 
their synthesis are developmentally regulated, so relative amounts of each one of them 
differ between procyclic and bloodstream forms (Sutterwala et al, 2008). In Leishmania, IPC 
corresponds to the major sphingophospholipid, unusually composed by long chain bases, 
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suggesting that the parasite preferentially uses myristoyl-CoA for ceramide synthesis, 
instead of palmitoyl-CoA as in T. brucei (Sutterwala et al, 2008), T. cruzi (Bertello et al, 
1995), mammalian cells and yeast (Pinto et al, 1992; Williams et al, 1984). A key enzyme 
of sphingolipid biosynthesis pathway is sphingolipid synthase, which has been implicated 
in T. brucei survival, using RNAi and chemical inhibition (Mina et al, 2009; Sheng et al, 
2009). On the other hand, neutral sphingomyelinase, responsible for the intracellular 
degradation of SM in T. brucei, is detrimental for growth, survival and proper VSG traffic 
(Young & Smith, 2010). Unlike trypanosomes, Leishmania parasites do not synthesize SM 
(Kaneshiro et al, 1986). 
Moreover, protein prenylation is an important regulatory mechanism for signal 
transduction. This is enzymatically achieved through the attachment of farnesyl to proteins, 
mediated by farnesyltransferase, which was genetically and chemically shown to be a good 
target in T. brucei (Ali et al, 1999; Eastman et al, 2006).  
In summary, the uniqueness of parasites lipid metabolism makes it a source of 
potential drug targets, inclusively, several enzymes have already been validated (Lee et al, 
2007). 
 
2.5.  Folates 
Folate is a crucial cofactor on DNA and amino acids biosynthesis, therefore the 
inhibition of its metabolism leads to profound alterations on cell replication and function 
(Vickers et al., 2011). 
Trypanosomatids do not have a de novo pathway for the synthesis of pteridines 
(folate and biopterins) and rely on salvage from the host. Indeed, they salvage folates and 
unconjugated pteridines from their mammalian hosts and insect vectors through multiple 
transporters. They also harbour a limited set of folate-dependent metabolic reactions. In 
these parasites, a bifunctional dihydrofolate reductase (DHFR) - thymidylate synthase (TS) 
and a novel pteridine reductase 1 (PTR1) reduce folates or both folates and unconjugated 
pteridines, respectively. Therefore, PTR1 can be a metabolic bypass of DHFR (Vickers & 
Beverley, 2011).  
The extent to which Leishmania can interconvert unconjugated pteridines into 
folates is debatable. These parasites usually grow upon biopterin supplementation alone. 
Nevertheless, it is hard to conclude whether Leishmania uses biopterin to synthesize folate, 
as trace levels of folate from serum or other medium components cannot be disregarded, 
along with Leishmania’s high-affinity folate transporters (FTs) (Petrillo-Peixoto & Beverley, 
1987). Regardless, it is clear T. brucei and Leishmania have distinct biopterin and folate 
requirements (Vickers & Beverley, 2011). 
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In higher plants and protozoa, such as trypanosomatids, the DHFR and TS occur as 
a fusion protein (DHFR-TS). TS performs the reductive methylation of deoxyuridine-
monophosphate (dUMP) to deoxythymidine-monophosphate (dTMP), the latter used for 
DNA biosynthesis (Gamarro et al, 1995). DHFR, in its turn, restores the tetrahydrofolate 
(H4F) pool, by reducing dihydrofolate (H2F) in a NADPH dependent manner (Gamarro et 
al, 1995). DHFR-TS has been chemically and genetically validated as a key drug target in 
T. brucei (Sienkiewicz et al, 2008). In L. major, DHFR-TS null mutants, obtained from an 
avirulent strain, survive for less than two months in the animal host, suggesting that reduced 
folates and thymidylate salvage does not suffice the parasites’ needs, rendering them 
unable to cause disease. Inclusively, a null DHFR-TS mutant has been used to induce 
immune protection (Cruz & Beverley, 1990; Titus et al, 1995). However, it has proven 
impossible to ablate DHFR-TS in fully virulent L. major (Cruz et al, 1993).  
PTR1 catalyses the reduction of both folate and biopterin, and belongs to the family 
of short-chain dehydrogenases/reductases (Robello et al, 1997). In T. brucei, its knockdown 
resulted in loss of viability and virulence (Sienkiewicz et al, 2010). Several scaffolds were 
identified as PTR1 selective inhibitors but displayed a reduced in vitro anti-parasitic activity 
(Mpamhanga et al, 2009; Tulloch et al, 2010). In Leishmania, similarly to DHFR-TS, PTR1 
is not essential in attenuated laboratory-adapted strains (Bello et al, 1994; Papadopoulou 
et al, 1994) nor required for animal virulence (Cunningham et al, 2001) but it has been 
proven difficult to ablate PTR1 in virulent L. major (Vickers & Beverley, 2011). The 
differences found between Leishmania and T. brucei concerning the dependency on PTR1 
may arise from the fact that trypanosomes lack quinonoid dihydropteridine reductase 
(QDPR) genes (Vickers & Beverley, 2011).  
Overall, the PTR1 bypass of DHFR much contributes for the low success rate of 
antifolates against trypanosomatids. One of the strategies that has been employed to 
overcome the current limitations is the identification of agents able to simultaneously inhibit 
both DHFR and PTR1 (Cavazzuti et al, 2008). This is a daunting task, regarding the 
enzymes’ structural divergence. A second approach consists in targeting the two activities 
with two separate inhibitors (Cavazzuti et al, 2008). It is noteworthy that the essentiality of 
PTR1 in trypanosomes suggests that PTR1-selective inhibitors per se may be successful, 
whereas in Leishmania joint inhibition may be necessary, due to the preservation of QDPR. 
Great efforts have been and are still employed in order to develop molecules that could 
target these QDPR in Leishmania (Cavazzuti et al, 2008; Gourley et al, 2001; Vickers & 
Beverley, 2011). 
Folate metabolism is a source of promising drug targets, with strong potential for 
“drug repurposing”, making use of compounds originally designed to treat human cancers 
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or other infectious agents (Vickers & Beverley, 2011). Currently, research encompasses the 
role of specific folate-pathway enzymes in metabolism, in virulence, in resistance to anti-
folates and their characterization as drug targets. 
 
3.  Living in the phagolysosome 
Many clinically relevant microorganisms are able to survive and replicate inside 
macrophages (MØ). Most of them have evolved mechanisms to divert or escape the 
phagocytic pathway, ultimately evading the microbicidal responses of these cells. 
Leishmania protozoans, in particular, somehow manage to counteract the phagolysosome 
hostile environment, living and proliferating inside this compartment.  
Remarkably, Leishmania promastigotes preferentially catabolise sugars via 
glycolysis, inclusively, a high glucose uptake and glycolytic flux can be observed in 
replicative forms (Opperdoes & Coombs, 2007). However, in contrast, Leishmania 
amastigotes have complex nutritional demands, and this has probably precluded these 
parasites from establishing themselves in compartments such as early endosomal or non-
hydrolytic vacuoles of MØ (McConville et al, 2007). The latter compartments are enriched 
in lipids, but lack sustainable levels of sugars or amino acids (Lorenz et al, 2004; Muñoz-
Elías & McKinney, 2005), and Leishmania is not able to use fatty acids as its primary energy 
source (McConville et al, 2007). Actually, the variable nutritional composition of the host cell 
phagolysosome might be one of the reasons why Leishmania promastigotes cannot 
replicate or differentiate into amastigotes in neutrophils (Van Zandbergen et al, 2004). Some 
of the metabolites Leishmania amastigotes can successfully uptake include hexoses, amino 
acids, polyamines, purines, vitamins, sphingolipids, heme, Fe2+ and Mg2+ cations, among 
others (Podinovskaia & Descoteaux, 2015).  
Despite the phagolysosome seems like an inhospitable environment, Leishmania 
amastigotes somehow manage to survive and proliferate long-term inside the mature 
phagolysosome of mammalian MØs (Saunders et al, 2014). Actually, considering many 
Leishmania auxotrophs do not display any loss of virulence or manage to persist for long 
terms in animal hosts, this suggests that the phagolysosome may be somehow a permissive 
niche (McConville et al, 2007).  
Amastigotes undergo a glucose-sparing state, characterized by a sharp decrease in 
glucose uptake and a negligible secretion of metabolic end-products. This phenotype can 
be classified as a “stringent metabolic response” (Saunders et al, 2014). However, 
importantly, the general decrease in glucose uptake is not associated to an increase in 
amino acid metabolism and only in a small extent to an increase in fatty acid β-oxidation. 
Thus, this unique metabolic state is related to a more efficient energy metabolism, coupled 
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with a decrease in protein and lipid biosynthesis, processes that occur at a great energy 
expense. There is inclusively a carbon redirection into intracellular carbohydrate reserves 
(Saunders et al, 2014). However, these parasites become much dependent on 
mitochondrial metabolism for glutamate and glutamine biosynthesis, which apparently they 
are unable to salvage in the required extent from the phagolysosome (Saunders et al, 
2014). The infectivity defects found for glucose transporter knockout (Rodríguez-Contreras 
et al, 2006) and gluconeogenic enzyme FBPase knockout (Naderer et al, 2006) mutants 
highlight the importance of carbohydrates in amastigotes, demonstrating that glucose 
transporters and gluconeogenesis are required for viability.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Rearrangement of L. mexicana carbon metabolism in different 
developmental stages. The image depicts key pathways of carbon utilization in 
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promastigotes (A) and amastigotes (B). Major carbon sources (blue box) and overflow 
metabolites (open box). Fluxes through dotted pathways are down-regulated relative to the 
other stage. Steps inhibited by NaFAc and MSO are illustrated. aKG, a-ketoglutarate; 
AcCoA, acetyl-CoA; Ala, alanine; Asp, aspartate; Cit, citrate; Fum, fumarate; FA, fatty acids; 
G6P, glucose-6-phosphate; G3P, glyceraldehyde 3-phosphate; Gln, glutamine; Glu, 
glutamate; Mal, malate; OAA, oxaloacetate; OAc, acetate; PEP, phosphoenolpyruvate; 
PPP, pentose phosphate pathway; Pro, proline; Pyr, pyruvate; SCoA, succinyl-CoA; Suc, 
succinate; TCA, tricarboxylic acid cycle. Adapted from Saunders et al, 2014. 
 
It has been proposed that this stringent metabolic state may facilitate a long-term 
amastigote survival in the nutrient-limited environment of the phagolysosome, but 
simultaneously and paradoxically increasing the dependency on carbohydrates uptake and 
metabolism (Saunders et al, 2014).  
 
4. Targeting the pentose phosphate pathway 
Apart from glycolysis, glucose is metabolized by PPP, whose role on protozoa and 
their interaction with their hosts has become very attractive.  
It is a key metabolic pathway that relies on the use of glucose and is classically 
divided in two branches: an oxidative branch and a non-oxidative branch, the latter is 
responsible for the interconvertion of phosphorylated saccharides (Fig. 24). The resulting 
products (ribose-5-phosphate - R5P), intermediates (glyceraldehyde-3-phosphate - G3P, 
fructose-6-phosphate - F6P) and cofactors (NADPH) are used to synthesize nucleic acids 
and lipids, as well as to maintain redox homeostasis (Stryer, 1999). PPP does not 
necessarily act as a cycle, as the enzymatic reactions can be adjusted according to the cell 
demands (Stryer, 1999). In most organisms, this pathway localises to the cytosol, but in 
trypanosomatids it localises between the glycosomes and the cytosol (Hannaert et al, 
2003).  
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Figure 24. Pentose phosphate pathway in trypanosomatids.  The green dots represent 
substrates and products that are shared with other pathways. The enzymes of the oxidative 
and non-oxidative branch are depicted in orange and light blue, respectively: G6PDH, 
glucose-6-phosphate dehydrogenase; 6PGL, 6-phosphogluconolactonase; G6PDH, 6-
phosphogluconate dehydrogenase; RPIB, ribose-5-phosphate isomerase B; RPE, ribose-
5-phosphate epimerase; TKT, transketolase; TAL, transaldolase; AL, aldolase. The figure 
also illustrates 1) membrane transporters of R5P and/or nucleotides; 2) the phosphorylation 
of ribose by ribokinase (question mark); 3) the riboneogenesis pathway that accounts on 
aldolase (AL), sedoheptulose biphosphatase (SBP) and tansketolase (TKT). DHAP, 
dihydroxyacetone phosphate. Essential enzymes are marked in yellow, and enzymes 
absent in Leishmania and T. brucei are marked in black and red, respectively. Adapted from 
Comini et al, 2013.  
 
On a drug development perspective, some PPP enzymes seem worthy to explore 
due to several crucial aspects: 1) detrimental for parasite survival or infectivity and/or 
substantial divergence to the mammalian counterparts; 2) ease of producing recombinant 
proteins in native conditions as well as ease of performing in vitro activity assays; 3) 
availability of structural data (Comini et al, 2013). 
 
4.1.  The oxidative branch 
The oxidative branch includes three steps, resulting in two NADPH molecules for 
each glucose-6-phosphate (G6P) molecule that is consumed, finally generating ribulose-5-
phopshate (Ru5P) (Barrett, 1997).  
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Glucose-6-phosphate dehydrogenase (G6PDH; Fig. 24) is the first enzyme of the 
oxidative branch of PPP, catalysing the oxidation of G6P to 6-phosphogluconolactone as 
NADP+ is reduced to NADPH. This enzyme shares approximately 50% identity to the human 
orthologue (Comini et al, 2013). It localises mostly to the cytosol, although there is a small 
fraction compartimentalized in the glycosomes, although a typical peroxisomal targeting 
sequence (PTS) is absent (Duffieux et al, 2000; Opperdoes & Szikora, 2006). T. brucei and 
L. mexicana have a single copy sequence, whereas T. cruzi has five copies, two of them 
being pseudogenes. This enzyme has been validated as a drug target in T. brucei, using 
RNAi, probably due to the depletion of nucleotide and NADPH pools (Cordeiro et al, 2009). 
The steroids dehydroepiandrosterone (DHEA) and epiandrosterone (EA) inhibit the T. 
brucei enzyme, and exhibit in vitro anti-parasitic activity against bloodstream forms 
(Cordeiro et al, 2009). A critical role in anti-oxidant defence has been demonstrated for 
G6PDH in T. cruzi and Leishmania (Ghosh et al., 2015; Gupta et al., 2011).  
The second step of this pathway is catalysed by 6-phosphogluconolactonase 
(6PGL; Fig. 24), which hydrolyses 6-phospogluconolactone into 6-phosphogluconate 
(Duffieux et al, 2000). In T. brucei, it localises mostly in the cytosol, but around 15% localises 
to the glycosomes, and a PTS-1 signal peptide can be found (Duclert-Savatier et al, 2009; 
Opperdoes & Szikora, 2006). It has only 20% identity to the human orthologue and the 
structure has been recently solved. Although its substrate, 6-phospogluconolactone, can 
spontaneously hydrolyse, in conditions of high NADPH demand, it may accumulate 
especially inside the glycosomes.  Due to its electrophilic character, it may irreversibly 
inactivate key metabolic enzymes. Therefore, 6PGL may have a detrimental role to prevent 
the accumulation of this PPP intermediate. However, its essentiality has not been 
addressed in any trypanosomatid (Comini et al, 2013). 
The last step is catalysed by 6-phosphogluconate dehydrogenase (6PGDH; Fig. 24), 
which is responsible for the oxidation and decarboxylation of 6-phosphogluconate to Ru5P, 
while again reducing NADP+ to NADPH (Dickens & Glock, 1951). It has only around 35% 
homology to the human counterpart, however there is a high conservation of the residues 
involved in the substrate and coenzyme binding, challenging the design of selective 
inhibitors (Barrett, 1997; Comini et al, 2013). Similarly to the first two enzymes of the 
pathway, it localises predominantly to the cytosol, and in a less extent to the glycosomes 
(Heise & Opperdoes, 1999). In T. brucei, deletion of 6PGDH leads to the accumulation of 
6-phosphogluconate, which inhibits phosphoglucose isomerase and consequently 
glycolysis. This is probably exacerbated in vivo with the increase of G6P flow through the 
PPP. Moreover, it remains to be investigated whether a decrease in R5P production also 
plays a role in the observed defect (Comini et al, 2013). Some analogues of the high energy 
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intermediate (hydroxamate derivatives of D-erythronic acid) were found to be potent and 
selective inhibitors of Tb6PGDH (Dardonville et al, 2004), however the best compounds did 
not have trypanocidal activity due to its poor membrane permeability. Therefore, phosphate 
prodrugs have been developed to overcome this limitation. In particular, aryl 
phosphoramidate prodrugs of 2,3-o-isopropylidene-4-erythrono hydroxamate displayed a 
high in vitro antiparasitic activity (Ruda et al, 2010). 6PGDH essentiality has not been 
addressed so far in Leishmania and T. cruzi. 
In summary, the oxidative branch is therefore crucial, as it supplies not only Ru5P, 
a precursor of the non-oxidative branch, but also NADPH, an essential molecule for lipid 
synthesis, defence against oxidative stress by regenerating GSH, among other important 
cellular processes (Comini et al, 2013). 
 
4.2.  The non-oxidative branch 
The non-oxidative branch generates important metabolites that can be then used 
for nucleic acids or amino acids synthesis. It starts with the conversion of Ru5P generated 
in the last step of the oxidative branch into R5P or xylulose-5-phosphate (X5P). Immediately 
downstream there two enzymes, transketolase (TKT) and transaldolase (TAL), which 
catalyse interconversion reactions between R5P/ X5P and glycolytic intermediates 
G3P/F6P (Stryer, 1999).  
Ribose-5-phosphate isomerase (RPI; Fig. 24) is responsible for the interconversion 
of R5P in Ru5P. Two types of RPI enzymes can be found. Type A RPI (RPIA) is represented 
in all life kingdoms, contrasting with the type B (RPIB), restricted to some bacteria and 
protozoans (Sorensen & Hove-Jensen, 1996). An adverse phenotype was observed in E. 
coli (Sorensen & Hove-Jensen, 1996) and also humans (Huck et al, 2004) upon RPI 
deficiency, suggesting a critical conserved role through evolution. Trypanosomatids 
possess a type B RPI with no mammalian homologue (Al-Mulla Hummadi et al, 2006; Cronin 
et al, 1989; Kaur et al, 2012; Loureiro et al, 2015; Stern et al, 2007; Stern et al, 2011). RPIB 
has been previously proposed as a drug target in Leishmania and T. cruzi, awaiting genetic 
validation (Kaur et al, 2012; Stern et al, 2011). Moreover, an analogue of the isomerization 
intermediate, 4-phospho-D-erythronohydroxamic acid (4-PEH), has been proven to inhibit 
TcRPIB (Stern et al, 2007). However, it also inhibits RPIA (Roos et al, 2005) and its anti-
parasitic has not been tested yet.  
Another player of the PPP non-oxidative branch is ribose-5-phosphate epimerase 
(RPE; Fig. 24), which interconverts Ru5P and X5P. In T. brucei RPE activity was detected 
in procyclics, but not in parasites isolated from mice (Cronin et al, 1989). In T. cruzi, the 
enzyme is expressed in all developmental stages (Comini et al, 2013). Leishmania encodes 
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for two isoenzymes that differ in the presence and absence of a PTS (Opperdoes & 
Coombs, 2007), and the first has been recently detected in L. donovani glycosomes 
(Jamdhade et al, 2015). Inclusively, its activity has been detected in L. mexicana 
promastigotes and was 3 fold higher than its competitor enzyme, RPIB (Maugeri et al, 
2003).  
TKT (Fig. 24) can catalyse two different reversible reactions, using thiamine 
diphosphate as a cofactor. The first converts X5P to R5P, producing G3P and 
sedoheptulose-7-phosphate (S7P). The second converts X5P to erythrose-4-phosphate 
(E4P), generating G3P and F6P (Stryer, 1999). In trypanosomatids, at least two residues 
involved in the substrate and cofactor binding are not conserved when comparing to the 
human counterpart (Comini et al, 2013). TKT is expressed in all developmental stages of 
T. cruzi and its activity has been reported in several Leishmania species (Comini et al, 
2013). In particular, in L. mexicana it displays dual localization (cytosol and glycosomes) 
(Veitch et al, 2004). TKT activity has not been detected in T. brucei parasites recovered 
from the mice (Cronin et al, 1989), very similarly to RPE. Therefore, these two enzymes do 
not qualify as drug targets against African trypanosomes. Apparently a great extent of the 
non-oxidative branch of PPP appears dispensable for T. brucei bloodstream forms contrarily 
to insect stage (Comini et al, 2013; Creek et al, 2015). This metabolic adaptation may be 
employed in order to channel sugar metabolization exclusively into R5P and NADPH 
generation, to support the high proliferation rate of the bloodstream forms (Comini et al, 
2013; Creek et al, 2015). Since T. cruzi and Leishmania present a fully operative PPP, the 
role of TKT in these parasites still awaits to be unravelled. This enzyme may prevent the 
accumulation of toxic metabolites or modulate NADPH production by redirecting sugar 
phosphates towards the oxidative branch of the pathway (Comini et al, 2013). 
Another enzyme is TAL (Fig. 24), which transfers a three-carbon fragment, 
dihydroaxyacetone, from S7P to G3P, producing F6P and E4P. It also catalyses the inverse 
reaction (Comini et al, 2013). TAL activity has been detected in Leishmania and 
trypanosomes (Comini et al, 2013). In T. brucei, due to its defective PPP non-oxidative 
branch, this enzyme can be disregarded as a drug target. However, in Leishmania and T. 
cruzi further studies should be undertaken in order to draw any conclusions.  
It is also noteworthy that organisms, like yeast, have an alternative pathway for R5P 
synthesis, designated riboneogenesis pathway, which is NADP-independent. This pathway 
transforms glycolytic intermediates into sedoheptulose-1, 7-biphosphate, by a combined 
action of TKL and ALD. Sedoheptulose-1, 7-biphosphate, through the action of 
sedoheptulose-1, 7-biphosphatase (Fig. 24), is converted into S7P, which can be a 
substrate of TKL to ultimately generate R5P (Clasquin et al, 2011). Genes encoding a 
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putative sedoheptulose-1, 7-biphosphatase are present in the genomes of T. brucei and T. 
cruzi, but absent in Leishmania (Opperdoes & Coombs, 2007). Importantly, it has not been 
formally demonstrated that this pathways operates in trypanosomes.  
Overall the components of the non-oxidative branch of PPP are more 
heterogeneous, comprising members that do not possess a mammalian homologue (RPIB) 
and others that are developmentally regulated and specifies-specific dispensable (RPE and 
TKT) (Comini et al, 2013). Furthermore, this branch deserves more attention in the context 
of drug target validation.  
 
5. Targeting asparagine metabolism 
Asparagine (Asn) metabolism has become very attractive in the recent years. Apart 
from cancer cells, in some pathogenic microorganisms, it has been surprisingly associated 
to survival, invasion and/or virulence (Baruch et al, 2014; Gesbert et al, 2014; Gouzy et al, 
2014; Hofreuter et al, 2008; Kullas et al, 2012; Leduc et al, 2010; Scotti et al, 2010; 
Shibayama et al, 2011).  
Asn is the last nonessential amino acid synthesised from glucose metabolism. This 
means it can be synthesized from central metabolic pathway intermediates and therefore is 
not required from the diet (Zhang et al, 2014b). Asn displays a high nitrogen/carbon ration, 
being associated to nitrogen homeostasis as well. For a long time, in contrast with the other 
nineteen common amino acids, it seemed Asn was not involved in any other pathway but 
protein synthesis in mammalian cells (Ubuka & Meister, 1971; Zhang et al, 2014b). 
However, recent studies suggest Asn somehow coordinates cell responses with metabolic 
reserves, ultimately regulating cell fate (Zhang et al, 2014b).   
In the context of basic cell biology, Asn (N)-linked glycosylation of proteins is one of 
the most important post-translational modifications, in which there is the covalent 
attachment of an oligosaccharide into an Asn residue of polypeptide chains. This protein 
modification is found both in eukaryotes and in prokaryotes and classically takes place in 
the endoplasmic reticulum (Schwarz & Aebi, 2011).  
There are two major pathways involved in Asn metabolism – tRNA-dependent and 
tRNA-independent pathways. Additionally, cells also uptake Asn from the extracellular 
environment (Min et al, 2002). Different environmental and physiological conditions 
challenge organisms to adjust their Asn intracellular production and uptake (Zheng & 
Haselkorn, 1996). Some cells, genetically manipulated or leukemic cells, may actually rely 
mostly on Asn uptake. Some mutants become auxotrophic to Asn and require exogenous 
supplementation in order to grow (Qian et al, 2013). Leukemic cells, for instance, have low 
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levels of Asn and therefore become especially sensitive to its extracellular depletion, which 
has been explored in a therapeutic perspective (Avramis, 2012).  
Across trypanosomatids’ species and life cycle stages, the amino acid transporters 
(AAT) repertoire has a high interspecific variation, regarding number, affinity, specificity and 
capacity (Jackson, 2007). However, few information is available regarding Asn transport. In 
T. brucei, a protein presenting putative orthologues in Leishmania (Aurrecoechea et al, 
2010; El-Sayed et al, 2005; Ivens et al, 2005) was characterized as a transporter of several 
neutral amino acids, among which Asn (TbAATP1) (Ebikeme, 2007). For instance, Asn 
transporter inactivation in Francisella tularensis does not compromise phagosomal escape 
but it is critical for bacterial multiplication in the cytosol of the host (Gesbert et al, 2014). 
Nonetheless, the redundancy in AATs suggests that targeting them would be pointless 
(Ebikeme, 2007).  
 
5.1.  tRNA dependent reactions 
Aminoacyl-tRNA synthetases are key enzymes in protein translation, as they 
synthesize the tRNAs required for the process, in an ATP dependent manner. They perform 
a reaction that comprises two steps: 1) generation of an aminoacyladenylate, as ATP and 
an amino acid enter the catalytic site; 2) esterification of the amino acid to the tRNA, 
ultimately generating the final ‘charged’ aminoacyl-tRNA (Pham et al, 2014).  
The synthesis of Asn-tRNAAsn can be catalysed by two independent aminoacyl-tRNA 
synthetases, a discriminating and a non-discriminating enzyme. In the presence of the first, 
a classical aminoacylation occurs resulting in Asn-tRNAAsn (Min et al, 2002). Interestingly, 
a great part of prokaryotes, bacteria and archaea, uses a undiscriminating aspartyl-tRNA 
synthetase (Blaise et al, 2011). The latter generates a misacylated Asp-tRNAAsn molecule 
that suffers an amidation catalysed by Asp-tRNAAsn amidotransferase, ultimately generating 
Asn-tRNAAsn (Blaise et al, 2011). The presence of undiscriminating aspartyl-tRNA 
synthetases normally occur in organisms that lack the asparaginyl-tRNA synthetase 
(AsnRS), with few exceptions of organisms that can simultaneously use both (Curnow et al, 
1998; Roy et al, 2003).  
For a long time, aminoacyl-tRNA synthetases have been pursued as drug targets in 
bacteria and fungi, and more recently in protozoa. Actually drug repurposing of inhibitors, 
firstly designed to inhibit the bacterial counterparts, is a very prominent strategy to obtain 
new anti-parasitic drugs (Pham et al, 2014). However, the major issue is selectivity, 
because humans encode for 36 aminoacyl-tRNA synthetases that have eukaryotic and 
bacterial origins. As several crystal structures for parasite enzymes have been solved, this 
may enable rational drug design (Pham et al, 2014). For the purpose, structures that diverge 
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from the human homologue or parasite specific modifications must be explored to achieve 
the desired selective inhibition (Bour et al, 2009; Gowri et al, 2012). Several aminoacyl-
tRNA synthetases appear to be promising drug targets against several parasites such as 
Plasmodium, Brugia (causative agent of lymphatic filariasis), trypanosomes and 
Leishmania (Pham et al, 2014).  
The cytoplasmic AsnRS has been a longstanding drug target in Brugia malayi 
(Pham et al, 2014), and recently, in T. brucei bloodstream forms, its knockdown led to a 
severe growth impairment (Kalidas et al, 2014).  
 
5.2.  tRNA independent reactions 
Within the t-RNA independent pathway for Asn synthesis, asparagine synthetase 
(AS) is a crucial player. It catalyses Asn formation from aspartate in an ATP dependent 
manner using ammonia or glutamine as nitrogen donors. The reaction mechanism 
comprises two crucial steps: 1) the formation of β-aspartylAMP, in which β-carboxylate 
group of aspartate is activated by ATP; 2) nucleophilic attack by an ammonium ion. This 
mechanism mirrors the close evolutionary relation to aminoacyl-tRNA synthetase enzymes 
(Nakatsu et al, 1998). There are two structurally distinct types of AS: A and B (Sugiyama et 
al, 1992).  
Type B (AS-B) uses preferably glutamine over ammonia, with exception of the 
human enzyme that uses both in the same extent. It can be found in prokaryotes and 
eukaryotes (mammalian cells, yeasts, Chlamydomonas reinhardtii, higher plants) (Andrulis 
et al, 1987; Andrulis et al, 1989; Ciustea et al, 2005; Humbert & Simoni, 1980; Merchant et 
al, 2007; Ramos & Wiame, 1980; Scofield et al, 1990). In the N-terminal there is a 
glutaminase domain that hydrolyses glutamine, releasing ammonia, which travels through 
an intramolecular channel till the C-terminal where the synthetase domain is assembled. 
The released ammonia performs the nucleophilic attack to the β-aspartylAMP, generating 
Asn and releasing AMP (Boehlein et al, 1994; Boehlein et al, 1998). It has been proposed 
that AS-B results from the fusion of an ancestral glutamine amidotransferase gene with an 
ancestral ammonia dependent AS gene homologous to ASA (Gaufichon et al, 2013). As 
previously stated, leukemic cells display low levels of Asn due to the lack of constitutive 
expression of AS-B, becoming particularly sensitive to Asn extracellular depletion, and for 
this reason L-asparaginase has been successfully employed in the treatment of acute 
lymphoblastic leukemia (Avramis, 2012). Resistance to this treatment has been associated 
to AS-B and therefore a combination therapy comprising L-asparaginase and AS-B 
inhibitors has been pursued (Stams et al, 2005). AS-B per se has been regarded as a 
potential drug target in some forms of solid cancer as well (Dufour et al, 2012; Yang et al, 
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2014). Importantly, in mammalian cells, AS-B is a transcriptional target of the well 
characterized GCN2/elF2α/ATF4 axis (Fig. 25), in response to amino acid starvation. The 
phosphorylation of elF2 leads to a repression of general protein synthesis, as well as an 
activation of gene-specific translation (Horiguchi et al, 2012; Ye et al, 2010).  
 
Figure 25. Translational control by elF2 kinases in mammalian cells. Mammals that 
possess four elF2 kinases: GCN2, HRI, PKR and PEK/PERK, which are activated under 
different stressful conditions, such as amino acid, glucose or purine deprivation, among 
others. The phosphorylation of elF2 leads to a repression of general protein synthesis, as 
well as an activation of gene specific translation. In the case of GCN2 mediated elF2 
phosphorylation, upon activation of ATF4, there is an increase in ASB transcription. ATF4, 
activating transcription factor 4; elF2α, eukaryotic initiation factor 2α; GCN2, general control 
nonderepressible kinase 2; HRI, heme regulator elF2α kinase; PERK, protein kinase RNA- 
like endoplasmic reticulum kinase; PKR, protein kinase R. Adapted from Trinh & Klann, 
2013. 
 
On the other hand, type A enzymes (AS-A) are found mainly in prokaryotes (E. coli 
and Klebsiella aerogenes) or in archaea (Pyrococcus abyssi) and initially described as 
strictly ammonia dependent (Blaise et al, 2011; Nakamura et al, 1981; Reitzer & Magasanik, 
1982). It has been proposed that AS-A descends from an aspartyl-tRNA synthetase 
ancestor, which first lost the anticodon binding domain, followed by a rearrangement of the 
catalytic site in order to acquire the ability to activate the β-carboxylate of aspartate (Blaise 
et al, 2011).  
Several roles have been attributed to bacterial AS. For instance, in Pasteurella 
multocida, AS-A is substantially upregulated during host infection, in Mycobacterium 
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smegmatis AS-B is involved in natural resistance to antibiotics and in Mycobacterium 
tuberculosis, AS-B was reported to be required for in vitro growth (Boyce et al, 2002; Griffin 
et al, 2011; Ren & Liu, 2006; Sassetti et al, 2003).  
Surprisingly, kinetoplastids and other protozoans, despite being eukaryotes, 
possess not only a putative AS-B but also a bacterial type AS-A (Gowri et al, 2012; Manhas 
et al, 2014). L. donovani AS-A was reported to be essential for parasite survival, and due 
to its absence in the human host, emerged as a novel drug target candidate (Manhas et al, 
2014).  
Another important player in t-RNA-independent pathway of Asn metabolism are 
asparaginases. These enzymes hydrolyse Asn into aspartate and ammonium ion. This 
reaction is performed in two subsequent steps: 1) generation an acyl-enzyme intermediate, 
as the nucleophilic threonine attacks the carbonyl group of the amide substrate, releasing 
ammonia; 2) aspartate production, as water attacks the acyl-enzyme intermediate 
(Michalska & Jaskolski, 2006). Asparaginases have been implicated in the virulence of 
several pathogens, and some striking examples include Helicobacter pylori, Campylobacter 
jejuni, Salmonella typhimurium and M. tuberculosis. H. pylori, C. jejuni, S. typhimurium 
secrete asparaginase into the periplasm, which is thought to contribute to Asn depletion 
and starvation mediated immune cell exhaustion, allowing the colonization of the host 
(Gesbert et al, 2014; Hofreuter et al, 2008; Kullas et al, 2012; Leduc et al, 2010; Scotti et 
al, 2010; Shibayama et al, 2011). In M. tuberculosis (Fig. 26), for instance, secretion of 
asparaginase into the phagosome is important for nitrogen and aspartate assimilation and 
allows mycobacterial growth in acidic conditions through ammonia release and pH buffering 
(Gouzy et al, 2014).   
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Figure 26. The role of asparagine catabolism in M. tuberculosis intracellular survival. 
In macrophages, Asn enters M. tuberculosis phagosome by an unknown mechanism. Asn 
is uptaken by the bacteria through AnsP2 and one or more additional transporter(s) yet to 
be identified. Further, it is hydrolysed by cytosolic AnsA resulting in nitrogen assimilation 
into glutamine and glutamate and release of ammonia. AnsA is also secreted in the 
phagosome and hydrolyses Asn, producing aspartate and ammonia. Aspartate is imported 
by AnsP1. The released ammonia neutralises the protons and allows pH buffering. AnsA, 
asparaginase; AnsP1/AnsP2, amino acid transporters; Asn, asparagine. Adapted from 
Gouzy et al, 2014. 
 
Another noteworthy example of the relevance of Asn metabolism in the context of 
infection is the extracellular pathogenic bacterium group A Streptococcus (GAS). The 
bacteria is able to elegantly modulate the host metabolism in order to regulate its own 
sensing and proliferation. Adhering GAS delivers streptolysins O and S to host cells 
triggering endoplasmatic reticulum stress and AS-B upregulation. Subsequent increased 
levels of Asn are sensed by GAS inducing the transcription of, among others, genes 
responsible for bacterial proliferation. Bacteremia without a defined focus is a hallmark of 
highly invasive GAS, and treatment with asparaginase successfully arrested GAS growth in 
an in vivo model of infection (Baruch et al, 2014). Considering that Staphylococcus aureus, 
Listeria monocytogenes and Clostridium botulinium also possess the same streptolysins, 
eventually, they may be able to manipulate host cell metabolism in their favour in a similar 
fashion, and therefore, treatment with asparaginase could be successful in a broad range 
of human pathogens (Baruch et al, 2014).  
In T. brucei, asparaginase does not seems to be present (Ginger et al, 2007). In 
contrast, L. donovani has genes encoding for putative asparaginase enzymes, however, 
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this has not been experimentally demonstrated, nor its role on parasite survival and 
development (Singh et al, 2015). 
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1. Scope of the thesis 
Leishmaniasis has a significant impact on public health worldwide. VL is the 
most severe form of the disease, and its control relies mainly on chemotherapy and 
vector control, both presenting several limitations that hinder disease eradication in 
endemic areas (Kedzierski, 2010). Traditional chemotherapy is often associated with 
high cost, toxicity, complex administration regimes and resistances (Maltezou, 2010). 
This preoccupying scenario renders the search for new drugs and novel drug targets a 
priority.  
Exploring the availability of genome sequence and in silico prediction tools, we 
have performed a comparative genomic analysis to identify potential molecular targets 
in trypanosomatids. L. infantum and L. major genomes have been considered 
representatives of VL and CL causative agents, respectively (Ivens et al, 2005; Peacock 
et al, 2007; Rogers et al, 2011). Additionally, the genomes of T. brucei and T. cruzi, 
which cause sleeping sickness and Chagas disease respectively, have also been 
screened (Berriman et al, 2005; El-Sayed et al, 2005). African and American 
trypanosomiasis are also neglected tropical diseases associated with a great world 
burden, whose chemotherapy has been facing similar challenges to leishmaniasis. 
Starting with a total of 5791 orthologue genes, the application of several consecutive 
filters led to seven hits: 1) crucial for survival; 2) absence of a human homologue; 3) 
involvement in several metabolic pathways; 4) previously validated as a drug target in 
other microorganism. AS-A and RPIB were selected among the seven last hits based 
on the following criteria: 1) gene copy number; 2) “workable” size of the gene and 
protein; 3) availability of homologous 3D structures; 4) availability of theoretical 
inhibitors.  
However, in silico selection demands a chemical or genetic validation. Indeed, 
one of the main purposes of this thesis was to evaluate the impact of AS-A and RPIB 
on L. infantum and T. brucei survival and infectivity. Furthermore, proteins expression 
levels throughout parasite development as well as their cellular localization were also 
investigated. Moreover, recombinant proteins were expressed and in vitro enzymatic 
assays were established allowing their biochemical characterization.  
The functional characterization of AS-A and RPIB candidate targets comprised 
the following specific objectives:  
i. In silico analysis of the theoretical 3D structures;  
ii. Expression, purification and biochemical characterization of the recombinant 
proteins;  
iii. Analysis of protein expression level in different parasite developmental stages; 
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iv. Protein subcellular localization studies; 
v. In vitro and in vivo phenotypic analysis of RNAi or gene knockout transgenic 
parasites. 
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2. Results 
 
2.1. Asparagine synthetase A 
 
2.1.1. Knockdown of asparagine synthetase A renders Trypanosoma 
brucei auxotrophic to asparagine 
Asparagine synthetase (AS) catalyzes the ATP-dependent conversion of aspartate into 
asparagine using ammonia or glutamine as nitrogen source. There are two distinct types of 
AS, asparagine synthetase A (AS-A), known as strictly ammonia-dependent, and 
asparagine synthetase B (AS-B), which can use either ammonia or glutamine. The absence 
of ASA in humans, and its presence in trypanosomes, suggested AS-A as a potential drug 
target that deserved further investigation. We report the presence of functional AS-A in 
Trypanosoma cruzi (TcAS-A) and Trypanosoma brucei (TbAS-A): the purified enzymes 
convert L-aspartate into L-asparagine in the presence of ATP, ammonia and Mg2+. TcAS-
A and TbAS-A use preferentially ammonia as a nitrogen donor, but surprisingly, can also 
use glutamine, a characteristic so far never described for any AS-A. TbAS-A knockdown by 
RNAi didn’t affect in vitro growth of bloodstream forms of the parasite. However, growth was 
significantly impaired when TbAS-A knockdown parasites were cultured in medium with 
reduced levels of asparagine. As expected, mice infections with induced and non-induced 
T. brucei RNAi clones were similar to those from wild-type parasites. However, when 
induced T. brucei RNAi clones were injected in mice undergoing asparaginase treatment, 
which depletes blood asparagine, the mice exhibited lower parasitemia and a prolonged 
survival in comparison to similarly-treated mice infected with control parasites. Our results 
show that TbAS-A can be important under in vivo conditions when asparagine is limiting, 
but is unlikely to be suitable as a drug target. 
 
Reprinted from PLoS Neglected Tropical Diseases 2013 Dec 5; 7(12): e2578. doi: 
10.1371/journal.pntd.0002578 
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2.1.2. Leishmania infantum asparagine synthetase A is dispensable for 
parasites survival and infectivity 
A growing interest in asparagine (Asn) metabolism has currently been observed in cancer 
and infection fields. Asparagine synthetase (AS) is responsible for the conversion of 
aspartate into Asn in an ATP-dependent manner, using ammonia or glutamine as a nitrogen 
source. There are two structurally distinct AS: the strictly ammonia dependent, type A, and 
the type B, which preferably uses glutamine. Absent in humans and present in 
trypanosomatids, AS-A was worthy of exploring as a potential drug target candidate. 
Appealingly, it was reported that AS-A was essential in Leishmania donovani, making it a 
promising drug target. In the work herein we demonstrate that Leishmania infantumAS-A, 
similarly to Trypanosoma sp and L. donovani, is able to use both ammonia and glutamine 
as nitrogen donors. Moreover, we have successfully generated LiASA null mutants by 
targeted gene replacement in L. infantum and these parasites do not display any significant 
growth or infectivity defect. Indeed, a severe impairment of in vitro growth was only 
observed when null mutants were cultured in asparagine limiting conditions. Altogether our 
results demonstrate that despite being important under asparagine limitation, LiAS-A is not 
essential for parasite survival, growth or infectivity in normal in vitro and in vivo conditions. 
Therefore we exclude AS-A as a suitable drug target against L. infantum parasites. 
Reprinted from PLoS Neglected Tropical Diseases in press doi: 10.1371/journal.pntd.0004365 
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Abstract  
A growing interest in asparagine (Asn) metabolism has currently been observed in 
cancer and infection fields. Asparagine synthetase (AS) is responsible for the conversion of 
aspartate into Asn in an ATP-dependent manner, using ammonia or glutamine as a nitrogen 
source. There are two structurally distinct AS: the strictly ammonia dependent, type A, and 
the type B, which preferably uses glutamine. Absent in humans and present in 
trypanosomatids, AS-A was worthy of exploring as a potential drug target candidate. 
Appealingly, it was reported that AS-A was essential in Leishmania donovani, making it a 
promising drug target. In the work herein we demonstrate that Leishmania infantumAS-A, 
similarly to Trypanosoma sp and L. donovani, is able to use both ammonia and glutamine 
as nitrogen donors. Moreover, we have successfully generated LiASA null mutants by 
targeted gene replacement in L. infantum and these parasites do not display any significant 
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growth or infectivity defect. Indeed, a severe impairment of in vitro growth was only 
observed when null mutants were cultured in asparagine limiting conditions. Altogether our 
results demonstrate that despite being important under asparagine limitation, LiAS-A is not 
essential for parasite survival, growth or infectivity in normal in vitro and in vivo conditions. 
Therefore we exclude AS-A as a suitable drug target against L. infantum parasites. 
 
Author Summary 
It was recently described that asparagine synthetase A (AS-A) of trypanosomatids 
uses not only ammonia but also glutamine for asparagine formation, which was a surprising 
feature for a type A AS. Interestingly, Leishmania donovani AS-A was reported to be 
essential for parasite survival, and once a human homologue was absent, this is enzyme 
emerged as a novel drug target candidate. Leishmania infantum encodes for a functional 
AS-A enzyme, which also uses either ammonia or glutamine as nitrogen donor for 
asparagine synthesis. In L. infantum, ASA ablation drives parasites auxotrophic to 
asparagine, however, LiAS-A is not detrimental for parasite survival, growth or infectivity. 
AS-A is therefore unlikely to be a suitable drug target against Leishmania parasites.  
 
Introduction  
Leishmaniasis is a vector borne human disease, caused by several species of 
digenetic protozoan parasites belonging to genus Leishmania. The clinical presentations of 
this neglected tropical disease vary from selfhealing cutaneous manifestations to potentially 
fatal, if untreated, visceral ailment [1]. The most severe form of the disease, designated as 
visceral leishmaniasis (VL) is mainly associated to Leishmania donovani or Leishmania 
infantum. Due to the absence of human vaccines, VL control relies mainly on chemotherapy 
and appropriate vector control [2]. The traditional therapeutic options are associated with 
significant limitations (cost, toxicity, complex administration regimes, resistance) averting 
disease control in endemic areas [3]. As consequence, according to World Health 
Organization between 20,000 and 30,000 people (mostly children) die every year, rendering 
the search for novel chemotherapeutic options a priority [4]. 
Asparagine (Asn) metabolism has been under the spotlight in the recent years. Asn 
is the last nonessential amino acid to be synthesised from glucose metabolism [5]. For many 
years it seemed it was not involved in any other pathway but protein synthesis in mammalian 
cells, contrasting with the other 19 common amino acids [6]. Nonetheless, several recent 
studies suggest Asn somehow coordinates cell responses with metabolic reserves and 
ultimately regulates cell fate [5]. In many pathogenic microorganisms, functional studies on 
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L-asparaginase and Asn transporters have implicated Asn metabolism in survival, invasion 
and/or virulence [7-14].   
Asparagine synthetase (AS) is another key player in Asn metabolism, it catalyses 
Asn formation from aspartate in an ATP dependent manner using ammonia or glutamine 
as nitrogen donors. The reaction mechanism comprises two crucial steps: 1) the formation 
of β-aspartylAMP, in which β-carboxylate group of aspartate is activated by ATP; 2) 
nucleophilic attack by an ammonium ion. This mechanism mirrors the close evolutionary 
relation to aminoacyl-tRNA synthetase enzymes [15]. There are two structurally distinct 
types of AS: A and B [16].  Type B (AS-B, EC. 6.3.5.4) uses preferably glutamine over 
ammonia and can be found in prokaryotes and eukaryotes (mammalian cells, yeasts, 
Chlamydomonas reinhardtii, higher plants) [17-23]. Type A (AS-A, EC. 6.3.1.1) are found 
mainly in prokaryotes (Escherichia coli [24] and Klebsiella aerogenes [25]) or in archaea 
(Pyrococcus abyssi [26]) and described as strictly ammonia dependent. Surprisingly, 
kinetoplastids and other protozoans, despite being eukaryotes, possess not only a putative 
AS-B but also a bacterial type AS-A [27-29]. Moreover AS-A from Trypanosoma brucei, 
Trypanosoma cruzi [28] and L. donovani [29] parasites were reported to use glutamine as 
nitrogen donor as well. 
Several roles have been associated to bacterial AS. For instance, in Pasteurella 
multocida, AS-A is significantly upregulated during host infection, in Mycobacterium 
smegmatis AS-B is involved in natural resistance to antibiotics and in Mycobacterium 
tuberculosis, AS-B was reported to be required for in vitro growth [30-33].  
Recently our group showed that in T. brucei bloodstream forms AS-A knockdown 
has no impact on parasites growth or infectivity, except upon Asn deprivation. These results 
suggest Asn main sources are AS-A mediated synthesis and extracellular uptake [28]. 
Surprisingly, in L. donovani, AS-A was claimed to be essential for parasites survival and 
emerged as a promising drug target due to the absence of a human homologue [29].  
Additionally, these results also suggest that Asn homeostasis could be differently regulated 
among trypanosomatids. These parasites present different amino acid requirements for 
either energetic or osmotic functions in different stages of their life cycles and as a reflex of 
the different environmental stimuli they receive in the vector or mammalian host [34]. Across 
trypanosomatids’ species, the amino acid transporters (AAT) repertoire has a high 
interspecific variation, regarding number, affinity, specificity and capacity [34]. For instance, 
in the case of cysteine, a crucial amino acid for thiol biosynthesis, Leishmania major 
contrarily to T. brucei, fails to uptake it at a rate that ensures the intracellular pool is enough 
for optimal growth. Therefore, these parasites rely mainly on pathways that enable cysteine 
synthesis [35].   
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In this work, we have biochemically characterized L. infantum AS-A (LiAS-A), and 
to gain further insights on AS-A essentiality across different Leishmania species, we have 
performed gene replacement studies in L. infantum. 
 
Methods 
Ethics statement. All experiments were carried out in accordance with the 
IBMC.INEB Animal Ethics Committee and the Portuguese National Authority for Animal 
Health (DGAV) guidelines, according to the statements on the directive 2010/63/EU of the 
European Parliament and of the Council. DGAV approved the animal experimentation 
presented in this manuscript under the license DGAV number 25268/2013-10-02. 
 
Chemicals and reagents. L-asparagine, L-aspartic acid sodium salt monohydrate, 
L-glutamine, L-glutamatic acid salt hydrate, ATP disodium salt hydrate, AMP disodium salt, 
sodium pyrophosphate decahydrate, ninhydrin, dNTPs, ammonium chloride, magnesium 
chloride, tween-20, tris-base, urea, thiourea, DTT, triton X-100 and IPTG (isopropyl-β-D- 
thiogalactopyranoside) were purchased from Sigma. Oligonucleotide primers were obtained 
from STAB VIDA. Restriction endonucleases were from New England Biolabs. Polyclonal 
antibodies against LiAS-A were obtained in rabbits inoculated with purified recombinant His-
tagged LiAS-A. E. coli L-asparaginase was purchased from Prospec. 
 
Parasites. L. infantum (MHOM/MA/67/ITMAP-263) promastigote forms were grown 
at 26ºC in complete RPMI 1640 medium [36]. For in vitro and in vivo characterization, 
different cell lines were firstly recovered from the spleen of infected BALB/c to restore 
virulence, and subsequently maintained in culture no longer than 10 passages [36]. Axenic 
amastigotes were grown in MAA complete medium [36], at 37ºC, 5% CO2. Depending on 
the analysis, protein extracts were prepared as follows: 1) 1 x 107 late-stationary 
promastigotes were resuspended in T8 lysis buffer (tris-base 0.6%, urea 42%, thiourea 
15%, DTT 0.3%, triton X-100 1%); or 2) 1 x 108 promastigotes or axenic amastigotes were 
resuspended in 100 µL of PBS containing protease inhibitor (Roche) and following 6 
freezing/thaw cycles, the parasite suspensions supernatants were recovered and then 
quantified using Bio-Rad DC Protein Assay (Biorad).  
 
AS-A protein alignments and LiAS-A/LmAS-A homology models. EcAS-A, 
LiAS-A, LmAS-A, TbAS-A and TcAS-A protein alignments were performed using the 
ClustalW program [37]. Aline program, Version 011208 [38], was used for editing protein 
sequence alignments. LiAS-A and LmAS-A homology models were obtained with SWISS-
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MODEL, using EcAS-A crystal structure (Protein Data Bank (PDB) 12AS [15]) as a template 
(percentage of sequence identity of ~50-60% in both cases) [39-41]. The 3D models were 
illustrated using PyMOL program (The PyMOL Molecular Graphics System, Version 1.3, 
Schrödinger, LLC). 
 
Cloning ASA genes. Asparagine synthetase A (ASA) from L. infantum 
(LinJ.26.0790; chromosome LinJ.26; 234298 - 235360) was obtained by performing PCR 
on genomic DNA, extracted using DNAzol (Invitrogen) [42-44], using primers 1 + 2 (Table 
S1). PCR conditions were as follows: initial denaturation (2 min at 94ºC), 35 cycles of 
denaturation (30 s at 94ºC), annealing (30 s at 50ºC) elongation (2 min at 68ºC) and a final 
extension step (10 min at 68ºC). Another restriction strategy was required to clone the gene 
into a Leishmania overexpression vector – pSPαBLASTα, and the sequence was amplified 
using primers 3 + 4 (Table S1). PCR conditions were as follows: initial denaturation (2 min 
at 94ºC), 30 cycles of denaturation (15 s at 94ºC), annealing (30 s at 55ºC) elongation (1 
min at 72ºC) and a final extension step (10 min at 72ºC). All PCR products were cloned into 
a pGEM-T Easy vector (Promega) and sent for sequencing. 
 
Expression and purification of poly-His-tagged recombinant LiAS-A. The 
LiASA gene was excised from the pGEM-T Easy vector (using NdeI/EcoRI), and subcloned 
into pET28a(+) expression vector (Novagen). The resulting construct presented a poly-His 
tag (6x Histine residues) at the N-terminal and was transformed into E. coli BL21DE3. The 
recombinant protein was expressed by induction of log-phase cultures with 0.5 mM of IPTG 
at 18ºC O/N. Bacteria were harvested and resuspended in buffer A (0.5 M NaCl, 20 mM 
Tris.HCl, pH 7.6). The sample was sonicated, according to the following conditions: output 
4, duty cycle 50%, 10 cycles with 15 s each (Branson sonifier 250), followed by 
centrifugation to obtain the bacterial crude extract. For enzymatic activity experiments and 
rabbit polyclonal antibody production, the recombinant enzyme was purified in one step 
using Ni2+ resin (Qiagen) pre-equilibrated in buffer A. The column was washed sequentially 
with buffer A, bacterial crude extract, and buffer A with increasing concentrations of 
imidazole. LiAS-A was eluted in the fractions of buffer A containing 100 to 500 mM of 
imidazole. Dialysis was performed against PBS.  
For additional activity tests, oligomeric form and Stokes’ radius assessment, a 
deeper purification was performed. Firstly, the enzyme was purified by affinity 
chromatography, using a Histrap HP column (GE Healthcare), charged with nickel sulphate 
and equilibrated in buffer A, and posteriorly mounted in an AKTAPrimer Plus (GE 
Healthcare) system, at 4ºC. Secondly, it was purified by size exclusion chromatography, in 
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a Hiprep 26/60 Sephacryl S-200 column (GE Healthcare), previously equilibrated with 
running buffer (150 mM NaCl, 20 mM Tris, pH 7.6). The last purification step was a 
preparative ion exchange chromatography, using an UNO Q-1 (Bio-Rad, Cat. No 720-0001) 
column, mounted in a BioLogic DuoFlow (Bio-Rad) device, at 4ºC. The fractions were finally 
analysed by analytic size exclusion chromatography and analytic ion exchange 
chromatography, using AktaPurifier10 system (GE Healthcare), using Superose 12 
10/300GL (GE Healthcare) column and a UNO Q-1 (Bio-Rad, Cat. No 720-0001) column, 
respectively. The final fractions were concentrated using Millipore centrifugal filter 30K 
(Amicon Ultra).  
Concentration was determined measuring the absorbance at 280 nm using the 
theoretical molar extinction coefficient of 46910 M-1.cm-1 for LiAS-A, making use of 
NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies). The purified 
recombinant protein was resolved in SDS/PAGE and stained with Coomassie Brilliant Blue 
G-250 (Biorad).  
For estimation of the LiAS-A oligomeric state the purified recombinant protein was 
analysed by analytic size exclusion chromatography, using the above described conditions. 
Blue dextran (2,000 kDa), catalase (MW 232 kDa, Stokes radius (SR) 5.22 nm), aldolase 
(MW 158 kDa, SR 4.81 nm), albumin (MW 67 kDa, SR 3.55 nm), ovalbumin (MW 43 kDa, 
SR 3.05 nm), chymotrypsinogen A (MW 25 kDa, SR 2.09 nm) and ribonuclease (MW 13.7 
kDa, SR 1.64 nm) were used as standards. A calibration curve relating Log (MW) or 
Log(SR) with Kav was performed (Kav is (Ve-V0)/(Vt-V0), in which Ve is elution volume, V0 is 
the exclusion volume given by blue dextran and Vt is the total volume of the column).   
 
Differential scanning fluorimetry. In a 96-well, thin-walled white PCR plate, 5 µl 
of LiAS-A (2.4 µM) were mixed with 5 µl of 10x SYPRO Orange (λexc 485 nm; λem 625 nm) 
and 40 µl of water or the ligands and ligands combinations to be tested. Plates were then 
sealed and placed into a BioRad iCycler5 PCR instrument. Measurements were taken every 
minute in 0.5ºC increments from 25º to 95ºC. Subsequent analysis of the fluorescent data 
using Biorad iCycler iQ Optical System Software Version 3.1 yielded the protein melting 
temperature (Tm) for LiAS-A. 
 
Western-blot analysis. Western-blot was performed aiming different purposes: (1) 
His-tag labelling of recombinant proteins, (2) LiAS-A labelling in total soluble parasite 
extracts to assess protein expression throughout the life cycle, (3) LiAS-A labelling in 
mutants and (4) to assess protein distribution upon digitonin fractionation. One μg of 
recombinant LiAS-A, 20 μg of total soluble extracts from both promastigote and amastigote 
Chapter III – Objectives and results 
 
147 
 
forms, or 1 x 107 parasites were resolved in SDS-PAGE and transferred onto a nitrocellulose 
membrane (TransBlot Turbo, Bio-Rad), which was blocked, probed, washed and developed 
as previously described [28]. The following primary antibodies were used: rabbit anti-His-
tag (MicroMol-413, 1:1000), mouse anti-α-tubulin (clone DM1A, Neomarkers, 1:1000), 
rabbit anti-LiAS-A (1:1000), rabbit anti-LiCS (cysteine synthase, 1:2000), rabbit anti-
LdHGPRT (hypoxanthine guanine phosphoribosyl transferase, 1:2000), and rabbit anti-
TbEnolase (1:5000). Horseradish peroxidase-conjugated goat anti-rabbit or goat anti-
mouse IgG (Amersham) (1:5000 for 1 h, at RT) were used as the secondary antibody. 
ImageJ software (version 1.43u) was used for protein semi-quantification. 
 
Enzymatic Assay. A 150 μl enzymatic mixture containing 85 mM Tris.HCl, 8.4 mM 
magnesium and varying concentration of aspartate, ammonia and ATP was assayed. The 
assay was performed as previously described [28], and ultimately absorbance at 340 nm 
was measured [45]. To determine the optimal conditions for kinetic parameter 
determination, reaction linearity was checked by varying enzyme concentration and time. 
The final reaction condition used 7.5 μg of enzyme per assay and 15 min incubation at 
37ºC. A pH range of 7.0 to 9.0 was assessed, and pH 7.6 was selected as the optimal one 
to perform the following enzyme assays. To determine the Km of each substrate a certain 
range of concentration was used and the remaining substrates were maintained in excess. 
For aspartate, ammonia, ATP and glutamine, the following concentrations were used: 1.25 
to 20, 0.78 to 50, 0.625 to 10 and 1.56 to 25 mM, respectively. 
 
Generation of LiASA null mutants. A targeted gene replacement strategy was 
used for L. infantum ASA gene knock-out. Briefly, ASA flanking regions were amplified from 
L. infantum genomic DNA and were linked to neomycin phosphotransferase (NEO) or 
hygromycin phosphotransferase (HYG) genes using a fusion PCR approach. The 5’ and 3’ 
UTR were amplified using primers 1 + 2 and 3 + 4 (Table S2), respectively. NEO and HYG 
were amplified from pSP72αNEOα and pGL345HYG templates, using primers 5 + 6 and 7 
+ 8 (Table S2) respectively, which possess around 30 nucleotides of the 5’ UTR in the sense 
primer and the first 30 nucleotides of the 3’ UTR in the antisense primer. 5’ UTR_NEO_3’ 
UTR and 5’ UTR_HYG_3’ UTR constructs were obtained using primers 1 + 4 (Table S2). 
Mid-log promastigotes were transfected with approximately 10 µg of linear construct, 
obtained by fusion PCR, using an AMAXA Nucleofector II device with Human T-cell 
nucleofector kit (Lonza). The day after transfection drug selection was carried out at 20 
µg/mL of G418 (Invitrogen) and 50 µg/mL of hygromycin B (InVivoGen). Parasite cloning 
was performed by diluting the parasite suspension to a concentration of 0.5 cells/well, using 
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SDM culture medium. The drug concentrations for clone maintenance correspond to half of 
the selection concentrations. 
  
Generation of LiASA overexpressor (OE) and null mutants’ complementation. 
LiASA gene was excised from the pGEM-T Easy vector (using XbaI/NdeI) and subcloned 
into pSP72αBLASTα vector. Mid-log promastigotes, WT and dKO mutants, were 
transfected with approximately 10 µg of plasmid DNA as above in order to generate an 
overexpressing line (OE) or complemented null mutants, respectively. Drug selection was 
carried out at 30 µg/ml of blasticidin (InVivoGen). 
 
PCR and Southern-blot analysis of LiASA mutants. LiASA mutants were 
analysed by PCR using Taq polymerase (NZYTech) for the following events: LiASA 
presence; NEO 5’ integration; NEO 3’ integration; HYG 5’ integration and HYG 3’ 
integration, using primers pairs 9 + 10, 11 + 12, 13 + 14, 15 + 16  and 17 + 18 (Table S2), 
respectively. Additionally, a non-related gene from chromosome 28, encoding a putative 
ribose-5-phosphate isomerase B (RPIB, ~570 bp) was used as control, using primers 19 + 
20 (Table S2). For Southern-blot analysis, total genomic DNA was extracted. Ten µg of 
genomic DNA were digested O/N with a 5 fold excess of SacI and NdeI, at 37ºC and 
samples were run O/N in an agarose gel. The gel was sequentially incubated with 0.25 M 
HCl, 1.5M NaCl 0.5M NaOH and 3M NaCl 0.5M Tris.HCl pH 7. DNA was then transferred 
O/N onto a Nylon membrane (Amersham), using 10x SSC (saline sodium citrate: 300 mM 
sodium citrate, 1 M NaCl). Nucleic acids fixation was achieved at 65ºC for 5 hours. 
Hybridization and revelation were undertaken using Gene Images AlkPhos Direct Labelling 
and Detection System kit (GE Healthcare Amersham). Pre-hybridisation, hybridisation and 
washes took place at 65ºC, probe labelling and membrane stripping were performed 
according to the manufacturer instructions. The blots were probed sequentially with 5’ UTR, 
LiASA, HYG and NEO, which were PCR amplified, using primers 1 + 2, 9 + 10, 7 + 8 and 5 
+ 6 (Table S2), respectively.  
 
In vitro growth of LiASA mutants. Cultures were launched and monitored 
microscopically every 24h for 8 days or were maintained in log phase by subculturing every 
2 days and cumulative growth was assessed for 5 consecutive passages. The growth 
experiments were performed in complete RPMI (cRPMI) or Asn depleted cRPMI (cRPMI + 
L-asparaginase) obtained by cRPMI O/N incubation with 1250 U/L of L-asparaginase at 
37ºC. Growth curves were also undertaken in a serum-free RPMI (sfRPMI [46]) incubated 
with L-asparaginase, that was removed afterwards by flowing the medium through a 3 kDa 
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Millipore centrifugal filter (Amicon Ultra), generating an Asn free medium (sfRPMI + L-
asparaginase). Asn was directly added to the Asn free sfRPMI (cf = 380 µM) to generate 
complemented sfRPMI (sfRPMI + L-Asparaginase + Asn). Finally, growth curves were 
performed in complete M199 (cM199) [29] or cM199 supplemented with Asn (cf = 380 µM). 
Growth curves of LiASA mutants and WT were seeded at 1 x 106 parasites/ml at 26ºC, 
except in the case ofsfRPMI, whose initial parasite density was 2 x 106 parasites/ml, grown 
with agitation. Before launching growth curves, the parasites were maintained in log phase 
for 2-3 passages in the absence of selection drugs. 
 
In vivo infectivity of LiASA mutants. Five to six weeks old female BALB/c mice 
were obtained from Charles River. For each mouse injection, 1 x 108 promastigotes 
recovered from 4 days old stationary culture were washed, resuspended in PBS, and 
injected intraperitoneally. Mice of each group (n=4) were sacrificed at 2 weeks post-
infection. The parasite burden in the spleen and liver was determined by limiting dilution as 
previously described [47].  
 
Digitonin Fractionation. For each sample condition, 1 x 108 promastigotes were 
washed once with cold trypanosome homogenisation buffer (THB), composed by 25 mM 
Tris, 1 mM EDTA and 10% sucrose, pH 7.8. Just before cell lyses, peptidase inhibitor 
(Roche) and different digitonin (Calbiochem) quantities (final concentrations of 12.5, 25, 50, 
100, 200, 500 and 1000 µg/ml) were added to 250 μl of cold THB, for cell pellet 
resuspension. Untreated cells and those completely permeabilised (total release, the result 
of incubation in 1% Triton X-100) were used as controls. Each sample was incubated 60 
min on ice, and then centrifuged at 13,000 rpm, 4°C, for 10 min. Supernatants were taken 
off into new pre-cold tubes and 250 µl of cold THB was added to each pellet and then mixed. 
All fractions were analysed by WB.   
 
Immunofluorescence. L. infantum mid-log promastigotes were fixed, 
permeabilised and stained as previously described [48]. Cells were incubated with primary 
antibody O/N at 4ºC. The following primary antibodies were used: rabbit anti-LiAS-A 
(1:1000) and sheep anti-LiTDR1 (thiol-dependent reductase 1, 1:2000). Subsequently, 
slides were incubated for 1h at RT in a dark humidified atmosphere with a secondary 
antibody (1:500). The following secondary antibodies were used: goat anti-rabbit Alexa 
Fluor 488 or 568 and donkey anti-sheep Alexa Fluor 488 (Molecular probes, Life 
Technologies). In the case of Mitotracker Orange (Invitrogen), we stained the parasites by 
adding 1 µM to culture medium (without FBS) for 1h at 26ºC, prior to the above described 
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procedure. Slides were stained and mounted with Vectashield-DAPI (Vector Laboratories, 
Inc.). Images were captured using fluorescence microscope AxioImager Z1 (Carl Zeiss), 
equipped with a Axiocam MR v. 3.0 camera (Carl Zeiss), using either 63x (Plan-Apochromat 
63x/1.40 Oil DIC) or 100x (Plan-Apochromat 100x/1.40 Oil DIC) objective. Images analysis 
and deconvolution was performed using ImageJ software (v. 1.47) and image deconvolution 
lab plugin (2010 Biomedical Imaging Group, EPFL, Switzerland) with Richardson-Lucy 
algorithm.  
 
Statistical Analysis. For statistical analysis, one-way ANOVA and two-tailed 
Student’s test were used. Statistical analysis was performed using GraphPad Prism 
Software (version 5.0): statistical significance p ˂ 0.05 (*), p ˂ 0.01 (**), p ˂ 0.001 (***), p ˂ 
0.0001 (****). 
 
Results 
LiAS-A and LmAS-A sequence alignment and homology models. The open 
reading frames (ORFs) encoding putative AS-A and AS-B enzymes were identified in the 
genomes of L. infantum JPCM5 (LinJ.26.0790; LinJ.29.1590) and L. major Friedlin 
(LmjF.26.0830; LmjF.29.1490) [42-44]. The ASA amplified sequence from L. infantum strain 
matched 100% the annotated sequence from JPCM5 genome. To obtain structural and 
functional insights on AS-A enzymes, we have performed in silico analysis using the L. 
infantum (LiAS-A), L. major (LmAS-A), T. brucei (TbAS-A), T. cruzi (TcAS-A) and E. coli 
(EcAS-A) sequences that generate polypeptides containing 353, 353, 351, 348 and 330 
residues, respectively (Fig. 1A). Overall, the sequence alignment shows a high conservation 
of the main structural features, including the active site residues (Fig. 1A). Indeed, the amino 
acids involved in Asn binding are strictly conserved across species, whereas in the case of 
AMP binding pocket, the majority of residues are conserved with a few exceptions. For 
instance, in the case of LiAS-A and LmAS-A, there is a sole residue replacement, namely 
EcAS-A L109, corresponding to I111 in both cases. This residue is not involved in polar 
interactions with AMP molecule, but instead integrates the outer wall of the nucleotide 
binding pocket [15]. 
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Fig. 1. Multiple-sequence alignment of prokaryote and eukaryote AS-A proteins and 
3D homology models of LiAS-A and LmAS-A. A) Alignment of LiAS-A (NCBI-Gene ID: 
5069795/ LinJ.26.0790), LmAS-A (NCBI-Gene ID: 5652811/LmjF.26.0830), TbAS-A (NCBI-
GeneID:3658321/ Tb927.7.1110), TcAS-A (NCBI-
GeneID:3534325/Tc00.1047053503625.10) and EcAS-A (NCBI-
GeneID:948258/pdb:12AS). A pre-established colour pattern was used, according to 
ALSCRIPT Calcons (Aline version 011208): red, identical residues; orange to blue, scale of 
conservation of amino acid properties in each column alignment; white, dissimilar residues). 
Secondary structure components of EcAS-A crystal structure (black) are represented above 
the alignment. In all sequences, binding residues for several ligands were represented: 
AMP (circles), asparagine (squares), ATP (triangle) and aspartate (inverted triangle). B) 
Superposition of EcAS-A structure (green) (PDB accession code 12AS), with LiAS-A (blue) 
and LmAS-A (purple) homology models (obtained from the SWISS-MODEL server, using 
PDB 12AS as a template). The dashed box points a structurally divergent region. 
 
Analysing the homology models of LiAS-A and LmAS-A (Fig. 1B) obtained by 
superimposition with EcAS-A crystal structure (PDB 12AS [15]), there is a divergent region 
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highlighted with a dashed rectangle (Fig. 1B) in L. infantum and L. major enzymes, which 
is strictly conserved in these two species. This region also exists in trypanosomes, although 
little conservation is found when comparing to Leishmania spp. (Fig. 1A, [28, 29]).  
 
Enzymatic characterization of LiAS-A. Recombinant LiAS-A , comprising a 6 
histidine N-terminal tag, was expressed in E. coli and purified by affinity chromatography in 
native conditions in order to evaluate and characterize its enzymatic activity. The protein 
presented the expected MW for the monomer, ~42 kDa, as presented on figure 2A and 2B, 
with either Coomassie staining or Western-blot analysis with an anti-HisTag antibody, 
respectively. Subsequently, LiAS-A was further purified sequentially by size exclusion and 
ion exchange chromatographies, and the final fractions were analysed by analytic size 
exclusion chromatography (Fig. 2C). Using the latter chromatography and calibration 
standards, Stokes’ radius (~3.52 nm, Fig. 2D) and MW (~78.8 kDa, Fig. 2E) were 
extrapolated in the protein native state. LiAS-A corresponds to a homodimer, as predicted.  
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Fig. 2. Analysis of recombinant LiAS-A.  A) Coomassie blue stained 12% SDS-PAGE 
gel of 10 µg of recombinant LiAS-A post affinity chromatography purification. B) Western-
blot analysis of 1 µg of purified recombinant LiAS-A using a rabbit anti-HisTag monoclonal 
antibody (1:1000). MW, molecular weight marker. C) Analytic size exclusion chromatogram 
of recombinant LiAS-A after purification by affinity, size exclusion and ion exchange 
chromatographies. D and E) Calibration curve for LiASA Stokes’ radius and MW 
determination, respectively. Kav was determined considering the elution volume of the 
proteins used as standards, the total volume of the column and the exclusion volume given 
by the elution of blue dextran. The used standards were as follows: ribonuclease (R), 
chymotrypsinogen A (CtA), ovalbumin (OA), albumin (A), aldolase (Ald), catalase (C). Data 
is representative of two independent experiments. . F and G) Differential scanning 
fluorimetry analysis of recombinant LiAS-A in the presence of several ligands, expressed in 
Tm variation (∆Tm - ºC) determined as Tm (protein + ligand) – Tm (protein without ligand). F) 
Single ligand effect at 1 mM concentration: ATP, AMP, pyrophosphate (Pyro), ammonium 
chloride (NH4Cl), magnesium chloride (MgCl2), asparagine (Asn), aspartate (Asp), 
glutamate (Glu), glutamine (Gln). G) Concentration dependent effect of AMP in LiAS-A 
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stabilization. These results represent the mean values of two independent experiments plus 
the standard deviation.  
 
For the characterization of the enzymatic activity of recombinant LiAS-A , a specific 
colorimetric assay that quantifies Asn formation was used [28, 45]. The optimal pH for the 
enzymatic activity was 7.6. The kinetic characterization of the enzyme was undertaken in 
steady-state conditions, using a fixed concentration of 8.4 mM of Mg2+ (Table 1). LiAS-A 
displayed ammonia and glutamine dependent activity. 
 
Table 1. Kinetic parameters of LiAS-A for aspartate, ATP, ammonia and glutamine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Specificity Constant (kcat / Km) 
The values are means ± standard deviations obtained from 3 independent experiments 
 
 When comparing Km values for ammonia and glutamine, no statistical significant 
difference is found (p = 0.03), but there is significance in the differences found in kcat (p = 
1.80 x 10-4). In order to discard the possibility that utilization of glutamine as a substrate was 
an artefact resulting from contamination with EcAS-B (EcAS-B ~120 kDa), highly purified 
fractions of LiAS-A (LiAS-A ~84 kDa) were tested and glutamine utilization were clear in all 
protein samples tested. 
Differential scanning fluorimetry was also used in order to further understand the 
relevance of the different substrates for thermal stabilization of the enzyme. AS-A forms a 
Substrate 
L. infantum  
Km (mM) kcat (s-1) Ksp* (M-1.s-1)   
Aspartate 6.21 ± 1.15 9.19 ± 0.69 1.48 x 103  
 
ATP 1.47 ± 0.04 4.18 ± 0.02 2.84 x 103   
Ammonia dependent activity    
Ammonia 1.12 ± 0.16 7.46 ± 0.33 6.66 x 103   
Glutamine dependent activity    
Glutamine 1.71 ± 0.28 4.51 ± 0.19 2.64 x 103  
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crucial β-AspartylAMP-Mg2+ intermediate, which then undergoes a nucleophilic attack of 
ammonia, forming Asn and releasing AMP e pyrophosphate [15]. According to our data, 
ammonia can be free or glutamine-derived, although the glutaminase domain of LiAS-A 
remains to be identified. Looking at the differential scanning fluorimetry data, AMP leads to 
a 10 degrees shift in LiAS-A Tm, thermally stabilising this protein (Fig. 2F) in a concentration 
dependent fashion(Fig. 2G).  
 
LiASA null mutants generation by targeted gene replacement. A targeted gene 
replacement strategy was used for inactivation of the ASA gene of L. infantum. Two 
constructs, obtained by fusion PCR, linking NEO or HYG to the 5’ and 3’ UTRs of the LiASA 
gene were used to remove the first and second LiASA allele, respectively. Two sKO mutants 
(clones A and B) were transfected with the HYG construct. We successfully obtained 5 dKO 
mutants, 3 from clone A (A1, A2 and A3) and 2 from clone B (B1 and B2). The integration 
of the resistance markers in the expected locus was confirmed by PCR using primers 
upstream of the 5’ UTR or downstream of the 3’UTR coupled with primers in their ORFs 
(the strategy is illustrated on Fig. 3A). NEO 5’ and 3’ integration was positive in both sKO 
and dKO mutants, as for HYG, only in dKO parasites, as expected (Fig. 3B). Also by PCR 
analysis, we could not amplify LiASA ORF in null mutants (a non-related gene – LiRPIB- 
was amplified as control – Fig. 3B). 
 
 
 
 
 
 
 
Chapter III – Objectives and results 
 
156 
 
 
Fig. 3. Genetic and post-translational analysis of the LiASA mutants. A) LiASA locus 
schematics: ASA allele and targeted gene replacement cassettes, containing NEO and 
HYG resistance genes. Horizontal black arrows and numbers represent the primer pairs 
used to assess the genotype of the mutants: the grey dashed line represents the expected 
PCR fragment. Southern-blot approach, upon digestion with NdeI (vertical black contoured 
arrows) and SacI (vertical black full coloured arrows) is also represented: dashed black lines 
represent the expected digestion fragments. B) PCR analysis of LiASA mutants to assess 
LiASA presence, NEO 5’ and 3’ integration and HYG 5’ and 3’ integration. Additionally, non-
related LiRPIB gene from chromosome 28 was amplified as a control. b, blank. C) Southern-
blot analysis of 10 µg of LiASA mutants (versus WT) genomic DNA, previously digested 
with NdeI and SacI, and probed using 5’ UTR. Subsequently, the blot was stripped and 
reprobed 3 additional times, using LiASA, NEO and HYG. D) Western-blot analysis of LiAS-
A expression in   promastigote mutants (versus WT) using LiCS as loading control (cysteine 
synthase). OE, overexpressor.  
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Southern-blot analysis confirmed the genotypes: the expected fragments upon 
digestion with SacI and NdeI are represented on figure 3A.  A first hybridisation was 
performed using 5’ UTR as a probe: in WT a single band of ~1696 bp corresponding to 
LiASA was generated, with twice the intensity observed in the sKO mutants that possess a 
single copy, and absent in the dKO mutants, confirming the successful gene removal (Fig. 
3C). In both sKO and dKO clones, a band of ~2973 bp was generated corresponding to 
NEO, and then only in dKO clones, a band of ~2052 bp corresponding to HYG was 
observed (Fig. 3C). The blot was then stripped and reprobed three additional times to 
confirm each one of the bands (faint bands of incomplete stripping can be observed), 
sequentially using LiASA, NEO and HYG. All the mutants were also analysed by Western-
blot, showing a protein reduction in sKO mutants and a complete absence in the dKO clones 
(Fig. 3D).  LiASA gene was cloned into a pSP72αBLASTα vector in order to obtain an 
overexpressor mutant (OE) as well (Fig. 3D). 
 
AS-A is localized in the cytosol of L. infantum promastigotes. Rabbit polyclonal 
antibodies produced against recombinant LiAS-A recognised a major band in total WT 
promastigotes extract with the expected molecular weight (~39.8 kDa 
[web.expasy.org/protparam], Fig. S1A), but not in a dKO mutant (dKO A2).  Prior to 
immunolocalisation studies, LiAS-A antibody was also validated (Fig. S1B) by performing 
an IFA and comparing the labelling intensity in WT promastigotes versus LiASA null mutants 
and OE. A positive correlation between protein level and fluorescence intensity was found 
on WT versus OE (Fig. S1C). As expected, no specific labelling was detected for the LiAS-
A null mutants (Fig. S1B and S1C). 
Using α-tubulin (~50 kDa) as loading control we compared the expression levels of 
LiAS-A in different developmental stages: promastigotes (logarithmic, early stationary and 
late stationary phase) and axenic amastigotes (Fig. 4A).  No significant differences were 
observed.  
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Fig. 4. LiAS-A expression and localization in L. infantum. A) AS-A expression in 
different stages of L. infantum life cycle. Promastigote forms: logarithmic phase (Log), early 
stationary phase (ES), late stationary phase (LS); axenic amastigote forms (Am). Twenty 
µg of total extract were analysed by Western-blot and probed with rabbit polyclonal anti-
LiAS-A. α-tubulin (mouse monoclonal antibody) was used as loading control. These results 
are representative of 3 independent experiments. B) Immunofluorescence analysis showing 
AS-A (red upper panel; green lower panel) localization in L. infantum promastigote form. 
Nucleus and kinetoplast DNA, cytosol and mitochondria were stained with DAPI (blue), 
sheep anti-LiTDR1 (thiol-dependent reductase in green) and Mitotracker Orange 
CMTMROS (red), respectively. Images were acquired with a 100x objective, using a Zeiss 
AxioImager Z1. The scale bar corresponds to 5 µm. Data is representative of 4 independent 
experiments. C) Digitonin fractionation of mid-log L. infantum promastigotes. Pellet (P) and 
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supernatant (S) fractions obtained using increasing concentrations of digitonin or positive 
control with 1% of Triton X-100 (TR – Total Release) were subjected to Western-blot 
analysis and probed with antibodies against LiEnolase (cytosolic marker) and hypoxanthine 
guanine phosphoribosyltransferase LiHGPRT (glycosomal marker). Data is representative 
of 5 independent experiments. 
 
Immunofluorescence analysis showed that in promastigotes LiAS-A co-localises 
with LiTDR1 (thiol-dependent reductase 1), which is a cytosolic protein involved in thiol 
metabolism [49] (Fig. 4B, upper panel). LiAS-A subcellular localisation in promastigotes was 
also assessed by digitonin fractionation. The fractioning profile was evaluated using 
antibodies for proteins present in different subcellular compartments, namely, anti-
TbEnolase (LiEnolase versus TbEnolase 79% identity, LiEnolase 39.6 kDa) as cytosolic 
marker [50], and anti-LdHGPRT (hypoxanthine guanine phosphoribosyltransferase, 23.6 
kDa) as glycosomal marker [51]. LiEnolase (Fig. 4C) can be found in the supernatant for 
digitonin concentrations as low as 12.5 µg/ml, and retained in the pellets up to 25-50 µg/ml.  
LiHGPRT (Fig. 4C), which localises to the glycosomes, is detected in the supernatant in 
appreciable amounts for higher digitonin concentrations and is retained longer in the pellet 
(up to 200-500 µg/ml, and residually at 1000 µg/ml of digitonin). As expected, LiAS-A 
presents a profile similar to LiEnolase, supporting a cytosolic location (Fig. 4C). 
Intriguingly, LdAS-A was reported to have dual localisation between the cytoplasm 
and mitochondria in promastigote form [29]. Due to the high identity (~99%) between both 
enzymes, we investigated whether LiAS-A also localised to the mitochondria. 
Immunofluorescence analysis of LiAS-A subcellular distribution on promastigotes labelled 
with mitotracker showed no evidence of mitochondrial location (Fig. 4B, lower panel). 
Moreover, by using tools for protein localisation prediction (TargetP, CELLO, MITOPROT 
and Predotar), mitochondria localisation seems unlikely and actually, CELLO predicts 
cytoplasmic localisation. In conclusion, our data shows LiAS-A localises to the cytosol.   
  
LiAS-A is required for promastigotes growth only in asparagine limiting 
conditions. All mutants displayed similar growth patterns comparing to WT promastigotes 
in cRPMI (Fig. 5A). However, in Asn depleted medium, achieved upon L-asparaginase 
treatment (cRPMI + L-asparaginase), the behaviour was quite different for some of the 
mutants. Parasites overexpressing LiAS-A displayed a significant higher growth during log 
phase when comparing to the WT, whereas the dKO mutants (clones A2 and B1) displayed 
a major growth defect (Fig. 5B). The complementation of these null mutants with an episome 
(pSP72αBLASTα) carrying LiASA gene rescued the growth (Fig. 5B). Moreover, an 
upregulation in LiAS-A levels could be observed in these mutants in Asn limiting conditions 
(Fig. 5C). Western-blot analysis also showed that in the same conditions, an upregulation 
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in LiAS-A could also be observed over time in the sKO parasites (clones A and B), enabling 
the growth recovery in these mutants (Fig. 5B, C, D and Table S3). This recovery was faster 
in sKO clone B that had higher basal levels of LiAS-A than clone A (Fig. 5B and 5C). We 
also evaluated the cumulative growth under constant multiplicative conditions, in which high 
amino acids levels are required. For that, parasites were maintained in log phase in Asn 
replete or Asn depleting conditions, and the same patterns were observed (Fig. S2).  
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Fig. 5. In vitro growth of LiASA mutants in normal or Asn depleted medium and 
respective LiAS-A expression levels. A and B) L. infantum promastigote growth curves 
in cRPMI or cRPMI + L-asparaginase, respectively, including dKO mutants (clones A2 and 
B1) complemented with pSPαBLASTα carrying LiASA gene. In B, a significant growth 
difference in comparison to WT (p ˂ 0.05, Graphpad Prism 5.0 version) was found for sKO 
A, sKO B, dKO A2 and B1, dKO A2 + LiAS-A, dKO B1 + LiAS-A and OE mutants for days 
1 to 8, days 1 to 6, days 1 to 8, days 2 to 6, days 2 to 7 and day 3, respectively. C) Western-
blot analysis of LiAS-A expression in 7 days old LiASA mutants (versus WT) cultured in 
cRPMI and cRPMI + L-asparaginase. D) Western-blot analysis of LiAS-A expression levels 
over time in WT, and clones A and B cultured in cRPMI (lane L-asparaginase -) or cRPMI 
+ L-asparaginase (lane L-asparaginase +). E and F) L. infantum promastigote growth 
curves in sfRPMI + L-asparaginase or sfRPMI + L-asparaginase + Asn, respectively. 
sfRPMI was Asn depleted through incubation with L-asparaginase, which was then 
removed by flowing the medium through an Amicon Column of 3 kDa pore (sfRPMI + L-
asparaginase). Asn was then added directly to the medium (sfRPMI + L-asparaginase + 
Asn). In E, a significant growth difference in comparison to WT (p ˂ 0.05, Graphpad Prism 
5.0 version) was found for sKO A, sKO B and dKO A2 and B1 mutants for days 2 to 7, days 
2 and 5 to 7 and days 2 to 7, respectively. G) Western-blot analysis of LiAS-A expression 
in 7 days old LiASA mutants (versus WT) cultured in sfRPMI + L-asparaginase (lane Asn -
) and sfRPMI + L-asparaginase + Asn (lane Asn +). H and I) L. infantum promastigote 
growth curves in cM199 and cM199 + Asn, respectively, including dKO mutants 
complemented with pSPαBLASTα carrying LiASA gene. In H, a significant growth difference 
in comparison to WT (p ˂ 0.05, Graphpad Prism 5.0 version) was found for dKO A2 and B1, 
dKO A2 + LiAS-A and dKO B1 + LiAS-A mutants for days 1 to 7, days 2 and 3, days 1 to 3, 
respectively. The results (A-I) are representative of 2 independent experiments. For the 
Western-blot analysis displayed in C, D and G, 1x107 parasites were used for total extract 
preparation and LiCS (cysteine synthase) was used as loading control. OE, overexpressor. 
 
To ensure the defective growth phenotype of sKO and dKO parasites in L-
asparaginase treated medium was due to Asn depletion, we supplemented this medium 
with Asn. Surprisingly the addition of this amino acid to L-asparaginase treated RPMI 
medium fails to reverse the observed growth delay/arrest phenotype. The fact that L-
asparaginase was not inactivated or neutralized, and consequently may have remained 
active, may explain this result. Consequently, we used another strategy by undertaking 
growth curves in a serum free medium (sfRPMI [46]) incubated with L-asparaginase that 
was removed afterwards using a 3 kDa Amicon column. In sfRPMI devoid of Asn (sfRPMI 
+ L-asparaginase), the same growth defect of the sKO and dKO mutants was observed 
(Fig. 5E). And then again, in the sKO clones the upregulation of LiAS-A allowed the growth 
rescue (Fig. 5G, Table S3). When adding back Asn (sfRPMI + L-Asparaginase + Asn), all 
mutants grew in a similar fashion (Fig. 5F). In the absence of drug pressure and in normal 
conditions, parasites provided of an episome carrying LiASA (OE) hardly overexpress AS-
A, however, under Asn depleting conditions, they upregulate its expression (comparing to 
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the levels in the WT, there is an increase from ~130% to ~300% and from ~110 to ~130%, 
in panels C and G, respectively, and Table S3).  
Moreover, besides the experiments using L-asparaginase treatment, we have also 
performed growth curves in a medium formally lacking Asn – complete M199 (cM199) - in 
order to further confirm Asn auxotrophy upon ASA ablation. In this medium, null mutants 
presented a growth defect comparable to the one observed in cRPMI + L-asparaginase, 
which again was reversed when these mutants were complemented with an ectopic copy 
of ASA gene (Fig. 5B versus 5H). The addition of Asn to the final concentration of 380 µM 
(like in RPMI) rescues the growth defect displayed by the null mutants in cM199 (Fig. 5I). 
Interestingly, the experiments to assess LiAS-A essentiality in L. donovani were performed 
in cM199 [29], therefore the inability to generate LdASA null mutants may be due to the 
performance of those attempts in Asn limiting conditions. 
In conclusion, ASA deletion renders parasites auxotrophic to Asn, but is dispensable 
for parasite growth in normal conditions.  
 
In vivo infectivity of LiASA mutants. Notwithstanding, we intended to evaluate the 
impact of LiASA ablation on, in vivo infectivity. Five to six old female BALB/c mice were 
infected and were sacrificed at 2 weeks post-infection. The parasite burden in the spleen 
(Fig. 6A) and liver (Fig. 6B) was not statistically different in LiASA mutants when compared 
to the WT.  The same scenario was observed for sKO A and dKO A2 mutants. No 
differences in LiAS-A expression levels were found when comparing parasites used in mice 
infection (Culture) to parasites recovered from spleen (S) or liver  
(L) (Fig. 6C). Thus, LiAS-A ablation does not compromise parasite infectivity in the context 
of an acute in vivo infection.   
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Fig. 6. In vivo infectivity of LiASA mutants in mice. A and B) Stationary promastigotes 
were intra-peritoneally injected in BALB/c mice that were sacrificed 2 weeks post infection, 
in order to determine parasite burden in spleen (A) and liver (B). The values represent the 
means of four independent animals ± standard deviation C) Western-blot analysis of LiAS-
A levels in WT and LiASA mutants: parasites maintained in culture (C) comparing with 
parasites recovered from spleen (S) or liver (L). The data is representative of 2 independent 
experiments carried out with 2 different clones for each genotype. For the Western-blot 
analysis displayed in C, 1x107 parasites were used for total extract preparation and LiCS 
(cysteine synthetase) was used as loading control. OE, overexpressor. 
 
Discussion  
Despite being eukaryotes, trypanosomatids, present AS-A enzymes of bacterial 
origin. Moreover, these enzymes are aminoacyl-tRNA synthetase paralogs, displaying an 
AsnRS catalytic core with conserved class II motifs, yet lacking the tRNA binding domain 
[27]. In this work, we have demonstrated that LiAS-A is able to synthesise Asn using either 
ammonia or glutamine as nitrogen donors, as previously described for TbAS-A, TcAS-A 
and LdAS-A [28, 29]. Km values for aspartate and ATP are close to the ones determined for 
TbAS-A and TcAS-A [27]. As for ammonia, the Km value found for LiAS-A is 5 fold lower in 
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comparison to TbAS-A, TcAS-A and LdAS-A [27, 28]. In the case of LdAS-A, the Km values 
for aspartate were around 10 fold lower [29] than the ones obtained for LiAS-A. Regarding 
the high conservation of the active sites among Leishmania AS-A enzymes, we cannot 
exclude that the observed kinetic differences may be due to the differences in the amount 
of protein that is properly folded, especially taking into account they are expressed in a 
heterologous system. Moreover, it is important to emphasize that the kinetic determinations 
for LdAS-A were performed using a different experimental set up. Importantly, TbAS-A and 
TcAS-A use preferably ammonia [28], whereas LiAS-A seems to use both roughly in the 
same extent (Table 1). AS-A activity in trypanosomatids more resembles AS-B enzymes, 
concerning both the optimal pH for enzymatic activity (7.6 instead of 8) and also the ability 
to use both nitrogen donors. AS-B enzymes use preferably glutamine, with exception of the 
human enzyme that presents approximately the same affinity for both nitrogen sources [18, 
19, 25, 52-57]. This biochemical feature, so far only described for trypanosomatids AS-A 
enzymes [28, 29], becomes particularly interesting in the context of the presence of an ORF 
encoding a hypothetical, yet non-classical, AS-B, in the genome of these organisms (L. 
infantum [LinJ.29.1590], L. major [LmjF.29.1490], T. brucei [Tb927.3.4060] and T. cruzi 
[Tc00.1047053510001.40]) [42-44]. These sequences contain a Pfam AS domain 
(pfam00733) and glutamine hydrolysing domains in the C and N-terminus, respectively. 
BLASTp analysis of L. infantum sequence, for instance, revealed several hits that 
corresponded to hypothetical proteins from a broad range of eukaryotes. However, we have 
no evidence AS-B is functional at all.  
Much remains to be disclosed regarding the AS-A enzymes from trypanosomatids, 
for instance, we still lack information on their glutamine binding and hydrolysing sites. TbAS-
A crystallisation only emphasised the high conservation of Asn and AMP binding pockets, 
as the only divergent region from EcAS-A (a 19 residues insertion, also present in LiAS-A 
and LmAS-A, Fig. 1) was not visible in the experimental electron density maps and therefore 
likely disordered [29]. This insertion displays little conservation when comparing Leishmania 
and trypanosomes, and its role on a structural or functional level is still unclear. 
AS-A is a key enzyme in Asn metabolism that was proposed as a potential drug 
target due to its absence in the human host. Moreover, AS-A was reported to be essential 
for L. donovani survival, contrasting with T. brucei bloodstream forms, as in the latter it was 
shown to be dispensable for both in vitro growth and infectivity. These findings pointed to a 
differently regulated Asn homeostasis across trypanosomatids. In L. infantum, our efforts to 
generate ASA null mutants were successful, indicating the gene is not essential for survival. 
Moreover, the null mutants did not present any growth or infectivity defect. Our in vitro 
growth data demonstrate that upon LiASA deletion, promastigotes become dependent on 
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extracellular Asn for optimal growth (Fig. 5). These results suggest that even if AS-B is 
functional, it does not compensate LiAS-A activity, as LiASA null mutants fail to grow in Asn 
limiting conditions. Additionally, WT parasites grew normally in Asn depleted medium 
without AS-A upregulation, suggesting Asn synthesis by basal AS-A suffices the cellular 
needs, although the mutants overexpressing this enzyme had a metabolic advantage in an 
Asn deprivation environment during log phase (Fig. S2B and S2E). We can actually infer 
the parasite can both synthesise and take up this amino acid, and the latter fully 
compensates the former. Furthermore, our results indicate that LiAS-A levels are regulated 
according to Asn availability, and it was equally surprising to see how fast and efficiently 
sKO mutants were able to upregulate AS-A when cultured in Asn limiting conditions (Fig. 
5D). It is also noteworthy that the two sKO mutants displayed a substantial difference in AS-
A levels, which has also been observed among other sKO mutants generated in this study. 
A possible explanation might be that the two allelic copies may differently affect ASA 
expression. 
In trypanosomatids, much remains to be unravelled concerning amino acid 
transporters (AATs) and mostly the pathways involved in amino acid sensing and regulation 
of their synthesis and uptake [34]. Very few data is available in the literature concerning Asn 
transport in these parasites. In T. brucei, a protein presenting putative orthologues in 
Leishmania [42-44] was characterized as a transporter of several neutral amino acids, 
including asparagine (TbAATP1) [58]. In mammalian cells, AS-B is a transcriptional target 
of the well characterized GCN2/elF2α/ATF4 axis, in response to amino acid starvation [59, 
60]. The phosphorylation of elF2 leads to a repression of general protein synthesis, as well 
as an activation of gene-specific translation. In Saccharomyces cerevisiae, GCN2, which is 
activated by amino acid, glucose or purine deprivation, is the only elF2 kinase, contrasting 
with mammals that possess some additional three, HRI, PKR and PEK/PERK [61]. T. brucei 
and L. donovani PERK orthologues [62, 63] have been implicated in the response to ER 
stress and their activation leads to a decrease in the overall translation [62]. At the moment, 
it is still not clear whether phosphorylation of elF2 in trypanosomatids would result in a 
downstream signalling cascade, as bZIP type transcription factors, that could act like GCN4 
or ATF4, are absent in these organisms [64].  
The close relation between L. infantum and L. donovani species and the 99% 
identity of AS-A between both makes the discrepant phenotype intriguing. In the literature, 
several cases in which knocking out a gene can have different impact on virulence 
depending on the species can be found. [65]. Nevertheless, to our knowledge, there is no 
documented example among cutaneous or among visceral species of a gene that is 
detrimental for survival in one species and dispensable in other closely related species. 
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However, we did find a case of differences at a strain level for instance [66].  Nonetheless, 
firstly we must highlight that LdASA essentiality was claimed solely based on the 
consecutive failure in the removal of the second gene copy [29]. Secondly, our results 
suggest that the medium in which the experiments were performed, cM199, may explain 
this difference. The former lacks Asn and LiASA null mutants could not grow unless upon 
Asn supplementation (Fig. 5H and 5I). These results reinforce the importance of the medium 
composition when attempting gene knock-out of metabolic enzymes, and supplementation 
may be detrimental when potentially generating auxotrophs [67, 68].  
LiASA dKO mutants displayed no compromised infectivity in mice, suggesting that 
in intracellular amastigote form, either AS-B is functional or, most likely, parasites are able 
to uptake Asn in such an extent that compensates the lack of intracellular synthesis. In vivo 
treatment with L-asparaginase, which induces a decrease in Asn bloodstream levels, has 
been successfully used for years in the treatment of acute lymphoblastic leukemia [69] and 
recently it was proposed as a promising strategy to treat bacteremia caused by group A 
Streptococcus and eventually other extracellular bacteria [13]. However, if for some 
extracellular pathogens, L-asparaginase treatment seems promising, in the case of an 
obligate intracellular microorganism, even when simultaneously inhibiting the microbial AS-
A, several issues may arise, namely the potential contribution of the host cell for Asn de 
novo synthesis.  
Taken all together, we conclude AS-A is not a suitable drug target candidate in L. 
infantum, and therefore, with regard to drug development, such a protein target becomes 
pointless against Leishmania.  
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Fig. S1. Rabbit polyclonal anti-LiAS-A antibody validation. A) Western-blot analysis of 
WT and LiASA null mutant (clone A2) promastigotes extracts using rabbit polyclonal anti-
LiAS-A (1:1000). B) Representative immunofluorescence images of different genotypes 
(WT, dKO clone A2 and OE) of mid-log L. infantum promastigotes, using rabbit polyclonal 
anti-LiAS-A antibody (1:1000). Upper and lower panels present brightfield and LiAS-A 
(green) + DAPI (blue) stained images, respectively. Images were acquired with a 100x 
objective, using a Zeiss AxioImager Z1. The scale bar corresponds to 5 µm. C) 
Fluorescence intensity quantification in WT, dKO clone A2 and OE parasites when stained 
with anti-LiAS-A antibody (1:1000). The values are expressed in CTCF (corrected total cell 
fluorescence), and background (BG) values are displayed as well. The quantification was 
performed on images acquired with 63x objective, using a Zeiss AxioImager Z1 and the 
same exposure time for all genotypes (LiAS-A 400 ms; DAPI 100 ms). Twenty different 
fields for each genotype were analysed in duplicate, and the fluorescence of an average of 
50-100 parasites was quantified using ImageJ (v 1.47) software. Statistical analysis was 
performed using Graphpad Prism 5.0 version: statistical significance p ˂ 0.05 (*), p ˂ 0.01 
(**), p ˂ 0.001 (***), p ˂ 0.0001 (****). The results (A-C) are representative of 2 independent 
experiments 
 
Chapter III – Objectives and results 
 
174 
 
 
Fig. S2. Cumulative in vitro growth of logarithmic LiASA mutants in normal or Asn 
depleted medium. A/D and B/E) L. infantum promastigotes growth curves of LiASA 
mutants (versus WT), cultured in cRPMI and cRPMI + L-asparaginase, respectively. 
Parasites were maintained in logarithmic phase by subculturing every 2 days. The results 
correspond to mean values of duplicates ± standard deviation. Statistical analysis was 
performed using Graphpad Prism 5.0 version: statistical significance p ˂ 0.05 (*), p ˂ 0.01 
(**), p ˂ 0.001 (***), p ˂ 0.0001 (****). C and F) Western-blot analysis of LiAS-A expression 
levels in 8 days old promastigotes, cultured in cRPMI and cRPMI + L-asparaginase. In A-F 
panels, the results are representative of two independent experiments. For the Western-
blot analysis displayed in C and F, 1x107 parasites were used for total extract preparation 
and LiCS (cysteine synthase) was used as loading control. 
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Table S1. Oligonucleotides sequences used to obtain LiAS-A recombinant protein (P1-P2) 
and pSPαBLASTαLiASA (P3-P4) 
 
 
 
 
 
Table S2. Oligonucleotides sequences used to obtain gene replacement cassettes (P1-P8) 
and to confirm LiASA mutants’ genotype (P9-P20) 
 
 
 
 
 
 
 
 
 
 
Primer                                Sequence  
1                        5' CAATTTGCATATGTCGTCCAGTCCGCAG 3' 
2                       5' CCCAAGCGAATTCTTACAATAAAGAGTAC 3' 
3          5' GTCTAGAATGTCGTCCAGTCCGCAGGAGTACATTGA 3' 
4              5' GCATATGTTACAATAAAGAGTACTGCGCCGTGACC 3' 
Primer                                                       Sequence  
1                                                             5' CAGCCTGGAGGAGAACATTG 3' 
2                                                           5' GGGATGAATGGAGGGGTGTTG 3' 
3                                                           5' CCACAAAATGCCAGGGAGAAG 3' 
4                                                             5' GTAATCGTCCACGCCAGAAG 3' 
5                   5' CCTTTTATTCAACACCCCTCCATTCATCCCATGATTGAACAAGATGGATT 3' 
6       5' CTGCAGAGAGCTTCTCCCTGGCATTTTGTGGTCAGAAGAACTCGTCAAGAAGGCGATAG 3' 
7       5' GTCGCCAAGCCCTTTTATTCAACACCCCTCCATTCATCCCATGAAAAAGCCTGAACTCAC 3' 
8            5' CTGCAGAGAGCTTCTCCCTGGCATTTTGTGGCTATTCCTTTGCCCTCGGACGAGTG 3' 
9                                                           5' TCGTCCAGTCCGCAGGAGTACA 3' 
10                                                     5' ACAATAAAGAGTACTGCGCCGTGACC 3' 
11                                                           5' CGGGTCCACGATTCACTGGAAG 3' 
12                                                         5' CAGGTAGCCGGATCAAGCGTATGC 3' 
13                                                           5' CGAGCACGTACTCGGATGGAAG 3' 
14                                                         5' GACCTCAACAGGAGCAACCTAAAG 3' 
15                                                              5' AACTTTATGCGCAGCGTCAC 3' 
16                                                            5' GGCCCAAAGCATCAGCTCATC 3' 
17                                                           5' GCAGGCTCTCGATGAGCTGATG 3' 
18                                                          5' AGGAAGGAAACACGCAAAGGTC 3' 
19                                                             5' ATGCCGAAGCGTGTTGCTCTG 3' 
20                                                         5' TTAAGACCTCCACAACCGCTGAAG 3' 
Chapter III – Objectives and results 
 
176 
 
 
Table S3. LiAS-A levels quantification in LiASA mutants in in vitro Asn replete or depleting 
conditions 
 
 
 
 
 
 
 
 
 
Results were normalized against LiCS (cysteine synthase) and are expressed in protein 
ratio against WT parasites cultivated in Asn non depleting conditions 
Results in C and G correspond to the Western-blots depicted in these panels of the figure 
5 (in the case of OE, the values correspond to the mean of 2 independent blots). 
SBG – Similar to the background 
ND – Non determined 
 
 
 
 
 
 
 
 
 
 
 
Mutants Asn cRPMI(C) sfRPMI(G) 
sKO A 
+ 0.05 0.01 
- 0.68 1.77 
sKO B 
+ 0.66 0.52 
- 0.93 0.99 
dKO A2 
+ SBG SBG 
- ND SBG 
dKO B1 
+ SBG SBG 
- ND SBG 
dKO A2 
+ LiAS-A 
+ 0.25 ND 
- 1.12 ND 
dKO B1 
+ LiAS-A 
+ 0.41 ND 
- 1.07 ND 
OE 
+ 1.30 1.10 
- 3.02 1.34 
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2.2. Ribose-5-phosphate isomerase B 
 
2.2.1. Ribose-5-phosphate isomerase B knockdown compromises 
Trypanosoma brucei bloodstream form infectivity  
Ribose 5-phosphate isomerase is an enzyme involved in the non-oxidative branch of the 
pentose phosphate pathway, and catalyzes the inter-conversion of D-ribose 5-phosphate 
and D-ribulose 5-phosphate. Trypanosomatids, including the agent of African sleeping 
sickness namely Trypanosoma brucei, have a type B ribose-5-phosphate isomerase. This 
enzyme is absent from humans, which have a structurally unrelated ribose 5-phosphate 
isomerase type A, and therefore has been proposed as an attractive drug target waiting 
further characterization. In this study, Trypanosoma brucei ribose 5-phosphate isomerase 
B showed in vitro isomerase activity. RNAi against this enzyme reduced parasites’ in vitro 
growth, and more importantly, bloodstream forms infectivity. Mice infected with induced 
RNAi clones exhibited lower parasitaemia and a prolonged survival compared to control 
mice. Phenotypic reversion was achieved by complementing induced RNAi clones with an 
ectopic copy of Trypanosoma cruzi gene. Our results present the first functional 
characterization of Trypanosoma brucei ribose 5-phosphate isomerase B, and show the 
relevance of an enzyme belonging to the nonoxidative branch of the pentose phosphate 
pathway in the context of Trypanosoma brucei infection. 
 
Reprinted from PLoS Neglected Tropical Diseases 2015 Dec 8; 9(1): e2578. doi: 10.1371/journal.pntd.0003430 
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2.2.2. Disclosing ribose-5-phosphate isomerase B essentiality in 
trypanosomatids  
Ribose-5-phosphate isomerase (RPI) belongs to the non-oxidative branch of the pentose 
phosphate pathway, catalysing the inter-conversion of D-ribose-5-phosphate and D-
ribulose-5-phosphate. Trypanosomatids encode a type B RPI, whereas humans have a 
structurally unrelated type A, making RPIB worthy of exploring as a potential drug target.  
Null mutants generation in Leishmania infantum was only possible when an episomal copy 
of RPIB gene was provided, and the latter was preserved both in vitro and in vivo in the 
absence of drug pressure. This suggests the gene is essential for parasite survival. 
Importantly, the inability to remove the second allele of RPIB gene in sKO mutants 
complemented with an episomal copy of RPIB carrying a mutation that abrogates isomerase 
activity suggests the essentiality is due to its metabolic function. In vitro, sKO promastigotes 
exhibited no defect in growth, metacyclogenesis or macrophages infection, however, an 
impairment in intracellular amastigotes’ replication was observed. Additionally, mice 
infected with sKO mutants presented a reduced parasite burden in the liver, rescued by 
RPIB complementation. Moreover, T. brucei is reluctant to complete RPIB gene removal, 
and mice experienced an extended survival upon infection with sKO mutants. Overall, our 
results genetically validate RPIB as a drug target candidate in trypanosomatids. 
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Abstract 
Ribose-5-phosphate isomerase (RPI) belongs to the non-oxidative branch of the 
pentose phosphate pathway, catalysing the inter-conversion of D-ribose-5-phosphate and 
D-ribulose-5-phosphate. Trypanosomatids encode a type B RPI, whereas humans have a 
structurally unrelated type A, making RPIB worthy of exploring as a potential drug target. 
Null mutants generation in Leishmania infantum was only possible when an episomal copy 
of RPIB gene was provided, and the latter was preserved both in vitro and in vivo in the 
absence of drug pressure. This suggests the gene is essential for parasite survival. 
Importantly, the inability to remove the second allele of RPIB gene in sKO mutants 
complemented with an episomal copy of RPIB carrying a mutation that abrogates isomerase 
activity suggests the essentiality is due to its metabolic function. In vitro, sKO promastigotes 
exhibited no defect in growth, metacyclogenesis or macrophages infection, however, an 
impairment in intracellular amastigotes’ replication was observed. Additionally, mice 
infected with sKO mutants presented a reduced parasite burden in the liver, rescued by 
RPIB complementation. Moreover, T. brucei is reluctant to complete RPIB gene removal, 
and mice experienced an extended survival upon infection with sKO mutants. Overall, our 
results genetically validate RPIB as a drug target candidate in trypanosomatids.  
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Introduction  
Some clinically relevant pathogens can survive and replicate in macrophages (MØ). 
However, only the protozoan Leishmania and Coxiella bacteria are known to thrive in fully 
mature phagolysosomes1, 2. Mammals become infected with Leishmania through the bite of 
an infected sand fly, which injects non-replicative metacyclic promastigotes in the skin, later 
phagocytosed by MØ2. Upon delivery to the phagolysosome, the internalized promastigotes 
differentiate into amastigotes3. The latter are able to rapidly re-infect other phagocytic cells 
(MØ or dendritic cells), as well as some non-phagocytic cells (fibroblasts), leading to several 
possible disease outcomes, like acute disease (ranging from self-healing cutaneous 
infections to fatal if untreated visceral forms), as well as chronic or latent infections3.   
Leishmaniasis is an important worldwide human health problem, affecting 
approximately 12 million people, with 1.3 million new cases every year4. Visceral 
leishmaniasis (VL), the most severe form of the disease, is mainly associated to infections 
by Leishmania donovani or Leishmania infantum. Currently, VL control relies mainly on 
chemotherapy and vector control, both presenting several limitations that hinder disease 
eradication in endemic areas5. Traditional chemotherapy is often associated with high cost, 
toxicity, complex administration regimes and the emergence of resistance5. Consequently, 
approximately 20,000 to 30,000 people die every year4, rendering the search for novel 
chemotherapeutic options a priority. 
The Pentose Phosphate Pathway (PPP) is a key metabolic pathway that relies on 
the use of glucose and is classically divided into two branches: an oxidative and a non-
oxidative branch. In these organisms, enzymes from the oxidative branch, namely glucose-
6-phosphate dehydrogenase (G6PD), 6-phosphogluconolactonase (6PGL) and 6-
phosphogluconate dehydrogenase (6PGDH) play an important housekeeping role and are 
related to their cyanobacteria and plant orthologues6, 7. The non-oxidative PPP is 
responsible for the interconversion of phosphorylated saccharides, giving rise to products 
(ribose-5-phosphate - R5P), intermediates (glyceraldehyde-3-phosphate - G3P, fructose-6-
phosphate - F6P) and cofactors (NADPH) used to synthesize nucleic acids and lipids and 
to maintain redox homeostasis8. Curiously, the enzymes involved in the non-oxidative 
branch, such as ribose-5-phosphate isomerase B (RPIB), ribose-5-phosphate-3-epimerase 
(RPE), transketolase (TKT) and transaldolase (TAL), constitute a more heterogeneous 
group, comprising a member that lacks any mammalian orthologue (RPIB9) and others 
(RPE and TKT) that are developmentally regulated and dispensable in a species-specific 
manner10-14. 
RPI enzymes catalyse the interconversion of ribose 5-phosphate (R5P) and ribulose 
5-phosphate (Ru5P), depending on the substrate and product concentrations15. Two types 
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of RPI enzymes can be found: type A (RPIA) is represented in all kingdoms of life, 
contrasting with the type B (RPIB) that is restricted to some bacteria and protozoans15. 
Trypanosomatids possess a RPI type B with no mammalian homologue9, 16-18. Indeed, we 
have recently demonstrated that in T. brucei bloodstream forms RPIB knockdown induces 
a dramatic impairment on parasite infectivity18. 
Taken all together, RPIB was suitable to be investigated as a drug target candidate 
in Leishmania. Thus, to evaluate the importance of this protein for Leishmania survival and 
infectivity, we have performed target gene replacement studies in L. infantum, and 
characterized the generated mutants. Target gene replacement studies were also 
undertaken in T. brucei. 
 
Results 
LiRPIB and LmRPIB sequence alignment. The open reading frames (ORFs) 
encoding a putative RPIB enzyme were identified in the genomes of L. infantum JPCM5 
(LinJ.28.2100) and L. major Friedlin (LmjF.28.1970)19, 20. The RPIB amplified sequences 
from these strains matched 100% the annotated sequences. RPIB sequences of L. infantum 
(LiRPIB), L. major (LmRPIB), T. brucei (TbRPIB) and T. cruzi (TcRPIB) generate 
polypeptides containing 172, 172, 155 and 159 amino acids, respectively (Fig. 1a). LiRPIB 
displays a 93% sequence identity with LmRPIB, and around 50% to RPIB of trypanosomes. 
LiRPIB shows only around 12% similarity to human RPIA. The amino acids involved in 
isomerisation (Cys69), phosphate stabilization (Arg113, Arg137, Arg141) and ring opening 
(His102, His138) have been identified in TcRPIB16 and are strictly conserved in LiRPIB, 
LmRPIB and TbRPIB (Fig. 1a). 
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Figure 1. Multiple-sequence alignment of RPIB proteins from trypanosomatids and 
analysis of recombinant LiRPIB and LmRPIB. (a) Alignment of LiRPIB (NCBI-Gene ID: 
5070424/ LinJ.28.2100), LmRPIB (NCBI-Gene ID: 5653408/LmjF.28.1970), TbRPIB (NCBI-
Gene ID: 3664062/ Tb927.11.8970) and TcRPIB (NCBI-Gene ID: 
3542840/TcCLB.508601.119). The amino acid conservation is coloured in blue (low 
conservation) to red (high conservation). Yellow, light green and light blue indicate the 
residues involved in the isomerisation, ring opening and phosphate stabilisation 
respectively. (b) Coomassie blue stained SDS-PAGE gel of 10 µg of recombinant LiRPIB 
and LmRPIB post affinity chromatography purification. (c) Western-blot analysis of 1 µg of 
purified recombinant LiRPIB and LmRPIB using a rabbit anti-HisTag monoclonal antibody 
(1:1000). (d) Western-blot analysis of recombinant LiRPIB or whole L. infantum 
promastigote extract using a rabbit polyclonal anti-LiRPIB (1:1000). MW, molecular weight 
marker. 
 
Enzymatic characterization of LiRPIB and LmRPIB. LiRPIB and LmRPIB 
recombinant proteins, containing a 6-histidine N-terminal tag, were expressed in 
Escherichia coli and purified by affinity chromatography under native conditions. Coomassie 
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staining and Western-blot analysis with an anti-HisTag antibody, are represented on figure 
1b and 1c, respectively, showing both proteins present the predicted MW for the monomer 
(LiRPIB ~20.83, LmRPIB ~20.78 kDa). The Coomassie staining also demonstrates that the 
purified recombinant proteins possess a suitable purity level to proceed to enzymatic 
studies.  Additionally, recombinant LiRPIB was used to immunise rabbits to produce 
polyclonal anti-LiRPIB antibodies. Those antibodies do recognise the recombinant protein 
and a single band in L. infantum promastigotes extract with the expected MW (~18.6 kDa, 
[web.expasy.org/protparam]) (Fig. 1d). Both LiRPIB and LmRPIB catalyse the conversion 
of R5P into Ru5P (direct reaction) or Ru5P into R5P (inverse reaction) in vitro, with similar 
kinetic constants, as shown in Table S1. The inverse reaction, which generates R5P, seems 
to be favoured, with both enzymes presenting lower Km values and higher vmax and kcat.  
 
RPIB has a dual localisation in L. infantum promastigotes. The rabbit anti-
LiRPIB polyclonal antibody was also validated by IFA, as the fluorescence intensity of WT 
promastigotes versus LiRPIB mutants (single knockout (sKO; clone 15) and overexpressing 
line (OE)) was measured and a positive correlation between protein levels and labelling 
intensity was found (Fig. S1).  
Using α-tubulin as a loading control, we compared RPIB expression in different 
stages of the parasite life cycle. RPIB was found to be more expressed in amastigotes (5 
fold increase) followed by logarithmic promastigotes (3 fold increase) when compared to 
late stationary promastigotes (Fig. 2a).  
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Figure 2. RPIB expression and localization in L. infantum. (a) RPIB expression in 
different stages of L. infantum life cycle. Promastigote forms: logaritmic phase (Log), early 
stationary phase (ES), late stationary phase (LS); axenic amastigote forms (Ama). Twenty 
µg of total extracts were analysed by Western-blot and probed with rabbit polyclonal anti-
LiRPIB. α-tubulin (mouse monoclonal antibody) was used as loading control. Quantification 
expressed in LiRPIB/tubulin ratio, is presented in the lower panel. Two-tailed unpaired t test 
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was performed: statistical significance p ˂ 0.05. (b) Digitonin fractionation of mid-log L. 
infantum promastigotes. Pellet (P) and supernatant (S) fractions obtained using increasing 
concentrations of digitonin or positive control with 1% of Triton X-100 (TR – Total Release) 
were subjected to Western-blot analysis and probed with antibodies against LiRPIB, 
LiEnolase (cytosolic marker) and hypoxanthine guanine phosphoribosyltransferase 
LiHGPRT (glycosomal marker). (c-e) Immunofluorescence analysis showing LiRPIB (red in 
c; green in e) localization in L. infantum promastigote form. Nucleus and kinetoplast DNA, 
cytosol and glycosomes were stained with DAPI (blue), sheep anti-LiTDR1 (thiol-dependent 
reductase 1, green) and rabbit anti-LiHGPRT (red), respectively. On panel d, red arrows in 
the zoomed areas correspond to sites of exclusive LiRPIB staining. On panels d and e, 
yellow arrows in the zoomed areas point to colocalisation sites. Images are maximal Z-
projections of 30 to 35 contiguous stacks separated by 0.1 µm and were acquired with a 
63x objective, using a LEICA SP5II confocal microscope. The scale bar corresponds to 5 
µm. Data displayed on a-e are representative of 3 independent experiments. 
 
To determine LiRPIB subcellular localization, we resorted to in silico prediction and 
performed digitonin fractionation and immunofluorescence analysis. Bioinformatics tools, 
Wolf Psort and CELLO, predicted a cytosolic localization for RPIB. Digitonin fractionation 
followed by Western-blot analysis was performed in promastigotes. The following antibodies 
were used to detect the fractioning pattern of proteins located in different subcellular 
compartments, namely, anti-TbEnolase (LiEnolase versus TbEnolase 79% identity, 
LiEnolase 39.6 kDa) as a cytosolic marker21 and anti-LdHGPRT (hypoxanthine guanine 
phosphoribosyl transferase, LiHGPRT 23.6 kDa) as a glycosomal marker22. Enolase (Fig. 
2b) was found in the supernatant for digitonin concentrations as low as 12.5 µg/ml, and 
retained in the pellets up to 12.5-25 µg/ml. HGPRT, in its turn, is longer retained in the pellet 
fractions (significantly up to 200 µg/ml of digitonin, and detected up to 1000 µg/ml), being 
detected in the supernatant only at 100 µg/ml. RPIB is less retained in the pellet fraction 
than HGPRT , however, it appears in the supernatant in a similar fashion to enolase. To 
further elucidate RPIB localization, we have also performed immunofluorescence analysis 
in promastigotes and confocal microscopy. TDR1 (thiol-dependent reductase 1)23 and 
HGPRT were labelled as cytosolic and glycosomal markers, respectively. Representative 
images of the labelling with these two markers are shown on figure 2c (also on Fig. S2a). 
RPIB labelling profile and the partial co-localization with the cytosolic marker TDR1 
indicates the protein is mainly localized in the cytosol (Fig. 2d and S2b).  However, some 
co-localization with the glycosomal marker, HGPRT, was frequently seen, suggesting this 
protein might have a dual localization (Fig. 2e and S2c). Indeed, in all the parasites we have 
analysed, partial RPIB co-localisation with TDR1 or HGPRT was always observed.  
In conclusion, RPIB despite mostly localised in the cytosol of promastigotes can also 
be found in association to the glycosomes. 
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LiRPIB facilitated null mutants generation by targeted gene replacement. A 
targeted gene replacement strategy was used for RPIB gene inactivation in L. infantum. 
The first transfection allowed the removal of one of the gene alleles generating sKO clones 
resistant to either neomycin (NEO) or hygromycin (HYG), depending on the cassette that 
was used. When attempting to remove the second gene allele, independently of using a 
HYG or NEO, no null mutants were obtained in a total of four independent attempts. Some 
of the mutants obtained following the dKO attempt were likely aneuploid (Table S2), as by 
PCR and by Southern-blot (data not shown), parasites carry both resistance cassettes and 
the gene at the target locus. The consecutive inability to remove the second allele, coupled 
with the constant aneuploidy generation was suggestive of gene essentiality. Therefore, a 
HYG construct has been transfected in parallel into parasites with the following genotypes: 
WT, sKONEO (sKO 15) and sKONEO complemented (sKO P15) with an episome carrying 
the RPIB gene (pSPαBLASTαRPIB). This approach enabled the generation of sKO mutants 
from the WT, dKO mutants only in the complemented sKO, and once more failed to 
generate mutants that were truly null to RPIB. The WT parasites were transfected with the 
pSPαBLASTαRPIB plasmid to generate an overexpressing cell line.  
The genotype of the facilitated null mutants (dKO P15.3, dKO P15.14 and dKO 
P15.15) was confirmed by PCR (Fig. 3b) and Southern-blot (Fig. 3c), whose strategies are 
illustrated on figure 3a. By PCR, the successful integration of the selectable markers, RPIB 
presence in the episome and absence in the chromosomic locus were verified. The 
genotypes were further confirmed by Southern-blot. A first hybridization was performed 
using 3’ UTR as a probe: the bands of ~7547 bp, ~3958 bp and ~4574 bp correspond to 
RPIB, NEO and HYG, respectively (Fig. 3c). The blot was then stripped and reprobed three 
additional times to confirm each of the bands. Reprobing with RPIB gene confirmed its 
presence in the chromosomes of WT, OE, sKO 15 and sKO P15 (~7547 bp) and in the 
episome in OE, sKO P15 and facilitated null mutants (~3606 bp) (Fig. 3c). All the clones 
were also analysed by Western-blot and shown RPIB reduction in sKO mutants, an 
overexpression in sKO P15 and OE mutants (Fig. 3d).   
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Figure 3. Genetic and post-translational analysis of the LiRPIB mutants. (a) LiRPIB 
locus (RPIB allele, targeted gene replacement cassettes, containing NEO and HYG) and 
pSPαBLASTαLiRPIB schematics. Horizontal grey arrows and numbers represent the primer 
pairs (sequence on Table S4) used to assess the genotype of the mutants: the grey dashed 
line represents the expected PCR fragment. Southern-blot approach, upon digestion with 
EcoRI (vertical black contoured arrows) and NaeI (vertical black full coloured arrows) is also 
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represented: dashed black lines represent the expected digestion fragments. (b) PCR 
analysis of LiRPIB mutants to assess LiRPIB, NEO and HYG presence in chromosome 28, 
as well as pSPαBLASTαLiRPIB presence. B, blank. (c) Southern-blot analysis of 10 µg of 
LiRPIB mutants (versus WT) genomic DNA, previously digested with EcoRI and NaeI, and 
probed using 3’ UTR. Following, the blot was stripped and reprobed using LiRPIB. (d) 
Western-blot analysis of LiRPIB expression in   promastigote mutants (versus WT), using 
LiCS (cysteine synthase) as loading control. (e) pSPαBLASTα quantification by qPCR using 
10 ng of genomic DNA from LiRPIB OE and facilitated null mutants (fdKO) P15.3, P15.14 
and P15.15 and from LiASA OE and complemented null mutants (cdKO) clones A and B. 
We used DNA of each one of the mutants left in culture for 3 and 6 months in the absence 
of blasticidin and calibrated against the correspondent mutant maintained in culture in the 
presence of the drug. rRNA45 was used a reference gene. The results correspond to means 
plus standard deviation of two independent experiments. 
 
The facilitated dKO mutants were subcultured weekly for 6 months in the presence 
or absence of blasticidin drug pressure. In the absence of drug pressure, LiRPIB facilitated 
mutants (fdKO) did not lose the plasmid, as assessed by qPCR (Fig. 3e). Contrarily, LiRPIB 
OE, as well as an unrelated non-essential protein (asparagine synthase A; AS-A) OE and 
its correspondent complemented null mutants (in which pSPαBLASTα was also used as a 
vector; cdKO), lost the plasmid. 
In conclusion, our results indicate RPIB is essential for L. infantum survival.  
 
LiRPIB is important for the replication of intracellular amastigotes. Several 
experiments using the different mutants were conducted in vitro to assess whether LiRPIB 
would have a role in promastigotes growth and metacyclogenesis, MØ infection or 
intracellular amastigote replication.  
All promastigotes mutants grew in a similar fashion to the WT (Fig. 4a), including in 
logarithmic phase (Fig. 4b). The expression of metacyclogenesis markers (Histone H4, 
SHERP, MET-124) in stationary cultures was not statistically different from the WT (Fig. 4c). 
Moreover, all the clones successfully differentiated into axenic amastigotes and apparently 
enter bone marrow derived MØ normally, as observed at 4 hours post infection, either by 
FACS (Fig. 4d) or microscopic analysis. Indeed, no differences in the percentage of infected 
cells nor the numbers of parasites per infected cell were seen at 4 and 24 hours post-
infection between WT and mutant parasites (Fig 4e-f). While the percentage of infected 
cells remained similar during the experiment for all the mutants, cells infected with sKO 
presented a statistically significant decrease in the average of amastigotes per cell at 72 
hours post-infection (Fig. 4g). This reduction is due to an increase in the percentage of cells 
with one amastigote and a decrease in the percentage of cells containing, at least, three 
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amastigotes (Fig. 4h-i). Importantly, this phenotype is not observed in complemented sKO 
(sKO P15). 
 
Figure 4. In vitro characterization of LiRPIB mutants: promastigotes growth, 
metacyclogenesis, MØ invasion and intracellular amastigote replication. (a and b) L. 
infantum promastigotes growth curves of LiRPIB mutants (versus WT), cultured in cRPMI. 
In b, parasites were maintained in logarithmic phase by subculturing every 2 days. Data 
correspond to mean values of duplicates ± standard deviation. (c) Histone H4, SHERP and 
MET-1 gene expression levels quantification by qRT-PCR. Prior, total RNA from WT and 
LiRPIB mutants stationary promastigotes was extracted and converted into cDNA. rRNA45 
was used as reference gene. Calibration was performed against WT.  Data correspond to 
mean values of duplicates plus standard deviation. (d) Percentage of infected bone marrow 
derived MØ determination by FACS analysis using CFSE-labelled WT or LiRPIB mutants 
stationary promastigotes, at 4 hours post infection. Infections were performed using a ratio 
of 2, 5 or 10 parasites per cell.  Data correspond to mean values of duplicates plus standard 
deviation. (e and f) Percentage of infected bone marrow derived MØ at 24 (e) and 72 (f) 
hours post infection. (g) Average of amastigotes per cell in bone marrow derived MØ at 24 
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and 72 hours post infection. (h and i) Percentage of infected bone marrow derived MØs 
that contain 1, 2 or ≥ 3 parasites, at 24 (h) and 72 (i) hours post infection. a-j are 
representative of 2 independent experiments. In e-i, WT or LiRPIB mutants stationary 
promastigotes were used in a ratio of 10 parasites per cell. In the appropriate timepoints, 
the cells were Giemsa stained and microscopically analysed. Data correspond to mean 
values of duplicates plus standard deviation. Two-tailed unpaired t test was performed: 
statistical significance p ˂ 0.05. 
 
In conclusion, the in vitro results suggest that LiRPIB might be important for the 
replication of intracellular amastigotes.  
 
LiRPIB has a role in mice infection. To evaluate the role of RPIB on parasites 
infectivity, BALB/c mice were infected with WT or LiRPIB mutant promastigotes and the 
parasite burdens in the spleen and liver determined at two (acute phase) and eight weeks 
(chronic phase) post infection. At two weeks post infection, no differences in the splenic 
parasite loads were detected, while in the liver, animals infected with sKO mutants (clones 
13 and 15) presented reduced parasite loads (Fig. 5a-b). Importantly, these differences 
were not seen in animals infected with sKO lines complemented with episomal RPIB (clones 
sKO P13 and sKO P15). Western-blot analysis of parasites recovered from the spleen and 
the liver in acute phase demonstrates RPIB downregulation in sKO and overexpression in 
the complemented sKO. A representative Western-blot and the respective quantification 
are shown on figure 5c-d. In the chronic phase, there is a partial clearance of the parasite 
burden in the liver compared to acute phase, but overall both WT and mutant parasites 
persist in both organs.  Mutant parasites recovered from the spleen and the liver of 
chronically infected animals were analysed by qPCR for the presence of the episome 
carrying RPIB. While the OE has lost the episome over time, the same did not occur with 
the facilitated null mutant clone P15.14 (Fig. 5e), suggesting RPIB is also essential in 
amastigote form.  
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Figure 5. Infectivity of LiRPIB mutants in mice. (a and b) 1 x 108 early stationary 
promastigotes were intra-peritoneally injected in BALB/c mice that were sacrificed 2 weeks 
post infection. The parasite burden in spleen (a) and liver (b) was assessed by the limiting 
dilution method. The values represent the means of four animals ± standard deviation. Two-
tailed unpaired t test was performed: statistical significance p ˂ 0.05. (c and d) Western-
blot analysis of RPIB levels in WT and LiRPIB mutants recovered from spleen (S) or liver 
(L). 1x107 parasites were used for total extract preparation and LiCS (cysteine synthase) 
was detected as loading control. The fold difference in of RPIB expression in LiRPIB 
mutants in comparison to WT recovered from the spleen and liver at 2 weeks post infection 
is shown in d. The results correspond to means plus standard deviation of two independent 
experiments. In c a representative Western-blot is shown. E) pSPαBLASTα quantification 
by qPCR using 10 ng of genomic DNA from LiRPIB OE and facilitated null mutant P15.14 
that were left in culture for 6 months in the absence of blasticidin or recovered from spleen 
or liver 2 months post infection relative to the respective mutant maintained in culture under 
drug pressure. rRNA45 was used as reference gene. The results correspond to means plus 
standard deviation of two independent experiments. 
 
These data suggest RPIB is important during Leishmania mouse infection, 
particularly in the liver. 
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LiRPIB essentiality is dependent on its isomerase function. We consider that 
assessing whether protein essentiality is due to the annotated metabolic function is 
particularly important in the context of a drug target validation. T. cruzi RPIB isomerase 
activity is abrogated by replacing cysteine 69 by an alanine without compromising the 
overall 3D conformation16. Therefore, we thought of evaluating whether the same mutation 
would abrogate LiRPIB isomerase activity and whether the second RPIB allele removal in 
a single KO complemented with a plasmid carrying the mutated RPIB (sKO P15 C69A) would 
be successful. This experimental approach would disclose whether protein essentiality is 
independent (Fig. 6a6) or dependent (Fig. 6a7) on RPIB isomerase function, respectively. 
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Figure 6. Assessing whether LiRPIB essentiality depends on its isomerase function. 
(a) Schematic overview of the strategy used to determine if LiRPIB essentiality depends on 
its isomerase function. The strategy was to transfect WT (1), sKO 15 provided of 
pSP72αBLASTαRPIBWT (sKO P15WT, 2) or pSP72αBLASTαRPIBC69A (sKO P15C69A, 3), 
with a HYG containing construct. Two series of mutant’s generation had to be successful 
for conclusions to be extracted: sKOHYG mutants’ generation from WT transfection (4), 
validating the construct, and facilitated null mutants generation from sKO P15WT transfection 
(5). Therefore, whether we were able to remove the second RPIB allele or not when 
transfecting sKO P15C69A would determine whether the protein essentiality was independent 
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(6) or dependent (7) on the isomerase function, respectively. (b) Coomassie blue stained 
SDS-PAGE gel of 10 µg of recombinant LiRPIBWT and LiRPIBC69A post affinity 
chromatography purification. (c) Measurement of LiRPIBWT and LiRPIBC69A activity, 
catalysing the direct reaction (R5P -> Ru5P), using either 25 or 50 mM of R5P and 0.5 or 1 
µg of enzyme and the direct spectrophotometric method at 290 nm. The data are 
representative of 2 independent experiments. (d) Western-blot analysis of LiRPIB 
expression in WT, sKO 15, sKO P15WT, sKO P15C69A and OE, before the transfection 
scheme represented in A. 1x107 parasites were used for total extract preparation and LiCS 
(cysteine synthase) was used as loading control. (e) PCR analysis of LiRPIB mutants to 
assess LiRPIB, NEO and HYG presence in chromosome 28, as well as 
pSPαBLASTαLiRPIB presence. See primers sequences on Table S4 and the expected 
fragments and annealing sites on figure 3A. B, blank. 
 
For this purpose, a mutated recombinant LiRPIBC69A protein was expressed to 
confirm the inactivation of the isomerase function.  The recombinant protein possessed the 
expected MW (~21.09 kDa, Fig. 6b) and failed to convert R5P into Ru5P (Fig. 6c) or Ru5P 
into R5P. The sKO 15 was complemented with pSP72αBLASTαRPIBC69A, and the 
expression levels of RPIB in sKO P15WT and sKO P15C69A were found to be similar (Fig. 
6d). Afterwards, WT (Fig. 6a1) and sKO 15 provided of pSP72αBLASTαRPIBWT (sKO 
P15WT, Fig. 6a2) or pSP72αBLASTαRPIBC69A (sKO P15
C69A, Fig. 6a3) were transfected 
with a HYG construct (Fig. 6a). As controls, two mutant series were successfully generated: 
sKOHYG mutants from WT transfection (Fig. 6a4) and facilitated null mutants from sKO 
P15WT transfection (Fig. 6a5). Eleven out of 12 (Table S2) facilitated null mutants from sKO 
P15WT transfection were obtained, while no facilitated null mutants were obtained with sKO 
P15C69A. PCR analysis of representative mutants of each series is shown on figure 6e, 
following the same strategies depicted on figure 3a. The previously generated facilitated 
null mutant clone P15.14 was used as positive control.  
These data indicate LiRPIB essentiality is due to its isomerase function.   
 
RPIB essentiality is conserved across trypanosomatids. Taking into account 
RPIB essentiality in L. infantum, and a previous report of its importance for T. brucei 
bloodstream forms infectivity18, we investigated whether essentiality would be preserved in 
this organism. To obtain TbRPIB null mutants, a target gene replacement strategy was also 
applied. One TbRPIB allele was replaced by HYG giving rise to sKO mutants right in the 
first attempt. PCR and Southern blot, whose approach is represented on figure 7a, 
confirmed the correct insertion of the cassette (Fig. 7b and d), and Western-blot shows a 
reduction in TbRPIB protein levels of approximately 50% in sKO cell lines compared to the 
WT (Fig. 7c). For the generation of TbRPIB dKO mutants, sKO parasites were transfected 
either with a BLEO construct or with a NEO construct, with no success. The NEO construct 
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reliability was assessed by simultaneous transfection of WT and sKO mutant. Resistant 
parasites were only obtained for the WT but not for the sKO (Fig. 7e), enabling the 
generation of sKO but not null mutants. Therefore, we have characterized the generated 
sKO cell lines. No significant differences were found on the in vitro growth of TbRPIB sKO 
bloodstream forms compared to WT (Fig. 7f). In vivo, TbRPIB sKO showed a reduced 
infectivity evaluated by the parasitemia (Fig. 7g) and by the increase of mice life span (Fig. 
7h) when compared to WT parasites. 
Figure 7. TbRPIB mutants generation and their in vitro and in vivo characterization. 
(a) TbRPIB locus schematics: RPIB allele, targeted gene replacement cassettes, containing 
NEO and HYG genes. Horizontal grey arrows and numbers represent the primer pairs used 
to assess the genotype of the mutants: the grey dashed line represents the expected PCR 
fragment. Southern-blot approach, upon digestion with BspHI (vertical black full coloured 
arrows) is also represented: dashed black lines represent the expected digestion fragments. 
(b) PCR analysis of TbRPIB sKO mutants to assess HYG 5’ integration. B, blank. (c) 
Southern-blot analysis of 10 µg of TbRPIB mutants (versus WT) genomic DNA, previously 
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digested with BspHI, and probed using 3’ UTR. (d) Western-blot analysis of RPIB 
expression in bloodstream mutants (versus WT) using aldolase as loading control. (e) PCR 
analysis of TbRPIB sKO mutant to assess NEO 5’ integration. B, blank. (f) Growth curve of 
WT versus a representative sKO cell line. Black and grey squares represent WT and sKO 
growth, respectively. Cumulative cell numbers (product of cell number and total dilution) are 
plotted. Values represent averages from two independent experiments using one 
representative sKO clone and ± error bars indicate standard deviation. (g) Groups of mice 
(n=3) were infected intraperitoneally with 1 x 104 control WT (black squares) or a 
representative sKO clone (grey squares). Parasitemias of each group are shown from 4th to 
6th day post-infection. Values are means and errors bars indicate + standard deviation. 5 × 
104 trypanosomes/ml of blood is the detection limit. For TbRPIB sKO, the mean of 
parasitemia at day 6 was below the detection limit and therefore not seen in the graphic. 
Mice were culled when parasitemia reached 1 x 108 cells/ml. (h) Kaplan–Meier survival 
analysis of mice infected with WT versus a representative sKO clone (black and grey line, 
respectively). Parasitemias and survival curve are representative of two independent 
experiments using two different sKO clones. 
 
Our data strongly suggest that a functional copy of TbRPIB gene is essential for 
parasites survival and that 50% decrease in RPIB levels is sufficient to compromise 
parasites infectivity. 
 
Discussion 
Trypanosomatids genomes have sequences that encode for a putative RPIB and 
recombinant enzymes from L. donovani17, T. brucei18 and T. cruzi9 have been formally 
demonstrated to have in vitro isomerase activity by catalyzing the interconversion of R5P 
and Ru5P. In this work we have demonstrated the same applies to L. infantum and L. major 
homologues. Leishmania enzymes share over 90% identity among them, and only around 
50% to RPIB of trypanosomes. Nevertheless, the protein residues so far associated to 
isomerization, ring opening and phosphate charge stabilization are strictly conserved. The 
Km values for both R5P and Ru5P were similar between Leishmania and trypanosomes, 
however, kcat values are considerably higher for Leishmania, in both direct and inverse 
reactions (Table 1 versus 9, 17-18). A decrease in Km and an increase in kcat were consistently 
observed for Ru5P in comparison to R5P (Table S1), suggesting that the conversion of 
Ru5P into R5P is favored, which might be explained by the important role of R5P as a 
building block for nucleic acid synthesis. 
Trypanosomatids have unique organelles to respond to their specific life cycle 
needs. Among those are glycosomes, peroxisome-related organelles that comprise 
enzymes of important metabolic pathways such glycolysis, PPP, among others25. This 
compartmentation of metabolic pathways can prevent the accumulation of toxic 
intermediates26 or enable a fast metabolic adaptation to environmental changes25. LmRPIB 
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possesses a peroxisome targeting sequence 2 (PTS-2) a glycosomal signal peptide 
sequence (–RVALGCDHA–27) that is conserved in L. infantum and L. donovani. Our study 
suggests a dual localisation despite most RPIB is detected in the cytosol of L. infantum 
promastigotes, it also localises in a certain extent to the glycosomes, similarly to what we 
have described for TbRPIB18. Moreover, other enzymes of the same pathway have been 
described to display the same pattern, for instance, the enzymes immediately upstream or 
downstream to RPIB, 6PGDH and TKL respectively11-12, 27-29. However, recent proteomic 
analysis of L. donovani glycosomes failed to detect RPIB30. This same analysis detected 
HGPRT (PTS-1), aldolase (PTS-2), as well as some enzymes of PPP, namely putative 
G6PD, TKL, putative RPE (PTS-1), putative 6PGDH and putative TAL (non-identified signal 
peptide), or other related proteins like putative ribokinase (PTS-2). We wonder whether this 
is due to RPIB amount in the glycosomes, or the fact it does not seem to be present in all 
the glycosomes (Fig. 2e, S2c).  
To assess the importance of RPIB for L. infantum survival and infectivity, we tried to 
generate null mutants. Consecutive inability to obtain mutants null to RPIB, coupled with 
constant aneuploidy generation were suggestive of gene essentiality31, 32. We have used a 
classical approach to demonstrate it33, 34, by providing the sKO parasites an episomal copy 
of RPIB and successfully removed the second gene copy, generating facilitated null 
mutants. Moreover, the plasmid was not lost even in the long-term absence of drug pressure 
in vitro (Fig. 3e) and in vivo (Fig. 5e) further supporting RPIB essentiality for L. infantum 
survival in both promastigote and amastigote forms. 
Due to the impossibility of generating mutants truly null to RPIB, we have performed 
phenotypic studies using the sKO lines that present a 50% downregulation of the protein 
levels. In vitro, sKO promastigotes grow, undergo metacyclogenesis, enter macrophages 
and differentiate normally. However, our data point to a defective replication of the 
intracellular amastigotes. Indeed, in these experimental conditions, amastigotes replication 
can be evaluated as the number of parasites per cell significantly increases from 24 to 72 
hours post-infection in the WT. Importantly, MØ infected with sKO mutants showed a 
reduced number of amastigotes per cell at 72h post-infection and this phenotype was 
rescued by complementation with episomal RPIB. It is noteworthy that probably the 
remaining protein amount suffices the parasite needs for a minimal intracellular replication 
and therefore the overall effect is not dramatic. Actually, in vivo, there was no parasite 
clearance, not even at later stages of infection (data not shown), meaning that the parasites 
persist. This type of phenotype is frequently described in Leishmania mutants for enzymes 
involved in energy metabolism, for instance, glucose transporter knockout in L. mexicana35 
and gluconeogenic enzyme fructose-1,6-bisphosphatase (FBPase) knockout in L. major36, 
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as promastigotes infect and differentiate, but the resulting amastigotes do not replicate 
falling to generate normal lesions in mice.  
The higher expression of RPIB in amastigotes (Fig. 2a), in accordance with a whole 
genome transcriptomic analysis37, and its importance for intracellular amastigote replication 
(Fig. 4g-i) suggests a major role in this stage.  
Moreover, RPIB knockdown in T. brucei bloodstream forms impacts their infectivity, 
with an appreciable extension of mice survival18. The defective phenotype observed in vivo 
for the TbRPIB sKO mutants (Fig. 7g-h) was less dramatic when compared to the one with 
RNAi18. This might be explained by the more pronounced RPIB downregulation achieved 
with the RNAi system. Three independent attempts to generate dKO mutants have failed, 
suggesting that RPIB is essential for T. brucei survival. A TbRPIB conditional knockout 
would ultimately prove gene essentiality38. Nevertheless, our results support that RPIB is a 
potential therapeutic target against both Leismania and T. brucei infections.  
Several enzymes have been reported to exhibit protein moonlighting in 
trypanosomatids39-41, particularly in carbohydrates metabolism40. In this sense, in a drug 
discovery perspective, it is crucial to assess if the expected metabolic function is the one 
that is detrimental for parasite survival and/or infectivity and therefore the one to be targeted 
by inhibitory molecules. We have unequivocally demonstrated that RPIB isomerase function 
is indispensable for L. infantum survival (Fig. 6).  
We can only speculate why an enzyme involved in the non-oxidative branch of PPP, 
in which substrate interconversion takes place, is essential. Amastigotes are known to have 
complex nutritional requirements, which may have precluded their establishment in early 
endosomal or non-hydrolytic vacuoles of MØ42, where the levels of amino acids and sugars 
do not suffice the parasite demands43, 44. Inclusively, the variable nutritional composition of 
host cells phagolysosomes might be one of the reasons why Leishmania promastigotes fail 
to differentiate and the ensuing amastigotes to replicate in neutrophils2, but do it 
successfully in MØs42. Actually, this may also explain why sKO mutants exhibit a more 
pronounced infectivity defect in the liver when comparing to the spleen.  
Many Leishmania auxotrophs do not exhibit any loss of virulence and manage to 
persist in animal hosts, suggesting that the apparently hostile environment of the 
phagolysosome is somehow a permissive niche42. Importantly, amastigotes undergo a 
“stringent metabolic response”, characterized by a sharp decrease in glucose uptake that 
allows a more efficient energy metabolism, associated to a decrease of energy expense in 
anabolic processes and redirecting the carbon to intracellular carbohydrate reserves45. It 
has been proposed it facilitates a long-term amastigote survival in the nutrient-limited 
environment of the phagolysosome, but simultaneously and paradoxically increasing the 
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dependency on carbohydrates uptake and metabolism, as they become dependent on 
mitochondrial metabolism for glutamate and glutamine synthesis45). If glucose uptake and 
carbohydrates availability in the phagolysosome is reduced for amastigote forms, the same 
should apply to ribose, in particular. Ribose can be imported46 and metabolized47 by 
Leishmania promastigotes and apart from its importance for nucleic acid synthesis it can 
also be a relevant source of energy for intracellular amastigotes48. Interestingly, organisms 
such as yeast present an alternative NADP-independent pathway for R5P synthesis, 
designated riboneogenesis pathway49. Although it has not been formally shown to be 
operational in trypanosomes, Leishmania lacks a sequence encoding for the putative key 
enzyme of the process13. The decrease of glucose and ribose import along with the absence 
of an alternative pathway for RPIB generation would render the parasites more dependent 
in enzymes that ultimately generate this metabolite.  
Apart from the effects of R5P pool diminishment, absence of RPIB may lead to the 
potential accumulation of Ru5P. Indeed, if the upstream enzymes are regulated by end 
products concentration, then the oxidative branch could become less operational leading to 
a decrease in NADPH production, which could render the parasites more susceptible to 
reactive oxygen species. Moreover, Ru5P accumulation could trigger another sort of 
outcome, considering observations made in hepatocarcinoma cells, upon human RPIA 
knockdown50. In this study, the accumulated Ru5P is converted into xylulose-5P by RPE. 
This metabolite can activate PP2A activity51, which negatively regulates ERK signalling for 
cell proliferation. Whether this sort of regulation takes place in Leishmania has not been 
described, however, it does encode for putative RPE19, 20, PP2A52 and several MAP 
kinases53.  
In summary, RPIB, which lacks a human homologue, is essential for L. infantum 
survival and infectivity. We have indications this can also be the case in T. brucei, thus in a 
broader perspective, RPIB can be a potential drug target in trypanosomatids. The fact that 
a simple in vitro activity assay could be used for the screening of inhibitory molecules 
coupled to the existence of structural data16, reinforce this protein to be a good target 
candidate. However, further studies approaching its druggability should be carried out in the 
future.  
 
Materials and Methods 
Ethics statement. All experiments were approved by the IBMC.INEB Animal Ethics 
Committees and the Portuguese National Authorities for Animal Health guidelines, 
according to the statements on the directive 2010/63/EU of the European Parliament and 
of the Council. 
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Chemicals and reagents. D-ribose-5-phosphate disodium salt hydrate, D-ribulose-
5-phosphate disodium salt, EDTA, cysteinium chloride, tetracyclin, carbazole, sulphuric 
acid, dNTPs, tween-20, tris-base, urea, thiourea, DTT, 2-mercaptoethanol, triton X-100 and 
IPTG (isopropyl-β-D- thiogalactopyranoside) were purchased from Sigma. Oligonucleotide 
primers were obtained from STAB VIDA. Restriction endonucleases were from New 
England Biolabs. Polyclonal antibodies against LiRPIB and TbRPIB were obtained in rabbits 
inoculated with purified recombinant His-tagged LiRPIB and TbRPIB, respectively. 
Parasites. L. infantum (MHOM/MA/67/ITMAP-263) promastigote and axenic 
amastigote forms were cultured in complete RPMI 1640 medium at 26ºC or in complete 
MAA medium at 37ºC, 5% CO2, respectively, as previously described24. For in vitro and in 
vivo characterization, different cell lines were firstly recovered from the spleen of infected 
BALB/c to restore virulence, and posteriorly maintained in culture no longer than 10 
passages24. T. brucei brucei Lister 427 bloodstream forms were cultivated in HMI-9 
medium, as previously described54. Depending on the analysis, protein extracts were 
prepared as follows: 1) 1 x 107 late-stationary L. infantum promastigotes or T. b. brucei 
bloodstream forms were resuspended in T8 lysis buffer (tris-base 0.6%, urea 42%, thiourea 
15%, DTT 0.3%, triton X-100 1%); or 2) 1 x 108 promastigotes or axenic amastigotes were 
resuspended in 100 µL of PBS containing protease inhibitor (Roche) and following 6 
freezing/thaw cycles, the parasite suspensions supernatants were recovered and then 
quantified using Bio-Rad DC Protein Assay (Biorad). All the samples were stored at -80ºC. 
RPIB protein alignments. LiRPIB, LmRPIB, TbRPIB and TcRPIB protein 
alignments were performed using the ClustalW program55 or CLC Sequence Viewer v. 6.9.  
RPIB in silico localization prediction. LiRPIB subcellular localisation prediction 
was performed using WoLF PSORT56 and CELLO57.  
Cloning RPIB genes. Ribose 5-phosphate isomerase B from L. infantum (LiRPIB) 
and L. major (LmRPIB) was obtained by performing PCR on genomic DNA, extracted using 
DNAzol (Invitrogen) from L. infantum (MHOM/MA/67/ITMAP-263) and L. major strain 
Friedlin. Fragments of the open reading frames of LiRPIB (LinJ.28.2100; chromosome 
LinJ.28; 781,581-782,099) and LmRPIB (LmjF.28.1970; chromosome LmjF.28; 766,756-
767,274)19, 20 were PCR-amplified, using primers 1 + 2 and 3 + 4 (Table S3), respectively. 
PCR conditions were as follows: initial denaturation (2 min at 94ºC), 35 cycles of 
denaturation (30 s at 94ºC), annealing (30 s at 45ºC,) elongation (2 min at 68ºC) and a final 
extension step (10 min at 68ºC). In the case of LiRPIB, another restriction strategy was 
required to clone the gene into a Leishmania overexpression vector – pSPαBLASTα 
(primers 7 + 8, table S3). PCR conditions were as follows: initial denaturation (2 min at 
94ºC), 30 cycles of denaturation (15 s at 94ºC), annealing (30 s at 62ºC,) elongation (1 min 
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at 72ºC) and a final extension step (10 min at 72ºC). In order to obtain LiRPIB with a point 
mutation on Cys69 (replaced by an alanine, C69A) – LiRPIBC69A, primers 5 + 6 and 7 + 6 
(Table S3) were used to amplify fragments of the ORF containing XbaI/AgeI or NheI/AgeI 
restriction sites and the desired point mutation, that were then cloned into pGEM-T in order 
to ultimately clone them into pET28a(+) (Novagen) and pSPαBLASTα vectors, respectively. 
PCR conditions were as follows: initial denaturation (2 min at 94ºC), 35 cycles of 
denaturation (15 s at 94ºC), annealing (30 s at 62ºC,) elongation (30 s at 72ºC) and a final 
extension step (10 min at 72ºC). All the PCR products were obtained using a Taq DNA 
polymerase with proofreading activity (Roche), isolated, cloned into a pGEM-T Easy vector 
(Promega) and sequenced.  
Expression and purification of recombinant LiRPIB (WT and C69A) and 
LmRPIB. The LiRPIBWT, LiRPIBC69A and LmRPIB genes were excised from the pGEM-T 
Easy vector (using NdeI/EcoRI, NheI/SacI and NdeI/EcoRI, respectively), gel purified and 
subcloned into pET28a(+) expression vector. The resulting constructs presented a 6-
histidine tag at the N-terminal and were transformed into E. coli BL21DE3 cells. Proteins 
were purified by affinity chromatography as previously described18. Concentration was 
determined measuring the absorbance at 280 nm using the theoretical molar extinction 
coefficient of 12950, 12950 and 7450 M-1.cm-1 for LiRPIBWT, LiRPIBC69A and LmRPIB, 
respectively, making use of NanoDrop ND-1000 Spectrophotometer (NanoDrop 
Technologies). Purified recombinant proteins were resolved in SDS/PAGE stained with 
Coomassie Brilliant Blue G-250 (Biorad).  
Western-blot analysis. One μg of LiRPIBWT, LiRPIBC69A and LmRPIB recombinant 
proteins, 20 μg of total soluble extracts from both promastigote and amastigote forms, or 1 
x 107 parasites were resolved in SDS-PAGE and transferred onto a nitrocellulose 
membrane (TransBlot Turbo, Bio-Rad), which was blocked, probed, washed and developed 
as previously described18. The following primary antibodies were used: rabbit anti-His-tag 
(MicroMol-413, 1:1000), mouse anti-α-tubulin (clone DM1A, Neomarkers, 1:1000), rabbit 
anti-LiRPIB (1:500 or 1:1000), rabbit anti-TbRPIB (1:1000), rabbit anti-LiCS (cysteine 
synthase, 1:2000), rabbit anti-LdHGPRT (hypoxanthine guanine phosphoribosyl 
transferase, 1:2000), rabbit anti-TbEnolase (1:5000) and rabbit anti-TbAldolase (1:5000). 
Horseradish peroxidase-conjugated goat anti-rabbit or goat anti-mouse IgG (Amersham) 
(1:5000 for 1 h, at RT) were used as the secondary antibody. ImageJ software (version 
1.43u) was used for protein semi-quantification. 
Enzymatic Assay. To determine the Km for R5P and for Ru5P, a direct 
spectrophotometric method at 290 nm or a modification of Dische’s Cysteine-Carbazole 
method were used, respectively9. The experimental set up was performed as previously18.   
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Generation of LiRPIB overexpressor (OE) and facilitated null mutants. A 
targeted gene replacement strategy was used for L. infantum RPIB gene knockout. All the 
primers sequences for gene replacement cassettes and mutants’ genotype confirmation are 
specified on table S4. Briefly, RPIB flanking regions were amplified from L. infantum 
genomic DNA and were linked to neomycin phosphotransferase (NEO) or hygromycin 
phosphotransferase (HYG) genes using a fusion PCR approach. The 5’ and 3’ UTR were 
amplified using primers 1 + 2 and 3 + 4, respectively. NEO and HYG were amplified from 
pSP72αNEOα and pGL345HYG templates, using primers 5 + 6 and 7 + 8 respectively, 
which possess around 30 nucleotides of the 5’ UTR in the sense primer and the first 30 
nucleotides of the 3’ UTR in the antisense primer. 5’UTR_NEO_3’UTR and 
5’UTR_HYG_3’UTR constructs were obtained using primers 9 + 10. To obtain an episomal 
copy of RPIB, LiRPIBWT or LiRPIBC69A, genes were excised from the pGEM-T Easy vector 
(using XbaI/NdeI), gel purified and subcloned into pSP72αBLASTα vector. Approximately 
10 µg of either linear fragments obtained by fusion PCR or plasmid were purified, 
concentrated and transfected into 5 x 107 mid-log promastigotes, using an Amaxa 
Nucleofector II device with human T-cell nucleofector kit (Lonza). The day after transfection 
drug selection was carried out at 20 µg/mL of G418 (Invitrogen), 50 µg/mL of hygromycin B 
(InVivoGen) and/or 30 µg/mL blasticidin (InVivoGen). Parasites cloning, except for 
transfections with episomes was performed by diluting the parasite suspension to a 
concentration of 0.5 cells per well in 96-well plates using SDM culture medium. Mutants 
overexpressing LiRPIB (OE) were obtained by transfecting WT parasites with 
pSP72αBLASTα LiRPIBWT. The facilitated null mutants were generated by complementing 
sKO mutants with pSP72αBLASTαLiRPIBWT, followed transfection with 
5’UTR_HYG_3’UTR. 
Generation of TbRPIB mutants. Three different DNA cassettes were generated. 
The DNA fragments consisted ORFs of the resistance genes (hygromycin, bleomycin and 
neomycin), flanked by the 5’ and 3’ UTRs of the TbRPIB gene. For the generation of sKO 
mutants, the plasmid used was the pGL345-HYG plasmid modified with the 5′ (924 bp, 
primers 19 + 20, Table S4) and 3’ (997 bp, primers 21 + 22, Table S4) RPIB flanks obtained 
through PCR from T. brucei genomic DNA template. The primers contained HindIII/SalI and 
SmaI/BgIII restriction sites were used for cloning into the appropriate pre-
digested pGL345HYG. To remove the second allele, pGL345BLEO or pGL345NEO 
plasmids were constructed by replacing the HYG with BLEO or NEO, respectively, in the 
plasmid used to obtain the sKOs, employing SpeI/BamHI restriction enzymes. Thereafter 
the final plasmids were digested with HindIII and BglII to obtain the final DNA fragment for 
transfection. Transfection was performed as described for LiRPIB mutants, using 10 μg of 
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DNA. Selection was undertaken using 7.5 μg/ml, 0.2 μg/ml and 5 μg/ml of hygromycin, 
bleomycin or neomycin, respectively. 
PCR and Southern-blot analysis of RPIB mutants. LiRPIB mutants were 
analysed by PCR (NZYTech or Invitrogen Taq Polymerase) for the presence of the following 
events: LiRPIB and selectable markers, LiRPIB, LiRPIB 5’ integration, NEO 5’ integration, 
HYG 5’ integration and pSP72αBLASTαLiRPIB, using primers pairs 9 + 10, 11 + 12, 1 + 12 
and 9 + 12, 13 + 14, 15 + 16 and 17 + 18, respectively (Table S4). TbRPIB mutants were 
analysed by PCR for the following events: HYG and NEO 5’ integration, using primers pairs 
23 + 24, 25 + 26, respectively (Table S4). For Southern blot (SB) analysis, total genomic 
DNA was extracted. Ten µg of genomic DNA were digested O/N with a 5 fold excess of 
EcoRI and NaeI (LiRPIB mutants) or BspHI (TbRPIB mutants) at 37ºC and samples were 
run O/N in a 0.8% agarose gel. The transfer into a nylan membrane, nucleic acid fixation, 
hybridisation and revelation were performed as previously described58. In the case of 
LiRPIB mutants, the blots were probed sequentially with 3’ UTR, LiRPIB (Fig. 3), NEO and 
HYG, which were PCR amplified, using primers 3 + 4, 11 + 12, 5 + 6 and 7 + 8 (Table S4), 
respectively. In the case of TbRPIB mutants, the blots were probed with 3’ UTR (Fig. 7d), 
amplified using primers 21 + 22 (Table S4). 
Real-Time quantitative PCR (qPCR) analysis of LiRPIB mutants. qPCR analysis 
was used to assess the expression of metacyclogenesis markers in LiRPIB promastigote 
mutants, as well as pSP72αBLASTαLiRPIBWT copy number. Concerning metacyclogenesis 
markers expression (MET1, Histone H4, SHERP (small hydrophilic endoplasmic reticulum 
associated protein)), total RNA extraction, reverse transcription and qPCR were performed 
as previously24.  To assess pSP72αBLASTαLiRPIBWT copy number, 10 ng of genomic DNA, 
primers 17 + 18 (Table S4), and purified plasmid (as positive control) were used.  In both 
cases, rRNA45 was used as reference gene and qPCR reactions were run in duplicate for 
each sample on a Bio-Rad My Cycler iQ5(BioRad).  
In vitro growth of RPIB mutants. Growth curves of LiRPIB mutants and WT were 
seeded at 1 x 106 parasites/ml. Cultures were launched and monitored microscopically 
every 24h for 7 days or maintained in log phase by subculturing every 2 days and cumulative 
growth assessed for 5 consecutive passages. Before launching growth curves, the 
parasites were maintained in log phase for 2-3 passages in the absence of selection drugs. 
For TbRPIB mutants and WT in vitro growth curves, cell lines were seeded at 1 x 105 
parasites/ml of complete HMI-9 medium, after 48h in the absence of selective drugs. Every 
24h, until day 10, cell growth was monitored microscopically. 
In vitro bone marrow derived macrophages (BMMø) infection by LiRPIB 
mutants. Cell suspension of bone marrow was obtained by flushing the femurs of 
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susceptible BALB/c mice and then cultured in 96-well plates (1 x 105 cells per well) or in 24-
well plates containing cover glasses (3.5 x 105 cells per well) in LCCM supplemented 
DMEM, as previously24. For FACS analysis, CFSE labelled promastigotes24 were incubated 
with the BMMø at a ratio of 2:1, 5:1 and 10:1 during 4 hours and then cells were washed to 
remove non-internalized parasites. The infection rates were determined at 4, 24 and 48 
hours post-infection using the BD FACS Canto II cytometer and analysed by FlowJo 
software. For microscopic analysis, at day 7 of culture, promastigotes were incubated with 
the BMMø at a 10:1 ratio and again after 4 hours, infection was stopped.  Infection ratios 
and number of parasites per cell were assessed at 4, 24 and 72 hours post infection. In 
those timepoints, cells were fixed with 3% p-formaldehyde (PFA), Giemsa stained and cover 
glasses were mounted on slides, using Vectashield (Vector Labs).  Microscopic analysis 
was performed using a Nikon eclipse 80i (Nikon). 
In vivo infectivity of RPIB mutants. To characterize LiRPIB mutants, five to six 
weeks old female BALB/c mice were obtained from Charles River. For mouse infections, 
promastigotes from 4 days old stationary cultures were collected, washed, resuspended in 
PBS to a final amount of 1 x 108 parasites/animal, and injected intraperitoneally. Mice were 
sacrificed at 2 or 8 weeks post-infection. The parasite burden in the spleen and liver was 
determined by limiting dilution as previously described59. To characterize TbRPIB mutants, 
after 48h in the absence of selective drugs, 1 x 104 WT and sKO parasites were inoculated 
intraperitoneally in 6–8 weeks old BALB/c mice. Parasitemia was measured at fourth, fifth 
and sixth day post-infection through tail blood extraction. 
Digitonin Fractionation. This procedure has been performed as previously 
described58. All fractions were analysed by WB.  
Immunofluorescence. L. infantum mid-log promastigotes were fixed, 
permeabilised and stained as previously described60. Parasites were spread on 8 well-IF 
slides (Polysciences) or 18 well-IF slides (Ibidi) for wide field and confocal microscopy, 
respectively. The following primary antibodies were used: rabbit anti-LiRPIB (1:500), sheep 
anti-LiTDR1 (1:500) and rabbit anti-LiHGPRT (1:500). The following secondary antibodies 
were used: goat anti-rabbit Alexa Fluor 488 or Alexa Fluor 568 and donkey anti-sheep Alexa 
Fluor 488 (Molecular probes, Life Technologies). In the case of RPIB and HGPRT 
colocalisation studies, parasites were sequentially incubated with rabbit anti-LiRPIB O/N at 
4ºC, unconjugated sheep anti-rabbit for 60 min at RT, donkey anti-sheep Alexa Fluor 488 
for 60 min at RT, rabbit anti-LiHGPRT for 2 hours at RT and goat anti-rabbit Alexa Fluor 
568 for 60 min at RT (sequential staining’s lacking only anti-LiRPIB or anti-LiHGPRT as well 
as single stainings of each one of these proteins were performed simultaneously as 
controls). Images were captured using wide field fluorescence microscope AxioImager Z1 
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(Carl Zeiss) and confocal Leica TCS SP5II microscope (Leica) for antibody validation and 
colocalisation studies, respectively. Images were analysed using ImageJ (version 1.47) or 
Fiji (version 1.45) software’s.  
Statistical Analysis. For statistical analysis, two-tailed unpaired t test was used. 
Statistical analysis was performed using GraphPad Prism Software (version 5.0) and 
significance was found when p ˂ 0.05. 
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Figure S1. Rabbit polyclonal anti-LiRPIB antibodies validation. (a) Western-blot 
analysis of WT, LiRPIB sKO 15 and OE promastigotes extracts using rabbit polyclonal anti-
LiRPIB (1:500). (b) Representative immunofluorescence images of different genotypes 
(WT, sKO 15 and OE) of mid-log L. infantum promastigotes, using rabbit polyclonal anti-
LiRPIB antibody (1:500). Upper and lower panels present brightfield and LiRPIB (red) + 
DAPI (blue) stained images, respectively. Images were acquired with a 63x objective, using 
a Zeiss AxioImager Z1. The scale bar corresponds to 5 µm. (c) Fluorescence intensity 
quantification in WT, sKO 15 and OE parasites when stained with anti-LiRPIB antibody 
(1:500). The values are expressed in CTCF (corrected total cell fluorescence), and 
background (BG) values are displayed as well. The quantification was performed on images 
acquired with 63x objective, using a Zeiss AxioImager Z1 and the same exposure time for 
all genotypes (LiRPIB 300 ms; DAPI 100 ms). Twenty different fields for each genotype 
were analysed in duplicate, and the fluorescence of an average of 50-100 parasites was 
quantified using ImageJ (v 1.47) software. Two-tailed unpaired t test was performed: 
statistical significance p ˂ 0.05.  The results (a-c) are representative of 2 independent 
experiments. 
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Figure S2. RPIB localization in L. infantum. (a-c) Immunofluorescence analysis showing 
RPIB (red in b; green in c) localization in L. infantum promastigotes. Nucleus and kinetoplast 
DNA, cytosol and glycosomes were stained with DAPI (blue), anti-LiTDR1 (thiol-dependent 
reductase 1, green) and anti-LiHGPRT (hypoxanthine guanine phosphoribosyltransferase, 
red), respectively. On panels b and c, yellow arrows in the zoomed areas point to 
colocalisation sites, and the red arrows point to sites of exclusive LiRPIB (b) or LiHGPRT 
(c) staining. Images were acquired with a 63x objective, using a LEICA SP5II confocal 
microscope. The scale bar corresponds to 5 µm. Data displayed on a-c are representative 
of 3 independent experiments. 
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Table S1. Kinetic parameters of LiRPIB and LmRPIB for R5P and Ru5P in the direct and 
inverse reaction, respectively 
 
* Ksp Specificity Constant (kcat/ Km) 
The values are means ± standard deviations obtained from 3 independent experiments. 
 
Table S2. Summary of the different cell lines obtained in several attempts to generate 
LiRPIB null mutants 
Clone Construct dKO clones 
Aneuploid 
clones 
sKOHYG clone 4 NEO 0/12 6/12 
sKOHYG clone 4 NEO 0/10 3/10 
sKONEO clone 13 HYG 0/7 3/7 
sKONEO clone 15 HYG 0/7 3/7 
sKONEO clone 15 + 
pSP72αBLASTαLiRPIBWT 
 
HYG 11/12 1/12 
sKONEO clone 15 + 
pSP72αBLASTαLiRPIBC69A 
HYG 0/11 7/11 
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Table S3. Oligonucleotides sequences used to obtain LiRPIBWT (P1 + P2), LmRPIB (P3 + 
P4), LiRPIBC69A (P5 + P6) recombinant proteins, pSPαBLASTαLiRPIB (P7 + P8) and 
pSPαBLASTαLiRPIBC69A (P7 + P6) 
 
 
 
 
 
 
 
 
Table S4. Oligonucleotides sequences used to obtain gene replacement cassettes (L. 
infantum P1-P10; T. brucei P19-P22) and to confirm RPIB mutants’ genotype (L. infantum 
P1, P9-18; T. brucei P23-P26) 
 
 
 
Primer                               Sequence  
1                      5’ CAATTTCCATATGCCGAAGCGTGTTGC 3’ 
2                       5’ CCCAAGCGAATTCTCTACTTTCCTTCC 3’ 
3                     5’ CAATTTCCATATGTCGAAGCGTGTTGCTC 3’ 
4                     5’ CGGATGCGAATTCTCACTTTCCTTCTTGG 3’ 
5                      5' GGCTAGCATGCCGAAGCGTGTTGCTCTG 3' 
6                   5' TGCCGATACCGGTGCCTGCGACAAGGATAC 3' 
7                      5' GTCTAGAATGCCGAAGCGTGTTGCTCTG 3' 
8                5' GCGCATATGTCACTTTCCTTCCTCCTTAAGACC 3' 
Primer Sequence  
 
1 
 
5' TTCGAGAGCGGGATGGAGAG 3' 
2 5' AGGGTGGATGGCTGGATGAG 3' 
3 5' CACAAGGCGATGGGTACAAG 3' 
4 5' GCACACGAGGTGCAGCAATG 3' 
5 5' AGCGCTCTCTCTCCATCCCGCTCTCGAAATGATTGAACAAGATGGATTGC 3' 
6 5' GATGAGGCCAACGGCCTTGTACCCATCGCCTTGTGTCAGAAGAACTCGTC 3' 
7 5' CACCACCAAGCGCTCTCTCTCCATCCCGCTCTCGAAATGAAAAAGCCTGAACTCAC 3' 
8 5’ TATGATGAGGCCAACGGCCTTGTACCCATCGCCTTGTGCTATTCCTTTGCCCTCGGAC 3’ 
9 5’ AGGGTGGATGGCTGGATGAG 3’ 
10 5' GCACACGAGGTGCAGCAATG 3' 
11 5' ATGCCGAAGCGTGTTGCTCTG 3' 
12 5' TTAAGACCTCCACAACCGCTGAAG 3' 
13 5' CCTGCTTCGTAGCCTGTGCAAGTC 3' 
14 5' GTGGTCGAATGGGCAGGTAG 3' 
15 5' AAGCGTTTGCGATGCTTCCTTC 3' 
16 5' CGCCATGTAGTGTATTGACC 3' 
17 5' CGCTTTCACTCTTCGAACAAACAC 3' 
18 
19                                         
20 
21 
22 
23 
24 
25 
26 
5' ACTATGCGGCATCAGAGCAG 3' 
5’ CGAAGCTTTAAGCGGTGATTGAGCGT 3’ 
5’ CGGTCGACTGTTGATTGTAAAAGGA 3’ 
5’ CGCCCGGGATATTTGGTAAATGATAATC 3’ 
5’ CGAGATCTGCATACGTTCAGTGGTTGTT 3’ 
5’ AACATGCCCCACCCCTCCCC 3’ 
5’ GCTGCATCAGGTCGGAGACGC 3’ 
5’ AACATGCCCCACCCCTCCCC 3’ 
5’ GTGGTCGAATGGGCAGGTAG 3’ 
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1. Trypanosomatids encode a bacterial type AS-A 
Trypanosomatids, despite eukaryotes, encode for AS-A enzymes of bacterial origin. 
These enzymes are aminoacyl-tRNA synthetase paralogues, displaying an AsnRS catalytic 
core with conserved class II motifs, yet lacking the tRNA binding domain (Gowri et al, 2012). 
In silico analysis comparing LiAS-A, LmAS-A, TbAS-A, TcAS-A with EcAS-A demonstrates 
there is a high conservation of the main structural features, including the active site 
residues. Indeed, the amino acids involved in Asn binding are strictly conserved across 
species, whereas in the case of AMP binding pocket, the majority of residues are conserved 
with a few exceptions. These organisms also encode a hypothetical, yet non-classical, AS-
B: L. infantum [LinJ.29.1590], L. major [LmjF.29.1490], T. brucei [Tb927.3.4060] and T. 
cruzi [Tc00.1047053510001.40] (Aurrecoechea et al, 2010; El-Sayed et al, 2005; Ivens et 
al, 2005). The latter sequences contain a Pfam AS domain (pfam00733) and glutamine 
hydrolysing domains in the C and N-terminus, respectively.  
 
1.1.  AS-A atypical biochemical features 
Our studies have demonstrated that LiAS-A, LmAS-A, TbAS-A and TcAS-A can 
synthesize Asn in an ATP-dependent manner, curiously using either ammonia or glutamine 
as nitrogen donors (Faria et al, 2015b in press; Faria et al, unpublished data; Loureiro et al, 
2013). The same has been observed for LdAS-A (Manhas et al, 2014). LiAS-A Km values 
for aspartate and ATP are close to the ones determined for TbAS-A and TcAS-A (Faria et 
al, 2015b in press; Loureiro et al, 2013). However, for ammonia, the Km value found for 
LiAS-A is 5 fold lower in comparison to TbAS-A, TcAS-A and LdAS-A (Loureiro et al, 2013; 
Manhas et al, 2014). In the case of LdAS-A, the Km values for aspartate were around 10 
fold lower (Manhas et al, 2014) than the ones of LiAS-A. Regarding the high conservation 
of the active sites among AS-A enzymes from Leishmania and trypanosomes, we cannot 
exclude that the observed kinetic differences may be due to differences in the amount of 
protein that is properly folded, especially taking into account they are expressed in a 
heterologous system. Moreover, it is important to emphasize that in the case of LdAS-A, 
the kinetic determinations were performed using a different experimental setup. 
AS-A activity in trypanosomatids more resembles AS-B enzymes in several aspects. 
Indeed, beyond the ability of using both ammonia and glutamine as nitrogen donors their 
optimal pH for enzymatic activity is 7.6 instead of 8 (data not shown). AS-B enzymes 
preferably use glutamine over ammonia, with exception of the human enzyme that presents 
approximately the same affinity for both nitrogen sources (Andrulis et al, 1987; Andrulis et 
al, 1989; Ciustea et al, 2005; Humbert & Simoni, 1980; Merchant et al, 2007; Ramos & 
Wiame, 1980; Scofield et al, 1990). While TbAS-A and TcAS-A use preferably ammonia 
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(Loureiro et al, 2013), LiAS-A and LmAS-A seem to use both practically in the same extent 
(Faria et al, 2015b in press; Faria et al, unpublished data). It is noteworthy that ideally these 
studies would have been performed with proteins purified from parasites extracts and not 
with recombinant enzymes expressed in E.coli.  
When analysing the homology models of LiAS-A, LmAS-A, TbAS-A and TcAS-A 
obtained by superimposition with EcAS-A crystal structure (PDB 12AS (Nakatsu et al, 
1998)), there is a divergent region (a 19 residues insertion) in trypanosomatids. This region 
is strictly conserved between LiAS-A and LmAS-A enzymes but little conservation is found 
when comparing to others trypanosomes enzymes. Aiming at identifying the glutamine 
hydrolysing domain, we have attempted to crystallize LiAS-A, and also co-crystallize it with 
glutamine. However, our endeavours were unsuccessful. In the meantime, TbAS-A was 
crystallized (Manhas et al, 2014), but it only emphasised the high conservation of Asn and 
AMP binding pockets, as the divergent region was not visible in the experimental electron 
density maps and therefore is likely disordered (Manhas et al, 2014). Furthermore, the 
structural or functional role of this insertion remains unclear. 
 
1.2.  Asn homeostasis in trypanosomatids 
Asn metabolism has become very attractive in the last few years on cancer and 
infection fields. In the latter, it has been shown to play an important role on the survival, 
invasion and/or virulence of several pathogens (Baruch et al, 2014; Gesbert et al, 2014; 
Gouzy et al,  2014; Hofreuter et al, 2008; Kullas et al, 2012; Leduc et al, 2010; Nagaraj et 
al, 2015; Scotti et al, 2010; Shibayama et al, 2011). A key player in this metabolism is AS, 
and in trypanosomatids, the presence of a type A with no human’s homologue made it 
appealing enough to investigate as a potential drug target. We have demonstrated that in 
T. brucei, AS-A knockdown renders the bloodstream forms auxotrophic to Asn, with no 
impact on growth or infectivity, except upon Asn deprivation. In vitro and in vivo studies in 
Asn replete and depleting conditions have shown that Asn can be obtained by two main 
sources: AS-A mediated synthesis and extracellular Asn uptake (Loureiro et al, 2013). 
Surprisingly, AS-A was proposed as a promising drug target in Leishmania as it was claimed 
to be essential for L. donovani survival due to the inability of generating null mutants 
(Manhas et al,  2014). This suggested a different regulation in Asn homeostasis in 
trypanosomatids. Such idea is conceivable as these organisms do have different amino 
acid requirements according to the developmental stage, reflecting the environmental 
pressure inflicted by the vector or the mammalian host (Jackson, 2007). Inclusively, 
whereas polyamine transporters are quite conserved, AATs repertoire is very diverse 
across trypanosomatids. Different species and life cycle stages may present AATs that 
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differ in number, affinity, specificity or capacity (Jackson, 2007). For instance, in 
Leishmania, arginine is an essential amino acid that fuels peptide and polyamine synthesis, 
whose homeostasis depends exclusively on external uptake (Darlyuk et al, 2009). However, 
in the case of cysteine, a crucial amino acid for thiol biosynthesis, contrarily to T. brucei, L. 
major fails to uptake it at a rate that ensures the intracellular pool is enough for optimal 
growth. Therefore, Leishmania parasites rely mainly on two pathways that enable cysteine 
de novo synthesis (Williams et al, 2009).  
In order to evaluate AS relevance in Leishmania genus, we have performed gene 
replacement studies in L. infantum, and our efforts to generate LiASA null mutants were 
successful. Thus, the gene is not essential for survival nor was it for growth or infectivity. 
WT promastigotes grew normally in Asn depleted medium without AS-A upregulation, 
suggesting Asn synthesis by basal AS-A suffices the cellular needs, although the mutants 
overexpressing this enzyme had a metabolic advantage in Asn limiting conditions. Our in 
vitro data on growth demonstrated that LiASA deletion rendered parasites auxotrophic to 
Asn, as null mutants relied solely on Asn uptake to grow ((Faria et al, 2015b in press). This 
also indicated that despite it is unlikely that AS-B is functional, even if it is, its activity 
definitely does not compensate ASA ablation. Importantly, Leishmania promastigotes can 
then both synthesise and uptake this amino acid, and the latter fully compensates the first 
(Faria et al, 2015b in press). For instance in Plasmodium, the Asn granted by haemoglobin 
degradation and extracellular sources does not support per se an optimal parasite growth 
(Nagaraj et al, 2015). Actually, upon ASB ablation, a suboptimal blood-stage development 
and an even more dramatic effect on sexual and liver stages are observed. In the latter 
stage, the phenotype is probably due to limiting levels of Asn in the mammalian 
hepatocytes. The higher dependency of Plasmodium on Asn intracellular synthesis may be 
due to the great enrichment of its proteins on this amino acid (Nagaraj et al, 2015).  
In the case of Asn uptake from the extracellular medium, not much information is 
available in trypanosomatids. In T. brucei, a protein presenting putative orthologues in 
Leishmania (Aurrecoechea et al, 2010; El-Sayed et al, 2005; Ivens et al, 2005) was 
characterized as a transporter of five neutral amino acids, including Asn (TbAATP1) 
(Ebikeme, 2007). 
It is interesting that trypanosomatids encode for AS-A and hypothetical AS-B 
enzymes regarding that: 1) our data on Leishmania promastigotes and T. brucei 
bloodstream forms suggest that AS-B may not be functional or at least has a negligible 
contribution for Asn synthesis even in Asn limiting conditions; 2) AS-A contrarily to what has 
been described for all the other bacterial type AS-A enzymes also uses glutamine as a 
nitrogen donor, in a fashion more concomitant with a type B AS. This may represent an 
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evolutionary upgrade, as one enzyme may have become sufficient to satisfy parasite 
demands and the other probably became redundant and eventually not functional. 
Especially in Leishmania enzymes, the fact that both ammonia and glutamine are used in 
the same extent may grant the parasite an opportunity to synthesize Asn using the more 
abundant nitrogen donor, depending on the environment. These parasites do experience 
dramatic environmental changes as they switch from one host to the other, or perhaps even 
by infecting different subsets of MØs, whose phagolysosome composition may be different 
as well. One of the great questions is how this may have occurred: 1) may this be the case 
of any sort of recombination? 2) did the divergent region play a role in this process?  
Considering that AS-A is dispensable in promastigotes, unless upon Asn 
deprivation, did not immediately exclude AS-A as a drug target. Amastigotes thrive in a 
phagolysosome, in which the access to certain amino acids may be limited, as described 
for glutamate or glutamine for instance (Saunders et al, 2014). Nevertheless, when infecting 
BALB/c mice with LiASA null mutants, no differences in the spleen and liver parasite 
burdens were observed in comparison to the WT. This means the null mutants found Asn 
levels that suffice their demands in the phagolysosome. Again we cannot exclude that AS-
B is functional, although it appears unlikely. 
In T. brucei, AS-A knockdown does not impact parasite infectivity as the parasite 
uptakes Asn directly from the bloodstream (Loureiro et al, 2013). In Leishmania, the 
scenario has multiple players, namely the ability of the host cell to uptake Asn from the 
extracellular medium and to synthesize it via AS-B. Moreover, since Leishmania infects 
MØs several phagosomes may be delivered to the phagolysosome, providing some extra 
nutrients, among which amino acids.  
Figure 27 depicts a model of Asn metabolism in L. infantum based on t-RNA 
independent reactions.  
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Figure 27. Asn homeostasis in L. infantum. The left and right panels represent 
promastigote and intracellular amastigote forms, respectively, the latter living inside the 
phagolysosome of MØs. Promastigotes are able to synthesize and uptake Asn in the same 
extent. AS-B is likely not functional in these forms. Intracellular amastigotes uptake Asn 
from the phagolysosome or synthesize it via AS-A. Again, AS-B can also play a role 
although it is unlikely. The host cell, MØs, is also able to uptake Asn and synthesize it via 
AS-B in this case. AAT, amino acid transporter; AS-A, asparagine synthetase A; AS-B, 
asparagine synthetase B. Red question marks indicate whether the transporter or the 
enzyme have not been identified/characterized.  
 
1.3.  The controversy on AS-A essentiality in Leishmania  
The discrepancy on AS-A essentiality in L. donovani and L. infantum is intriguing 
due to the close relation between both species and the 99% identity between the two 
enzymes (Faria et al, 2015b in press; Manhas et al., 2014).  
In the literature, there are several cases in which knocking out a gene can have 
different impact on virulence depending on the species. For instance, when knocking out 
LPG1, an enzyme involved in LPG synthesis, L. major, contrarily to L. mexicana, has its 
virulence dramatically reduced (Turco et al, 2001). However, to our knowledge, there is no 
documented example among cutaneous or among visceral species of a gene that is 
detrimental for survival in one species and dispensable in other closely related. But we did 
find a case of differences at a strain level, as null mutants of L. major DHFR were obtained 
in a lab strain but endeavours for the same accomplishment in virulent strains have lapsed 
(Cruz et al, 1993).  
The most likely explanation comes from the fact that L. infantum AS-A null mutants 
do not growth in the medium M199, where the attempts to generate AS-A null mutants in L. 
donovani were made (Faria et al, 2015b in press; Manhas et al, 2014). Indeed, M199 lacks 
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Asn and the mutants’ growth defect is rescued when this amino acid is provided. These 
results reinforce the importance of the medium composition when attempting gene knockout 
of metabolic enzymes, and supplementation may be detrimental when potentially 
generating auxotrophs (Nare et al, 1997; Wilson et al, 2012). 
Nonetheless, we must discuss that AS-A essentiality in L. donovani was defined 
based on the consecutive failure in the removal of the second gene copy. According to the 
authors, when attempting to remove the second allele, there was aneuploidy generation, as 
resistance cassettes were integrated in the target locus, preserving a copy of the LdASA 
gene (Manhas et al, 2014). Ideally, essentiality should be confirmed by providing an ectopic 
copy of the gene to the sKO mutants and then attempt the second allele removal, which 
must be successful in these conditions, unless a technical limitation is obscuring the results. 
Additionally, if the ectopic copy is provided on a plasmid, the obtained facilitated null 
mutants must retain the vector even in the absence of drug pressure. We were surprised to 
realise that some of our sKO mutants in L. infantum displayed a quite bizarre profile: despite 
NEO cassette integration in the target locus and decreased levels of LiAS-A, assessed by 
PCR and western-blot, respectively, Southern-blot analysis showed several copies of the 
NEO were present (data not shown). Along with chromosome aneuploidy, DNA 
amplification by gene rearrangement, which is a highly dynamic and stochastic process, is 
one of the strategies Leishmania successfully explores in order to respond to environmental 
changes, such as drug pressure (Ubeda et al, 2014). Due to the massive genetic plasticity 
of these organisms, conclusions on essentiality must be taken cautiously, and consecutive 
inability to generate null mutants per se must not suffice.  
 
1.4.  Amino acids sensing in trypanosomatids 
One of the most interesting observations in this study concerns the parasites ability 
to regulate AS-A levels depending on Asn availability. In particular, sKO mutants were able 
to upregulate AS-A presumably to restore Asn intracellular levels required for optimal 
growth. In Asn limiting conditions, these mutants had a growth delay followed by a partial 
or total recovery as AS-A levels increase over time. This indicates that parasites sense Asn 
levels and must have regulatory mechanisms oriented to the control of AS-A expression 
and probably Asn transporter as well.  
In these parasites, much remains to be unravelled concerning the pathways involved 
in amino acid sensing and regulation of their synthesis and uptake (Jackson, 2007). In 
mammalian cells, AS-B is a transcriptional target of GCN2/elF2α/ATF4 axis, in response to 
amino acid starvation. GCN2 phosphorylates elF2 that subsequently leads to a repression 
of general protein synthesis, and the activation of gene-specific translation via ATF4 
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(Chamtranupong et al, 2015; Horiguchi et al, 2012; Ye et al, 2010, depicted on Fig. 25). In 
Saccharomyces cerevisiae, GCN2, which is activated by amino acid, glucose or purine 
deprivation, is the only elF2 kinase, contrasting with mammals that possess some additional 
three, HRI, PKR and PEK/PERK (Chamtranupong et al, 2015; Lahav et al, 2011). T. brucei 
and L. donovani PERK orthologues have been implicated in the response to ER stress and 
their phosphorylation activity leads to a decrease in the overall translation (Gosline et al, 
2011). Moreover in L. donovani, it has a role in the differentiation into amastigote form 
(Chow et al, 2011).  T. brucei PERK orthologue localises to the flagellar pocket, is able to 
phosphorylate yeast and mammalian elF2α, albeit TbelF2α is not a target of GCN2 or PERK 
in vitro (Moraes et al, 2007). At the moment, it is still not clear whether phosphorylation of 
elF2 in trypanosomatids would result in a downstream signalling cascade, as bZIP type 
transcription factors that could act like GCN4 or ATF4, are absent in these organisms 
(Moraes et al, 2007). To the date, it seems this signalling may only lead to a general 
downregulation of translation upon specific stimuli (Moraes et al, 2007). 
As previously addressed, these organisms lack transcriptional regulation of gene 
expression in a great extent, relying mostly on post-transcriptional mechanisms (Clayton, 
2002; Requena, 2011; Alsford et al, 2012). This encompasses modulation of mRNA stability 
(Brittingham et al, 2001; Muller et al, 2010a; Muller et al, 2010b) or protein translation rate 
(Boucher et al, 2002; Zeiner et al, 2003).  
Related or not, in several Western-blots, the appearance of two close bands that 
react with polyclonal anti-LiAS-A antibody were consistently observed (in some cases more 
clearly than others). We questioned the possibility of a post-translational modification. In L. 
donovani, a phosphoproteomic study identified two phosphorylated isoforms, but only in 
amastigotes (Morales et al, 2008). We did check for cleavage sites, and for calpain for 
instance, we have used GPS-CCD (Liu et al, 2011), which predicted 5 possible sites. Three 
of this hypothetic cleavage sites could generate peptides with 39.7, 39.6 and 39.5 kDa 
(versus 39.8 kDa), which could explain the two bands we consistently observe. Inclusively, 
other of those predicted sites could generate a 32.21 kDa peptide, and interestingly, we 
often got a band around that size in our extracts. However, the biological significance 
remains non-identified.  
Taken all together, we believe that the AS-A expression regulation most likely relies 
on a novel mechanism in comparison to higher eukaryotic cells. Unravelling such 
mechanisms may have biological relevance, as it may be per se a source of novel drug 
target candidates.  
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1.5.  Asn unexpected roles challenge preconceived notions 
GCN2/eIF2α/ATF4 pathway has been shown to be activated in primary solid 
tumours, contrasting with GCN2- or ATF4-deficient cells that failed to generate tumours in 
vivo (Horiguchi et al, 2012; Ye et al, 2010). These observations support that the 
maintenance of Asn production is critical for solid tumour progression (Zhang et al, 2014b). 
These results also point AS-B as a potential drug target in solid tumours, but so far its 
inhibition has only been tested in L-asparaginase-refractory cases of acute leukemia 
(Horiguchi et al, 2012; Ye et al, 2010; Zhang et al, 2014b). For a long time, Asn was strictly 
associated to protein synthesis in mammalian cells (Ubuka et al, 1971; Zhang et al, 2014b). 
However, recent studies point to an additional role, surprisingly as a signalling molecule. 
Therefore, Asn has joined the growing list of metabolites that cells utilize to coordinate cell 
responses with metabolic reserves, ultimately regulating cell fate.  
It appears that this amino acid is a critical suppressor of apoptosis in many human 
tumours (Zhang et al, 2014b). Proliferating cells utilize glutamine to maintain anaplerosis of 
the TCA cycle, the production of nucleotides and non-essential amino acids (Wise & 
Thompson, 2010). Inclusively, many cancer cells are dependent on glutamine for cell 
survival and growth (Wise et al, 2008). Actually, glutamine deprivation in cancer cells lead 
to cell cycle arrest, a general reduction in the protein translation rate and translation of stress 
response RNAs that ultimately result in apoptosis (Zhang et al, 2014b). Supplementation 
with a single amino acid, Asn, was sufficient to suppress apoptosis, however, it failed to 
restore the levels of TCA cycle intermediates or other non-essential amino acids, supporting 
the model that anaplerosis per se is not required for survival (Zhang et al, 2014b). Indeed, 
the cells experience long term survival despite cell cycle arrest. Moreover, even in glutamine 
replete conditions, AS-B inhibition or Asn depletion alone leads to apoptosis even if 
glutamine and other non-essential amino acids supplies are abundant (Zhang et al, 2014b). 
Altogether, these results suggest that Asn not only suppresses apoptosis as it promotes 
cellular adaptions to the depletion of glutamine and other non-essential amino acids. 
Therefore, in cancer the challenging notion that Asn is a signalling molecule has 
emerged and repeatedly gains ground. However, to our knowledge, nothing similar has 
been addressed in pathogens. But we did make an interesting observation in our studies 
regarding Asn availability. Indeed, LiASA null mutants do not grow in L-asparaginase 
treated cRPMI, however, they did not die either, at least for a month. By that time, Asn 
supplementation was provided and parasites immediately started multiplying again. Of 
course we cannot claim this to be a specific effect, as we did not perform any control with 
another non-essential amino acid. A hibernatory state has been described in P. falciparum 
for instance regarding isoleucine (Babbitta et al, 2012). Plasmodium is auxotrophic to 
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isoleucine and its extracellular depletion makes the parasite slow down its metabolism and 
progress through life cycle at a reduced rate. These parasites lack canonical eukaryotic 
nutrient stress response pathways and manage to circumvent isoleucine restriction by 
hibernating and waiting for a potential nutrient repletion. Actually in the case of Plasmodium, 
proteolysis played an important role for the maintenance of parasite viability during such 
state, and autophagy may also contribute (Babbitta et al, 2012). Whether this takes place 
in Leishmania, again we have not explored, but we did observe morphological changes in 
LiASA null promastigotes, especially concerning size, as they became much smaller and 
could be indeed “recycling” intracellular material during this possibly dormant state. 
 
1.6.  AS-A is not a suitable drug target  
The results on BALB/c mice infection with ASA null or RNAi mutants in L. infantum 
and T. brucei, respectively, indicate that AS-A is not a suitable drug target in 
trypanosomatids, as the outcome of the infection is comparable to the WT parasites.  
In vivo treatment with L-asparaginase, which induces a decrease in Asn 
bloodstream levels, has been successfully used for years in the treatment of acute 
lymphoblastic leukemia (ALL) (Avramis, 2012). Recently it was proposed as a promising 
strategy to treat bacteremia caused by GAS and eventually other extracellular bacteria 
(Baruch et al, 2014). 
The simultaneous TbAS-A knockdown and L- asparaginase treatment prolonged 
BALB/c mice survival (Loureiro et al, 2013). This suggested that simultaneous inhibition of 
the parasite AS-A and L-asparaginase treatment could be a possible therapeutic strategy 
(Loureiro et al, 2013). In Plasmodium, a similar proposal has been made (Nagaraj et al, 
2015). In the case of Leishmania infection, in vitro preliminary data in Asn depleting 
conditions suggest that intracellular levels of Asn could be maintained by Asn de novo 
synthesis by the host MØs (data not shown). Also in vivo, the MØs phagocytic capacity may 
continuously provide nutritional supplies to the phagolysosome. Therefore, L-asparaginase 
treatment coupled with AS-A inhibition would probably be unsuccessful in an in vivo model 
of VL. Besides, L-asparaginase is very expensive and has several adverse effects (Avramis, 
2012). A more suitable strategy to all three organisms could be simultaneous inhibition of 
AS-A (AS-B in Plasmodium case) and Asn transporter.  
Regardless, a drug combination approach such as this would not be appropriate to 
treat neglected tropical diseases, not only due to the financial implications, but also the 
higher likelihood for drug resistance emergence. Taken all together, we conclude LiAS-A is 
not a suitable drug target against trypanosomatids. 
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2. Trypanosomatids RPIB 
Trypanosomatids, despite being eukaryotes, encode for type B RPI enzymes. 
LiRPIB, LmRPIB, TbRPIB and TcRPIB generate polypeptides containing 172, 172, 155 and 
159 amino acids, respectively. LiRPIB displays a 93% sequence identity with LmRPIB, and 
around 50% to RPIB of trypanosomes. Importantly, human RPIA and RPIB enzymes from 
trypanosomatids are not homologues. The amino acids involved in isomerisation, 
phosphate stabilization and ring opening have been identified in TcRPIB (Stern et al, 2011) 
and are strictly conserved in LiRPIB, LmRPIB and TbRPIB. 
 
2.1.  RPIB has classical isomerase activity 
Recombinant enzymes from L. donovani (Kaur et al, 2012) and T. cruzi (Stern et al, 
2007) have been formally demonstrated to have in vitro isomerase activity by catalyzing the 
interconversion of R5P and Ru5P. We have demonstrated the same applies to L. infantum, 
L. major and T. brucei (Faria et al, 2015a submitted; Loureiro et al, 2015) homologues. The 
Km values for both R5P and Ru5P were close between Leishmania and trypanosomes, 
however, Kcat values are considerably higher for Leishmania, in both direct and inverse 
reactions (Faria et al, 2015a submitted; Kaur et al., 201 Kaur et al, 2012; Loureiro et al, 
2015; Stern et al, 2007). A decrease in Km and an increase in Kcat were consistently 
observed for Ru5P in comparison to R5P, suggesting that the conversion of Ru5P into R5P 
is favored, which might be explained by the important role of R5P as a building block for 
nucleic acid synthesis.  
 
2.2.  RPIB has a dual localisation 
Trypanosomatids have several unique organelles in order to respond to their specific 
lifestyle needs. Among those are glycosomes, peroxisome-related organelles that comprise 
enzymes of important metabolic pathways such as glycolysis, PPP, β-oxidation, 
gluconeogenesis, purine salvage and biosynthesis of pyrimidines, both lipids and squalenes 
(Michels et al, 2006). This compartmentation of metabolic pathways can prevent the 
accumulation of toxic intermediates (Haanstra et al, 2008) or enable a fast metabolic 
adaptation to environmental changes (Michels et al, 2006). LmRPIB possesses a PTS-2 
signal sequence (–RVALGCDHA–, Opperdoes et al, 2006), which is conserved in L. 
infantum and L. donovani. However, recent proteomic analysis of L. donovani glycosomes 
failed to detect RPIB in these organelles (Jamdhade et al, 2015). The same analysis 
detected HGPRT (PTS-1), aldolase (PTS-2), as well as some enzymes of PPP that are 
upstream RPIB, namely putative G6PD (PTS-1), putative 6PGDH (non-identified), or 
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enzymes downstream RPIB, such as TKL (PTS-1), putative RPE (PTS-1) and putative TAL 
(non-identified signal peptide), or other related proteins like putative ribokinase (PTS-2 
signal peptide). Our localisation studies in L. infantum promastigotes suggest a dual 
localisation with a higher content in the cytosol, similarly to T. brucei bloodstream forms 
(Faria et al, 2015a submitted; Loureiro et al, 2015). Other enzymes of the same pathway 
have been described to display dual localisation in Leishmania (Duffieux et al, 2000; Heise 
& Opperdoes, 1999; Opperdoes & Szikora, 2006), inclusively, the enzyme immediately 
upstream, 6PGDH (Heise & Opperdoes, 1999), and the one immediately downstream, TKL 
(Maugeri et al, 2004; Veitch et al, 2004) that localise predominantly to cytosol but also to 
glycosomes.  
We have not quantified the amount of RPBI that is in the cytosol or the glycosomes, 
as well as if the distribution changes throughout the parasite life cycle. 
Targeting studies with reporter proteins have demonstrated that changes in the 
PTS-1, as well as modifications in the vicinity, can cause dual localization, probably due to 
a reduced affinity for the PTS-1 receptor (Lametschwandtner et al, 1998; Sommer et al, 
1992). Only recently, the crystal structure of PTS-2 bound to its receptor has been solved, 
providing a structural framework for studying the import of PTS-2 cargo into peroxisomes 
and glycosomes (Pan et al, 2013). However, the biological relevance of this dual localization 
to the parasites remains unanswered. 
 
2.3. RPIB is essential for L. infantum survival 
To assess the importance of RPIB for L. infantum survival and infectivity, we tried to 
generate null mutants. Attempts to generate dKO lines from reliable sKO mutants have 
consecutively failed, suggesting gene essentiality for parasite survival. That was also 
supported by constant aneuploidy generation in the resultant mutants. Although, whether 
there was a whole genome amplification (Cruz et al, 1993), a chromosomal amplification 
(Cruz et al, 1993) or intrachromossomal tandem duplication (Mukherjee et al, 2011) remains 
to be addressed. We have used a classical approach to demonstrate gene essentiality 
(Pedrosa & Cruz, 2002), as facilitated null mutants were successfully generated. Moreover, 
the plasmid was not lost even in long-term absence of drug pressure. L. infantum 
promastigotes have preserved the plasmid in the absence of blasticidin over more than one 
year now as control lines have lost it long before. Facilitated null mutants recovered from 
chronically infected mice also preserved the vector carrying RPIB in opposition to the 
overexpressing line for instance, suggesting that the gene is detrimental for amastigotes as 
well.  
Chapter IV – Discussion and conclusions 
 
244 
 
In Leishmania, the absence of conditional knockout systems, previously addressed 
in the first chapter of this dissertation, render gene replacement studies dependent on very 
limiting approaches. It is debatable in the field whether the above described approach gives 
the ultimate proof of essentiality, as some defend this can merely mean that the ectopic 
gene provides an advantage for in vitro or in vivo growth (Dacher et al, 2014). It would be 
interesting to use pXNG vector in this context to address essentiality (Dacher et al, 2014; 
Murta et al, 2009). Moreover, with the recent advances in inducible expression systems and 
CRISPR/Cas9 technology, a new era may begin in Leishmania genetic manipulation 
(Kraeva et al, 2014; Sollelis et al, 2015; Zhang et al, 2015). 
 
2.4.  RPIB partial ablation has impact on L. infantum infections 
Often, gene essentiality in Leishmania limits functional studies, as only facilitated 
null mutants can be achieved, thus, total absence of the protein of interest is never 
achieved. Sometimes the remaining protein levels in the sKO mutants are enough to grant 
parasites a normal development and no defects can be observed. There are some 
approaches that try to overcome this limitation like plasmid shuffle analysis (Dacher et al, 
2014). Nevertheless, RPIB sKO mutants have some impairment in vitro and in vivo, 
therefore providing hints on the infection steps the protein may be important for.  
In vitro, sKO promastigotes grow, undergo metacyclogenesis and infect host 
macrophages as the WT. The percentage of MØs infected by the mutants does not change 
over time. Moreover, the average of amastigotes per cell remained alike when comparing 
the sKO with the WT at 24 hours post infection, suggesting that differentiation into 
amastigotes occurs normally. In contrast, sKO mutants presented a lower average of 
amastigotes per cell at 72 hours post infection. This phenotype is reversed in complemented 
sKO mutants, which overexpresses RPIB. This suggests that RPIB is important for 
amastigote replication.  
In vivo, BALB/c infected with the sKO mutants presented a lower parasite burden in 
the spleen and the liver at two weeks post infection, but statistical significance was only 
found for the latter. This effect was rescued in the complemented sKO mutants (Faria et al, 
2015a submitted). In chronic infections (2 months post infection), no parasite clearance was 
observed in the mice infected with the sKO mutants. 
Similarly, the ablation of other enzymes involved in energy metabolism such as 
glucose transporter in L. mexicana and the gluconeogenic enzyme FBPase in L. major, 
have led to defects exclusively in amastigote stage. In both cases, promastigotes invade 
and differentiate normally, but the resulting amastigotes fail to replicate, persisting in 
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infected mice, however failing to generate normal lesions (Naderer et al, 2006; Rodríguez-
Contreras et al, 2006).  
Our results point to a role of RPIB particularly in amastigotes development. This may 
help to explain why the enzyme is more expressed in this stage, which is in agreement with 
a whole genome transcriptomic analysis (Rochette et al, 2009). We can hypothesize the 
remaining protein (~50%) suffices the parasite needs for a minimal intracellular replication 
and therefore the overall effect is not dramatic. Inclusively in vivo, there is no parasite 
clearance even in later stages of infection. Actually even earlier, during infection and 
differentiation, we cannot exclude the protein may play a role, as only 50% of it may be 
enough to allow these steps to occur without disturbance. Moreover, the inability to 
inactivate RPIB in promastigotes indicates the gene is essential for survival of the insect 
infective form.  
Again, the availability of conditional knockout/knockdown systems in Leishmania 
would facilitate functional studies on essential genes. Another alternative would be 
attempting plasmid shuffle (Dacher et al, 2014). Switching the episome carrying RPIB for 
one carrying a mutated version devoid of isomerase activity would be lethal, as we have 
proven this function to be essential for parasite survival.  
 
2.5.  RPIB isomerase function is indispensable for L. infantum 
Although we cannot exclude RPIB may have an additional function, we have 
demonstrated that the isomerase function is essential for L. infantum survival.  
One of the things that would be worthy of exploring concerns the metabolic 
implications of RPIB inactivation/inhibition. At this point, we can only speculate why an 
enzyme involved in the non-oxidative branch of PPP, in which interconversion reactions 
take place, is essential. As previously mentioned, considering the evidence for a role of 
RPIB in amastigotes development, we will focus on the metabolic particularities of these 
forms.  
Leishmania amastigotes have nutritional requirements that are more complex than 
those of the majority of prokaryotes and fungal pathogens. Curiously, even though, 
Leishmania is one of the very few pathogens that infect MØs and does not escape or 
subvert the endocytic pathway, oddly dwelling in a mature phagolysosome (McConville et 
al, 2007). This compartment may appear very hostile. However, it may be a permissive 
niche regarding nutrient availability. But to benefit from this large nutrient supply, pathogens 
must establish successful strategies to counteract the host cell microbicidal mechanisms, 
and Leishmania has efficiently mastered it (McConville et al, 2015).  
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The phagolysosome compartment appears to be extremely dynamic fusing with 
phagocytic, endocytic, autophagic or endoplasmic reticulum vesicles that deliver a broad 
range of macromolecules that are hydrolysed into free sugars, lipids and amino acids. 
Amastigotes can uptake the nutrients or even directly internalize those host 
macromolecules and degrade them on their own (McConville et al, 2015; Fig. 28).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Nutrient availability within the phagolysosome of MØs. The phagolysosome 
contains several carbon sources, such as amino acids, sugars or lipids that are delivered 
via endocytic, autophagic or endoplasmic reticulum vesicles or lysosomal membrane 
transporters. Arg, arginine; EE, early endosome; Glc, glucose; Glc6P, glucose 6-phosphate; 
GlcA, glucuronic acid; GlcN, glucosamine; His, histidine; Ile, isoleucine; LE, late endosome; 
Leu, leucine; Lys, lysine; Man, mannose; Phe, phenylalanine; Rib, ribose; TAG, 
triacylglycerol; Trp, tryptophan; Tyr, tyrosine; Val, valine; Xyl, xylose. Adapted from 
McConville et al, 2015.  
 
As promastigotes differentiate into amastigotes, there is a profound metabolic 
rearrangement, and the latter forms enter a stringent energy-sparing metabolic state 
(Saunders et al, 2014). Consequently, a decrease in glucose uptake accompanied by an 
increase in fatty acid utilization is observed. Carbon is redirected to intracellular reserves 
and processes like protein and lipid biosynthesis are minimized as they occur at a great 
energy expense. Despite the decrease in sugars uptake, the parasites are still dependent 
on carbohydrates, particularly on mitochondrial metabolism to produce glutamate and 
glutamine, which parasites salvage poorly from the phagolysosome (Saunders et al, 2014). 
This rearrangement is thought to make the parasites energetically more efficient and may 
underlie their resistance to stressful conditions, like pH or temperature and tolerance to 
nutrient limitation or excess (McConville et al, 2015; Saunders et al, 2014).  
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A very dramatic modification in amastigotes concerns the global downregulation of 
nutrient transporters as the stringent metabolic response is activated (Vince et al, 2011). 
Whereas promastigotes can exploit high concentrations of glucose and avoid excessive flux 
into the TCA cycle by secreting partially oxidized metabolites, this would be deleterious for 
intracellular parasites and could also affect the host cell physiology (McConville et al, 2015). 
Therefore in amastigotes, decreasing the nutrient uptake can minimize the reductive stress 
as well as prevent limiting (micro)nutrient exhaustion within the phagolysosome 
compartment (McConville et al, 2015; Saunders et al, 2014; Vince et al, 2011).  
Besides its importance for nucleic acid synthesis, ribose can also be an important 
energy source for amastigotes (Burchmore & Barrett, 2001) as Leishmania can import 
(Maugeri et al, 2003) and metabolize it (Berens et al, 1980). A ribose transport system has 
been identified in promastigotes (Maugeri et al, 2003; Pastakia & Dwyer, 1987), and a 
glucose-transporter mutant also has a defective ribose import (Naula et al, 2010). The 
overall decrease in nutrient uptake in amastigotes as they enter the described metabolic 
stringency may render the parasites more dependent on RPIB for R5P synthesis. In this 
sense, it is important to look at alternative sources for R5P production. One of them is 
through the action of ribokinase (Feng et al, 2011; Jamdhade et al, 2015; Maugeri et al, 
2003; Ogbunude et al, 2007) that directly phosphorylates ribose. However, it may not 
compensate RPIB activity, as it depends on the available ribose that is uptaken or that 
originates from intracellular catabolism, which again may be limiting in amastigotes. 
Ribokinase was reported to be essential in T. brucei, although trace amounts of the protein 
allow the fulfillment of its metabolic role such R5P production and phosphate homeostasis 
in the glycosomes (Kerkhoven et al, 2013). In Leishmania, its essentiality for parasite 
survival and contribution to amastigotes metabolism has not been addressed; only its 
upregulation upon glucose transport ablation has been reported in promastigotes (Feng et 
al, 2011).  
Organisms like yeast have an alternative NADP-independent pathway for R5P 
synthesis. This so-called riboneogenesis pathway transforms glycolytic intermediates into 
sedoheptulose-1, 7-biphosphate, by a combined action of TKL and aldolase. 
Sedoheptulose-1, 7-biphosphate, through the action of sedoheptulose-1, 7-biphosphatase, 
is converted into S7P, which can be a substrate of TKL leading ultimately to R5P generation 
(Clasquin et al, 2011). 
Trypanosomes encode a putative sedoheptulose-1, 7-biphosphatase, although 
riboneogenesis has not been formally shown to operate in these organisms (Creek et al, 
2015; Opperdoes & Coombs, 2007). Leishmania in opposition to trypanosomes lacks this 
sequence: could this render it more dependent on RPIB function then?  
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Another possibility is that the absence/inhibition of RPIB may lead to the 
accumulation of Ru5P, which may modulate by negative feedback the activity of the 
upstream PPP enzymes. Two of those produce NADPH, and a decrease in their activity 
and consequently of NADPH production may render the parasites more susceptible to ROS. 
This sort of regulation is absent in several key enzymes of central carbon metabolism in 
trypanosomatids (Blangy et al, 1968; Newsholme et al, 1967).  
Moreover, a study has demonstrated that human RPIA modulates 
hepatocarcinogenesis (Ciou et al, 2014), and its knockdown leads to Ru5P accumulation, 
which is further converted into X5P by RPE. It has been reported that X5P can activate 
PP2A (Kabashima et al, 2003), which negatively regulates ERK signalling for cell 
proliferation. Whether this sort of regulation takes place in Leishmania is unknown. 
However, Leishmania genome encodes for a RPE (Ivens et al, 2005; Jamdhade et al, 2015; 
Maugeri et al, 2003), PP2A (Brenchley et al, 2007) and MAP kinases (Parsons et al, 2005).  
Figure 29 illustrates a model concerning RPIB critical role for Leishmania 
amastigotes survival and replication.   
 
Figure 29. RPIB isomerase activity is detrimental for Leishmania parasites. The 
dashed rectangles represent steps that may be critical for the parasites in the absence of 
RPIB. Particularly in amastigotes there is a general decrease in nutrient uptake, thus a lower 
ribose import may render the parasites more dependent on RPIB function for R5P synthesis 
(dashed rectangle and arrows in blue). In Leishmania, the riboneogenesis pathway is 
absent, rendering the parasites more dependent on RPIB (dashed rectangle in purple). The 
accumulation of Ru5P may decrease the activity of the enzymes of the oxidative branch by 
negative feedback, leading to reduced levels of NADPH, ultimately rendering the parasites 
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more susceptible to ROS (dashed rectangle and arrows in black). The accumulation of 
Ru5P may also lead to increased levels of X5P, which may block cell proliferation by 
interfering with MAPK signaling. This has only been described in mammalian cells so far 
(dashed rectangle and arrows in orange). The red squares represent substrates and 
products that are shared with other pathways. The enzymes of the oxidative and non-
oxidative branch are depicted in dark and light green, respectively: G6PDH, glucose-6-
phosphate dehydrogenase; 6PGL, 6-phosphogluconolactonase; G6PDH, 6-
phosphogluconate dehydrogenase; RPIB, ribose-5-phosphate isomerase B; RPE, ribose-
5-phosphate epimerase; TKT, transketolase; TAL; transaldolase. Enzymes from glycolysis 
(AL, aldolase) and riboneogenesis (SBP, sedoheptulose biphosphatase) are represented 
in red and violet, respectively. Glycolysis, oxidative PPP, non-oxidative PPP and 
riboneogenesis metabolic flow are depicted with red, dark green, light green and violet lines. 
6PG, 6-phosphogluconate; 6PGL, 6-phsophogluconalactone; DHAP, dihydroxyacetone 
phosphate; E4P, erythrose-4-phosphate; F6P, fructose-6-phosphate; G3P, glyceraldehyde-
3-phosphate; G6P, glucose-6-phosphate; R5P, ribose-5-phosphate; Ru5P, ribulose-5-
phosphate; S7P, sedoheptulose-7-phosphate; S1,7BP, sdoheptulose-1, 7-biphosphate; 
X5P, xylulose-5-phosphate. Modified from Comini et al, 2013.  
 
2.6.  RPIB essentiality appears to be conserved in trypanosomatids 
RPIB knockdown in T. brucei bloodstream forms dramatically reduces their 
infectivity, resulting in the extension of mice survival. This phenotype is not due to any off-
target effect as it was reversed by functional complementation with TcRPIB whose mRNA 
sequence is sufficiently different to avoid RNAi (Loureiro et al, 2015).  Moreover, three 
independent attempts to generate dKO mutants have failed, suggesting that RPIB is 
essential for parasite survival (Faria et al, 2015a submitted), although only a TbRPIB 
conditional knockout would be the ultimate proof. Using this system, parasites are 
engineered to express a regulable allele of the gene, which ceases to be expressed upon 
tetracycline removal, and a lethal phenotype should follow if the gene is indeed essential 
(Wyllie et al, 2009). The sKO mutants alone did not have any in vitro growth impairment but 
did display an infectivity defect in vivo. The latter was not as dramatic as the one observed 
in RNAi studies, probably because the protein knockdown is 50 and 90%, respectively 
(Faria et al, 2015a submitted; Loureiro et al, 2015).  
These results point to a conservation of RPIB essentiality in trypanosomatids, 
reinforcing its potential as a drug target in these organisms.  
 
2.7.  Future perspectives on RPIB as a drug target 
Target-based approach has not been as successful as initially expected over the 
years for several reasons previously listed in the second chapter of this dissertation. Those 
reasons concern normally poor membrane permeability or metabolic inactivation of the 
enzymatic inhibitors when tested against the whole parasites. Of course, in our view other 
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reasons may underlie such disappointing results: 1) the enzyme may be abundantly 
expressed and/or present a fast turnover; 2) the compound can have higher affinity for other 
targets that are dispensable for the parasite; 3) the Leishmania ability for DNA amplification 
may allow a higher expression of the molecular target; 4) protein moonlighting, in which the 
atypical function is the one detrimental for parasite survival.  
In the case of the mammalian stage of Leishmania, a drug has to cross the host cell, 
the phagolysosome and the parasite membranes, and if the enzyme is inside an organelle, 
another membrane has to be crossed. In the case of RPIB, it displays a dual localization, 
as it localises mainly to the cytosol, but also in part to the glycosomes. We have not 
quantified the exact amount in each compartment, though, or whether the distribution 
changes during the parasite development. Another question is whether the localization in 
the glycosomes is essential for the parasite, as its activity inside the organelle may be 
harder to target. We could do a similar experiment to the one we have done to assess 
whether RPIB essentiality was dependent on the isomerase function, but instead of the 
mutated form devoid of isomerase function, we could use a truncated version lacking the 
PTS-2 signal peptide.  
Another important issue to be addressed shortly is the enzyme druggability. The Km 
values for both R5P and Ru5P are quite high and little physiological. This can be related to 
RPIB improper folding in the bacterial expression vector, the presence of the protein tag or 
even the sensitivity of the methods used for the activity determinations. We are currently 
trying to address the last two by cleaving the tag in the recombinant proteins, as well as 
trying to set up another assay, if possible, robust enough for a potential HTS scale up.  
Moreover, an analogue of the isomerization intermediate, 4-PEH, has been proven 
to inhibit TbRPIB and TcRPIB (Loureiro et al, 2015; Stern et al, 2007). However, it also 
inhibits RPIA (Roos et al, 2005) and its anti-parasitic activity remains to be demonstrated. 
4-PEH and several derivatives are extremely hydrophilic, but perhaps prodrugs can be 
developed to overcome this limitation as it has been done for Tb6PGDH (Ruda et al, 2010). 
The human RPIA crystal is not available yet, but TcRPIB (Stern et al, 2011) has been 
crystallized and so has TbRPIB and LiRPIB (unpublished data), which can be useful for 
rational drug design.  
In summary, RPIB lacks a human homologue, is essential for survival and infectivity 
in L. infantum and likely in T. brucei. Furthermore it is a suitable drug target candidate, 
currently awaiting druggability studies.  
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